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Foreword 
The present thesis dissertation is the result of four years of research at the Animal 
Cell technology Unit of ITQB-UNL/IBET, Oeiras, Portugal, under the supervision of 
Dr. Paula Alves. The work described on Chapter V was performed at the Alternative 
Methods Unit of Institute for Health and Consumer protection at the EC JRC-Ispra, 
Italy. All together, it gave me the opportunity to be introduced to the field of 
Biotechnology and Toxicology to culture hepatocyte cells in stirred tank bioreactors 
towards the development of alternative methods for animal testing. 
 
This thesis pretends to explore the use of stirred tanks with and without environment 
control on the improvement and extended maintenance of liver-specific functions on 
hepatocytes cultured as 3D spheroids. For that rat hepatocytes in mono- and co-
culture, human hepatocytes and HepaRG cells were used. 
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ABSTRACT 
Drug Development is a long and costly process that starts with thousands of 
drug candidates and ends with one compound, which often fails in clinical trials. This 
high percentage of failure of the drug development process results from the lack of 
highly predictable models in the pre-clinical tests.  
Being metabolism a bottleneck in in vitro drug testing, special efforts have 
been made towards the development of metabolic competent liver cell cultures. The 
major drawback of standard hepatocyte cultivation systems is the spontaneous cell 
dedifferentiation that results in the decrease of metabolic competency and other liver 
specific functions and ultimately will compromise the effective biotransformation of 
drugs. Therefore, novel culture strategies presenting an improved hepatocyte viability 
and functionality for extended periods are required. 
Within this context, the main goal of this PhD project was to develop an 
efficient strategy for culturing hepatocytes as 3D spheroid structures since this better 
mimics the in vivo tissue. Within these 3D structures, cells can re-establish cell-cell 
interactions and specific microenvironments resulting in a better retention of 
important hepatic functions.  
The work here depicted has focused on the use of primary cultures of 
hepatocytes, since they better retain the liver functional profile. Additionally, the 
developed strategy has been applied to a human hepatocarcinoma cell line with the 
aim of generating a more physiological model with cells that are easier to obtain then 
fresh isolated hepatocytes. Within this context, and also to confirm the robustness of 
the 3D culturing strategy, three relevant cellular models were used namely, human 
hepatocytes, rat hepatocytes and the HepaRG cell line. 
In Chapter I the importance of having alternative methods to animal testing, 
regarding both the ethical problems and the inter-species variances, is explained. 
Furthermore, the relevance of having metabolic competent methods towards the 
accomplishment of the 3R’s is discussed, highlighted the advantages of having 3D 
liver cultures for toxicity tests. Special focus is given to the bioreactors used for this 
purpose, which are a robust and controlled way of cell maintenance. 
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Although primary cultures of human hepatocytes are the best culture model 
for liver cells, their use still relies on scarce sources. Thus, the novel strategy 
developed during the course of this thesis was firstly optimised using rat hepatocytes 
as described in Chapters II and III. Moreover, the development of highly predictable 
cultures of rat hepatocytes is also a way to reduce and refine the animal testing. 
In Chapter II, the identification of critical parameters used to develop the 3D 
hepatocyte culture in stirred tanks is described, namely the testing of different stirring 
impellers, culture media and cell inoculum. The best strategy – culturing rat 
hepatocytes in 3D spheroids using a paddle impeller, William’s E medium with an 
inoculum of 1,2x105 cell/ml – has shown to improve specific hepatocyte functions up 
to 10x and also extend it to 3 weeks when compared with the 1-2 weeks of the 2D 
cultures. Also, the cells were further challenged to perform the physiological 
phenomenon of drug clearance. 
The system was then tested for further improvement. Aiming at creating a 
more physiological milieu, other cell types were introduced into the system, more 
specifically fibroblasts were co-cultured with rat hepatocytes as described in Chapter 
III. The study started by testing different parameters such as type of fibroblasts, ratio 
between the concentration of the two cell types and the total cell inoculum. As 
expected, it was confirmed that over the same period of time, co-cultures had a 
higher and more stable albumin production as well as improved phase I and II 
enzymes activities. The best results were obtained for co-cultures of hepatocytes 
with mouse embryonic fibroblasts in a ratio of 1:2 with a total inoculum of 1,2x105 
cell/ml. Moreover, CYP induction under different oxygenations (reflecting the 
heterogeneous hepatic exposure to oxygen in vivo) was observed, confirming the 
biotransformation capacity of the cells. 
After the optimisation of the system, Chapter IV describes the implementation 
of a 3D culture of human hepatocytes in a perfusion system using cells from different 
donors. Besides the expected inter-donor variability, culturing cells under the 
described conditions has been shown to be highly reproducible regarding albumin 
and urea secretion. Additionally, hepatocytes have shown CYP inducibility and re-
 x
inducibility after 2 to 4 weeks for CYPs 1A2, 2C9 and 3A4. Moreover, 
immunostaining of the cell spheroids has shown that they present an in vivo like 
structure with biliary structures and polarised arrangement.  
Chapter V describes the generation of a more physiological culture of 
HepaRG cell lines as an attractive alternative to the use of primary cultures of human 
hepatocytes. This cell line has shown a biotransformation activity within the range of 
what is observed for human cells (both in vitro and in vivo) and for a longer period, 
up to 7 weeks (a great improvement when compared to the 3-4 weeks longevity 
observed for the 2D HepaRG cultures). Moreover, the application of the system to 
screening toxicological studies and to a multidisciplinary integrative model, has been 
shown. The test of Acetaminophen toxicity in 3D spheroids generated with a stirred 
tank and using 96-well plates, suggests that the developed culture model is a 
potential model to be used as a cell-feeder system for high-throughput assays. 
Furthermore, the integration of these results in a computational model has shown the 
flexibility of the system to integrate with in silico approaches, contributing to the 
generation of animal replacement strategies for toxicology applications. 
Chapter VI consists of a general discussion integrating all the results 
described in the previous chapters and the state-of-the-art of hepatic cultures. The 
main achievements of the work are discussed, namely the generation of a more 
predictable metabolic model. Final conclusions are then presented as well as 
discussing the future outlook towards the accomplishment of the 3R’s policy. 
In conclusion, the 3D spheroid hepatocyte culture systems developed in this 
work are promising tools that may be used for the establishment of more robust and 
predictable in vitro models for Drug Discovery. 
 xi
RESUMO 
O desenvolvimento de fármacos é um processo longo e dispendioso que 
começa com milhares de compostos candidatos e termina com uma única, que na 
maior parte das vezes é reprovada na fase de ensaio clínico. A elevada 
percentagem de insucessos que ocorrem durante a otimização de fármacos resulta, 
em grande parte, da inexistência the modelos para teste na fase pré-clinica que 
sejam mais fiáveis. 
Sendo o metabolismo um ponto fulcral dos testes in vitro, nos ultimos anos 
tem vindo a ser feito um grande investimento no desenvolvimento the culturas the 
células de figado que sejam competentes metabolicamente. O modo tradicional de 
cultura de hepatócitos leva à sua desdiferenciação expontânea, por decréscimo das 
funções hepáticas, comprometendo a correta biotransformação dos xenobióticos. 
Assim sendo, é necessário o desenvolvimento de novas estratégias para a cultura 
de hepatócitos, de forma a aumentar a sua viabilidade e manter as suas funções 
específicas durante mais tempo.  
Neste contexto, o principal objetivo deste trabalho de Doutoramento foi 
desenvolver uma estratégia eficaz para cultura de hepatócitos em estructuras 3D 
que mimetizam melhor o tecido in vivo. Neste tipo de estruturas, as células podem 
restabelecer as interações célula-célula e o microambiente específico do fígado, 
verificando-se assim uma melhor mimetização do desempenho da função hepática. 
O trabalho focou-se essencialmente na ultilização de culturas primárias, tendo 
em conta que conseguem reter melhor o perfil funcional do fígado. No entanto, esta 
estratégia foi também utilizada para a cultura de uma linha celular de 
hepatocarcinoma, de forma a obter um modelo mais fisiológico com células que são 
mais fáceis de obter que os hepatócitos provenientes diretamente do tecido vivo. 
Assim, neste contexto e também para confirmar a robustez da estratégia de cultura 
em 3D, foram usados três modelos celulares relevantes, nomeadamente, 
hepatócitos Humanos, hepatócitos de Rato e a linha celular HepaRG. 
O Capítulo I revê a importância da existência de métodos alternativos à 
experimentação animal, considerando a responsabilidade ética, mas também a 
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variabilidade inter-espécie entre animais e humanos. É também mostrada a 
relevância da existência de modelos metabolicamente competentes no sentido de 
concretizar a politica dos 3R’s (Substituir-Reduzir-Refinar, em inglês: Replace-
Reduce-Refine), mostrando a vantagem de ter culturas 3D de células de fígado, 
para testes toxicológicos. É ainda dada especial relevância aos biorreatores 
atualmente usados para este propósito, como modelos de cultura controlados e 
robustos para manutenção de células. 
Apesar das culturas primárias de hepatócitos humanos serem o melhor 
modelo celular para mimetização in vitro do fígado, a sua disponibilidade é bastante 
limitada. Desta forma, a estratégia de cultura de hepatócitos desenvolvida nesta tese 
foi primeiramente otimizada usando culturas primárias de hepatócitos de rato 
descritas nos Capítulos II e III. Adicionalmente, o desenvolvimento de culturas 
rubustas de hepatócitos de rato irá também contribuir para a redução e refinamento 
dos testes em animais. 
No Capítulo II está descrita a escolha dos parâmetros para o 
desenvolvimento das culturas 3D em tanques agitados, nomeadamente  o efeito de 
diferentes tipos de pás de agitação, o meio de cultura e o inóculo celular. A 
estratégia que demonstrou ser a melhor – cultura de hepatócitos em esferoides (3D) 
em tanque agitado por pás, usando o meio de cultura William’s E com um inóculo de 
células de 1,2x105 cell/ml – demonstrou poder aumentar as funções específicas dos 
hepatócitos até 10x comparando com as culturas 2D, ao mesmo tempo que foi 
possível aumentar o tempo de cultura de 2 para 3 semanas. No final foi ainda 
testada a capacidade das células de desempenhar uma função fisiológica, a 
depuração hepática. 
O Capítulo III, o melhoramento do sistema de cultura descrito no capítulo 
anterior ao introduzir outro tipo de células, neste caso, fibroblastos. O estudo iniciou-
se testando diferentes parâmetros nomeadamente o tipo de fibroblastos, a razão 
entre as duas concentrações celulares e o inóculo celular. Como esperado, para o 
mesmo período de tempo, os hepatócitos em co-cultura apresentaram uma maior e 
mais estável produção de albumina, bem como atividade dos enzimas de fase I e II. 
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A estratégia que apresentou melhores resultados foi a que manteve os hepatócitos 
em cultura com fibroblastos embrionários de ratinho, numa proporção 1:2 com 
inóculo total de células de 1,2x105 cell/ml. Adicionalmente, as células responderam à 
indução das CYPs, dependendo a amplitude de resposta da oxigenação (refletindo a 
exposição heterogénea a oxigénio característica das células no fígado), confirmando 
a capacidade de  desempenhar a biotransformação. 
Após otimização do sistema, o Capitulo IV descreve a implementação de 
culturas 3D de hepatócitos humanos em biorreator de perfusão usando células de 
diferentes dadores. Apesar da natural variabilidade entre dadores, a manutenção 
das células em tanques agitados como 3D em condições de cultura controladas 
demonstrou elevada reprodutibilidade em termos de secreção de albumina e ureia. 
Em termos de capacidade de biotransformação as células demonstraram 
capacidade de indução e re-indução após 2 a 4 semanas, das CYPs 1A2, 2C9 e 
3A4. Adicionalmente, a marcação por imunofluorescência dos esferoides mostrou 
uma estrutura semelhante ao fígado in vivo com estruturas biliares e organização 
polarizada. 
O Capítulo V descreve o desenvolvimento de uma cultura mais fisiológica da 
linha celular HepaRG, como uma alternativa atrativa ao uso de culturas primárias de 
hepatócitos. As células demonstraram atividade de biotransformação dentro do 
mesmo intervalo observado pelos hepatócitos humanos (tanto in vitro com in vivo) 
até 7 semanas (em comparação com as 3-4 semanas previamente obtidas com as 
culturas 2D de HepaRG). Foi também possível demonstrar a aplicação das células 
em estudos de toxicologia e integração multidisciplinar. O teste de toxicidade de 
Acetominofen em esferoides gerados em tanques agitados, usando placas de 96-
poços, demonstra a compatibilidade do modelo desenvolvido com testes high-
throughput. A integração dos resultados gerados em mdelos computacionais 
demonstrou a flexibilidade do sistema conjuntamente com aplicações in silico no 
sentido de gerar uma subtituição aos testes toxicológicos em animais. 
O Capítulo VI consiste na integração de todos os resultados dos restantes 
capítulos desta tese numa discussão geral. São demonstrados os principais 
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resultados do trabalho desenvolvido originando um modelo metabólico com melhor 
preditividade; a conclusão geral e as perspetivas futuras. 
Em resumo, a cultura de esferoides 3D de hepatócitos desenvolvida neste 
trabalho é uma ferramenta promissora para a obtenção de modelos in vitro mais 
robustos e preditíveis no desenvolvimento de fármacos. 
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1. ALTERNATIVE METHODS TO ANIMAL EXPERIMENTATION: assessment of 
ADME towards the 3R’S policy  
The development of a medical drug takes several years (5 to 10), involving 
thousands of compounds and costing millions of dollars (Fig. 1.1) until it is on the 
market to be used by patients (innovation.org 2007). The recent advances on 
genomics, proteomics and computational sciences have given scientists a better 
understanding of the human body at the molecular level, enforcing the first steps of 
the drug discovery process on the producing of more effective compounds. However, 
there is still a high rate of compound failure on the clinical trial and approval phases 
(Service 2004), either for inducing human toxicity or for not producing the 
desire/expected effect.  
 
 
 
Figure 1.1: Process of Drug Development. (adapted from (innovation.org 2007; Mattisson and Matison 
Faye 2008) ) 
 
Besides medical drugs, with the continuous development of the industrialized 
world, the human body is increasingly exposed to different compounds present in 
chemicals, pesticides, food or cosmetics. These compounds can enter the body 
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through different routes reaching distinct targets, and in spite of acute effects being 
quickly detected, for many of the compounds, chronic toxicity remains unknown.  
In this context, the development of methods and strategies that will allow a 
better prediction of the impact of the new formulations on human health is of capital 
importance. 
 Animal models have been used for a long time in order to access the effect of 
compounds as an integrative ADME (Administration, Distribution, Metabolization and 
Excretion) model. However, despite the advantages of being an in vivo system there 
are several reasons that have convinced the scientific community of the importance 
of developing alternative methods. Besides the ethical implications of sacrificing 
animals for research purposes and the economical impact involved, animal models 
have been shown to produce false positives regarding the prediction of human 
toxicity specially at the metabolic level (Turpeinen et al. 2009); this is the case with 
the catastrophic use of Thalidomide and Valpromide in humans. 
In 1959, William Russel and Rex Burch introduced the 3R's concept in The 
Principles of Humane Experimental Technique (Russel and Burch 1959), that stands 
for Refinement, Reduction and Replacement of animal testing. The 3R’s concepts 
were defined as: Refinement – any method that reduces or eliminates pain and 
distress in animals during experiments; Reduction – methods that seek to use fewer 
animals in an experimental protocol to obtain the same or similar information of 
scientific value, or use the same number of animals to obtain more scientifically 
valuable information; and Replacement – the use of techniques that do not require 
living animals. 
In 1986 a European Directive was established on the protection of laboratorial 
animals for experimental purposes developing and validation of alternative 
techniques to animal testing, that latter lead to the creation of ECVAM (European 
Centre for the Validation of Alternative Methods). Within this scenario, several 
industries adopted strategies towards the development of alternative methods. 
REACH (European Regulation on Chemicals) encourages the use of alternative 
methods and avoidance of tests’ duplication; and for Cosmetics legislation a ban has 
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been gradually introduced on the marketing of cosmetics containing ingredients 
tested in animals.  
However,  this year a report  prepared for DG SANCO by experts in the field 
concluded that full animal replacement is still not possible (Adler et al. 2011). 
Nevertheless, contrarily to what is many times assumed, the 3R's policy is not a 
replacement based strategy. The improvement of alternative methods consists on 
the development of strategies that can better mimic the in vivo system by using less 
animal sources. The establishment of this policy is based on a set of concepts that 
have to be considered in order to achieve methods that better predict human toxicity. 
 
 
Figure. 1.2: ADME resume of a drug intake, possible paths within the body. ADME (Adapted from 
Topics on Biotechnology (http://www.biology.iupui.edu/biocourses/Biol540/4pipeline09Full.html) and 
http://www.humanillnesses.com) 
 
ADME (Fig. 1.2) is a concept that more and more has becoming a fulcral point 
in Drug Development. Many compounds tested in high-throughput screens, often 
present undesirable features in the clinical phase, namely increased hydrophobicity 
and decrease solubility (Pelkonen et al. 2011). This has made the scientists realize 
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that ADME testing has to be moved earlier in the drug discover pipeline (Pelkonen et 
al. 2011). 
Toxicokinetics (TK) of a compound is the characterization of its ADME, 
absorption, distribution, metabolism and excretion in the body. Towards the 
implementation of the 3R’s policy, TK has become an essential information that is 
important to determine parameters such as the bioavailability of metabolites towards 
the targets; the translation of in vitro nominal concentration to the actual in vivo levels 
and to understand  if the cell or tissue under human exposure conditions is exposed 
to the external xenobiotic and/or its metabolite. 
With the aim of following the European directives, more reliable methods have 
been developed and  there is already a remarkable set of alternative methods on 
ADME (Table 1.1) some of them have already been validated.  
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The accomplishment of an approved certified alternative method is a process that 
includes 7 steps: 1) Research; 2) Development; 3) Prevalidation; 4) Validation; 5) 
Independent Review; 6) Regulatory acceptance and 7) Implementation. 
Method validation is part of toxicity testing (Pelkonen 2010). Even being a 
tedious and time consuming process (5-10 years), the validation of an alternative 
method, involving several laboratories and a reliable scientific board is a way to 
ensure the reliability, transferability and robustness of the test method (Pelkonen 
2010). This way, the financial and human resources are used more efficiently, having 
a greater likelihood to meet the expectations of those in the scientific, regulatory and 
animal welfare communities on alternative methods benefiting and the human society 
in general. 
One of the major drawbacks to achieve viable alternative approaches is the 
lack of efficient conversion approaches of in vitro data, generated at tissue/cell or 
sub-cellular level, into dose-response information on human body.  Within the TK 
approach, towards the full replacement models, there are several concepts such as 
Threshold of Toxicological Concern (TTC), biokinetics, IVIVE and integrative 
approaches that should be taken into consideration (Adler et al. 2011). 
All together, the alternative methods need then to fulfill the needs and 
questions of human toxicology, using relevant and competent models and 
addressing fundamental issues. 
When testing the toxicity level of a compound, upfront, is important to 
determine its TTC value of human exposure: below the TTC there is a very low 
probability of an appreciable risk to human health (Adler et al. 2011). This is a 
concept that is already being used by the food authorities and is the base of further 
research projects (Adler et al. 2011). If human exposure is above the external TTC it 
becomes important to access the biokinetics of the compound – the process that the 
compound will suffer until it reaches its internal concentration and the concentration 
at which it will reach the target organ(s).  
In an in vitro approach, besides using the relevant doses, is also important to 
have bioactivated substances, meaning that the tested substance should be the 
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substance that in vivo would indeed reach the target organ after passing the 
metabolic organs. It is then important to study the mode of toxic action, and the 
resulting effects on the physiological processes in an organism. In cell culture it is 
important to establish strategies that ensure to have enough bioactivated substances 
in vitro such as the use of cell co-culturing, having in culture both the activating cells 
and the target cells. 
First, it is important not only to have competent cell cultures, but ensure also 
that the cells  have a behavior which is as close as possible to the organ itself. To 
achieve this, several strategies have been developed that will be further explored in 
the sub-Chapters of Chapter I, but a better predictability will be reached if the cell 
culture strategy is combined with other approaches and tools. The more extensively 
characterized a compound is in terms of metabolism, disposition, bioactivation, cell 
membrane transposition, interaction with molecular processes and cell structures 
and functions, the higher chances of success in the late stages of the drug 
development. 
 The use of in silico strategies on kinetic data has been a development 
strategy used to bridge the in vitro and in vivo. Today’s softwares, can already 
simulate chemical properties and interactions. When these are used together with 
other computational models, in silico strategies have shown to be the most cost-
effective approach (Ekins et al. 2010) and to be able to translate the experimental 
data using the so called Physiologically based Toxicokinetic models (PBTK). To have 
an efficient in vivo in vitro extrapolation (IVIVE) using in silico models it is important 
to have massive generation of data. Thus, it is important to use down-scale and 
automated models that can screen large amounts of compounds. Metabolic data 
contributes to explain possible toxicities and modes of action and their relation to 
dose level and route of exposure are described by Toxicokinetics. Moreover, REACH 
legislation also requires the testing of thousands of chemicals within a short period of 
time (few years) (Pelkonen 2010) thus it is of significant importance that the in vitro 
models include or are compatible with high-throughput and high-content approaches 
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through which a high number of compounds and/or conditions can be screened 
simultaneously. 
While full replacement of animal testing is still not yet accomplished, partial 
replacement and reduction are forthcoming. For this purpose it is important to 
develop multidisciplinary strategies that include in vitro, in silico and "omics" 
approaches. A close collaboration between academia, regulatory authorities and 
industry is of primordial importance. The creation of consortiums, such as DNT 
(Developmental Neurotoxicity), to discuss and set the necessary path to follow are of 
utmost importance. 
Unlike other toxicokinetic steps, there is still a lack of validated in vitro models 
for metabolization prediction (Adler et al. 2011) which is a result of the complexity of 
maintaining viable and functionally active Liver in vitro models. 
 
2. METABOLISM AND BIOTRANSFORMATION 
To have a competent in vitro toolbox it is important to identify important 
metabolic pathways of the compound and to provide knowledge on: the metabolic 
stability of the chemical; the type and structure of metabolites involved. It is also 
important to  determine any metabolism-dependent toxic effects, test the compound’s  
capacity to induce or to inhibit the cell enzymes, check for drug-drug interactions and 
evaluate its clearance (Coecke et al. 2006; Pelkonen et al. 2008). 
Since metabolism is the bottleneck of in vitro toxicology (Coecke et al. 2006), 
it is important to have competent metabolic methods that can accurately determine 
all the parameters involved on the transformation of a compound before it reaches its 
target. From the pharmaco-/toxicokinetic point of view, liver is the most important 
organ in the body. Hepatocytes, present in the liver, have an enzymatic machinery 
that allows the metabolization of many different foreign chemicals (Coecke et al. 
2006). 
 
INTRODUCTION 
 
13 
C
h
ap
te
r 
I 
A
Canalicular, 
apical side
Sinosoid, 
basoleteral side
Sinosoid, 
basoleteral side Space of Disse
Space of Disse
HEPATOCYTE
EPITHELIAL CELL
bile flow
sinusoid
BILE DUCT
EPITHELIAL CELL
Blood flow
HEPATOCYTE
bile canaliculus
Space of Disse
EPITHELIAL CELL
bile duct
 
 
 
Figure. 1.3. Hepatocyte organization within the liver and specific architecture in vivo (Adapted from 
(Pelkonen et al. 2008) and (Dunn et al. 1989)). Hepatocytes at the level of functionally important 
molecules, at the level of tissue architecture, and at the level of kinetic modeling. 
 
Generally, the properties of hepatic cells result from the presence of a 
comprehensive set of enzymes that guide compounds through a one or two phase 
process called biotransformation as well as the presence of multiple transporter 
proteins, some of them with polarized distribution, that perform both influx and efflux 
functions (Fig. 1.3 A) (Pelkonen et al. 2008). The polarized structure is a result of the 
different hepatic surroundings in the liver (Fig. 1.3 B), the blood flow is on one side of 
the cell (sinusoid) and while the bile flow is on the other side (bile canaliculi). 
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2.1 Phase I of Biotransformation 
During Phase I of biotransformation the compound (xenobiotic) undergoes  
oxidative and reduction reactions, carried by monooxygenases becoming more polar. 
The enzymes involved on phase I are mainly clustered in two groups such as 
Cytochrome P450 (CYP450), the largest group of membrane associated heme 
proteins, and flavine monooxygenases. The human CYPs involved in the majority of 
marketed drugs are CYP3A4, CYP2D6, CYP2C9, and CYP1A2 (Zanger et al. 2008). 
One of the major drawbacks of the development of liver-predictive models is 
the high inter-individual metabolic variability. The main cause of these differences is 
the variation of phenotype and genotype among the enzymes involved in 
biotransformation, specially the Phase I CYP450 cluster. This is mainly a result of 
environmental and/or hereditary gene polymorfisms specially on CYPs 2C9, 2C19, 
and 2D6 (Hewitt et al. 2007). On the other hand, although gene expression of CYP 
1A1, 2E1 and 3A4 is well conserved, variations on their activity levels can still be 
observed (Hewitt et al. 2007). In this case, the inter-individual differences are the 
result not only of genetic predisposition but also of many other factors such as 
hormonal expression, age, sex, diet, smoking, drug consumption, exposure to 
environmental chemicals and disease state.  Among all these factors the interference 
of other drugs by drug-drug interaction, induction or inhibition is the major and more 
frequent effect (Hewitt et al. 2007). Moreover, the induction of enzymatic capacity 
has been used as a quality control property, as a way to access the metabolic 
competence of hepatocytes in vitro and thus it has been used as a control factor in 
validation studies (Richert et al. 2010).  
The process of enzymatic induction (CYP induction) is the increase of a 
specific CYP activity upon the addition of specific compound. The classical definition 
of induction is the de novo synthesis of an enzyme (protein) reflecting an increased 
transcription of the correspondent gene following a specific stimulus. In more detail, 
once it reaches the cell, the inducer compound will act on the cytosolic receptor 
ligand which will travel into the nucleus after releasing repressor proteins binding to 
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the upstream regulatory elements on CYPs (O’Brien 2004). Among the transcription 
factors, the nuclear receptors such as androstane receptor (CAR), the pregnane X 
receptor (PXR) as well as the aryl hydrocarbon receptor (AhR) can be distinguished 
as the main regulators of CYPs activity, acting as sensors for lipophilic xenobiotics, 
including drugs (Handschin and Meyer 2003; O'Brien et al. 2004). 
As explained before, induction is a complex process involving several cellular 
machineries, thus  the addition of specific known inducer compounds is a good tactic 
to check the quality of the metabolic competence of a system for more than one day 
(Coecke et al. 2006). Furthermore, induction has very specific characteristics such as 
being tissue-specific, rapid, dose-dependent, and reversible upon removal of the 
inducer (Handschin and Meyer 2003). 
However the capacity to respond to one or other compound as well as the fold 
increase of the enzyme activity is not only species dependent but also donor-
dependent (Richert 2009).  
Table 1.2 resumes the main xenobiotic CYP metabolizers in human and 
rodent species, as well as the specific inducers and receptors involved in the 
induction. It can be observed that the same compound does not always induce the 
same CYP in one or another species. This differences between species is due 
sequence differences in the ligand domain of the nuclear receptor genes and CYP 
response elements (Lin 2006). 
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Table 1.2: Human and rodent main CYP P450 isoforms with the respective inducers and receptors 
associated. Adapted from (Handschin and Meyer 2003) and (Ogu and Maxa 2000; Pascussi et al. 
2000; Borlak et al. 2002; Brandon et al. 2003; Meredith et al. 2003; Tamrazi et al. 2003; O'Brien et al. 
2004; Marek et al. 2005; Dail et al. 2007; Chanda et al. 2009; Richert et al. 2009) 
P450 isozyme Inducer compound Receptor associated 
Human CYP1A1/2 β-Naphtoflavone 
Omeprozole 
3-Methylcholantrine 
Aroclor 1254 
AhR 
CYP2A6  Rifampicin PXR 
Phenobarbital CAR 
Pyrazole ER (estrogen receptor) 
CYP 2B6 Rifampicin PXR 
Phenobarbital CAR 
β-Naphtoflavone AhR 
CYP 2C9/19  Rifampicin 
Dexamethasone  
PXR 
Phenobarbital CAR 
CYP 2E1  Rifampicin 
Isoniazid 
PXR 
Phenobarbital CAR 
CYP 3A4 Rifampicin 
Dexamethasone 
Dieldrin 
PXR 
Phenobarbital CAR 
Omeprazole AhR 
CYP 4A Fenofibrate 
Methylclofenapate 
PPARα (Peroxisome proliferator-activated 
receptor alpha) 
Rodent CYP 1A1 β-Naphtoflavone 
Thiabendazole 
CAR 
Aroclor 1254 AhR 
Isoniazid PXR 
CYP 2A5 Pyrazole ER (estrogen receptor) 
CYP 2B1/2 Phenobarbital 
Dieldrin 
CAR 
Aroclor 1254 AhR 
CYP 2C Dexamethasone PXR 
CYP3A1/2 Dexamethasone 
Pregnenalone-16-
Carbonitrile 
PXR 
Aroclor 1254 AhR 
CYP4A1 Methylclofenapate PPARα (Peroxisome proliferator-activated 
receptor alpha) 
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2.2 Phase II of Biotransformation 
After the oxidative pathway of phase I, the xenobiotic can then be excreted or, 
if it is still not polar enough, it will undergo the conjugation process – Phase II of 
biotransformation. Conjugation path consists of reactions of glucuronidation, 
sulfation, methylation, acetilation and mercapture formation, at the end of which more 
soluble metabolites are obtained; these are ready to be eliminated (Gomez-Lechon 
et al. 2006). 
Phase-II metabolization of a compound is dictated by its chemical properties. 
Within phase II reactions, glucoronidation represents more than 35% of the 
conjugation reactions in human drug metabolism by the UDP-glucuronsyltransferase 
(UGT) family of enzymes (Trubetskoy et al. 2007). UGT enzymes catalyze the 
conversion of substrates (exogenous or endogenous compounds) into more polar 
glucuronides by covalent linking (conjugation) to UDP-glucuronic acid (UDPGA) 
(Chen et al. 2003; Donato et al. 2010). 
Recent studies have shown that these enzymes can also be induced by some 
of the prototypical CYP inducers following the same path of ligand-activated 
transcription factors (Donato et al. 2010). 
 
The physiological function of biotransformation is to detoxify the body from 
foreign compounds. However, the metabolites of biotransformation are often highly 
reactive and toxic causing hepatotoxicity, being sometimes  more toxic than the 
parent compound (Gomez-Lechon et al. 2006). For this reason, in a toxicological test 
it is important to access toxicity of the compound as well as its metabolite. 
The biotransformation capacity is dependent not only on the activity of the 
enrolled enzymes but also on the activity of the membrane transporters with 
polarized distribution, for instance, apically transport bile acids on the basal site 
conduct trafficking of metabolites from the bloodstream. The main superfamily of 
transporters is the Multidrug resistance-associated superfamily-2 (MRP2) that is a 
drug efflux pump located on the biliary pole of hepatocytes (Fig. 1.3 B) (Courtois et 
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al. 2002). MRP2 belongs to the ATP-binding cassette (ABC) protein superfamily 
together with other relevant transporters such as MRP1, MRP3 and P-glycoprotein 
(PGP), the latest also localized on the hepatic biliary side (Borst et al. 2000). As it 
happens with the CYP enzymes, the pump transporter enzymes also respond with 
increased activity upon the addition of inducer compounds such as dexamethasone 
and Phenobarbital (Courtois et al. 2002). 
The role of biotransformation within the organism and the variability 
associated to it show how important it is to have, in the drug development process, 
earlier models that behave as close as possible to what is observed in vivo, with all 
the hepatocyte specific functions operating in a reproducible and stable mode. 
Having good reproducible liver models is an important step forward towards the 
accomplishment of the 3 R’s policy. 
 
3. HEPATOCYTE CULTURES 
Besides biotransformation, hepatocytes are responsible for many other body 
functions that contribute to the regulation of the body homeostasis and to the 
detoxification of incoming compounds. Under external stimuli (e.g. hormones, 
nutrients, ions) the hepatocytes secrete and degrade a large number of molecules. 
The main functions of  hepatocytes (besides biotransformation), schematically 
represented on Figure 1.4 (De Maria et al. 2008) are: 
 Regulation of the metabolism of carbohydrates,  proteins and lipids and 
their levels in the blood; 
 Synthesis of important serum proteins such as albumin, protrombin, 
fibrinogen, etc., (with the exception of immunoglobulins);  
 Storage of glycogen, triglycerides, iron, copper and liposoluble vitamins; 
 Catabolism of endogenous substances, such as hormones and serum 
proteins, to maintain a balanced body concentration; 
 Excretion of the liver metabolites such as conjugated bilirubin, biliar acids, 
phospholipids, cholesterol and electrolytes to the bile canaliculum. 
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Figure. 1.4. Metabolic hepatic functions (Adapted from (De Maria et al. 2008)) 
 
When in culture, the maintenance of these functions is attempted by culturing, 
under chemical defined conditions, appropriate culture medium and supplements and 
a robust cell culture apparatus. However, it is first of all important to choose the most 
adequate cell model. Extracellular signals play an important role in the preservation 
of differentiated liver-specific functions. Within this context, for years researchers 
have been trying to decrease the spontaneous de-differentiation of in vitro 
hepatocytes by mimicking the extracellular signals using different strategies such as 
modification of the culture conditions (such as the use of hormonally defined and 
highly enriched media), addition of soluble factors (such as hormones, growth 
factors, cytokines and amino acids) (Feldhoff et al. 1977; Coecke et al. 1999; 
Schmelzer et al. 2009; Takeba et al. 2011), increase of cell-cell contacts (Pampaloni 
et al. 2007), addition of matrixes (such as collagen, matrigel, etc.), (Dunn et al. 1989) 
and better control of oxygen levels (Stevens 1965). 
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Specific medium components such as Serum, Dexamethasone, Insulin, 
Glucagone and Growth Hormone have shown to have high impact on the 
physiological maintenance of hepatocytes in vitro (Coecke et al. 1999; Schmelzer et 
al. 2009), however some of these factors can also decrease and/or suppress 
important hepatic machineries such as CYP activity, transporters or protein synthesis 
(Coecke et al. 1999). The solution is to try to balance the importance of the addition 
of each component according to the aim of the study. 
When reproducing the in vivo environment in cultured hepatocytes, cell-
extracellular membrane (-ECM) interactions, soluble growth factors and cytokines, 
physical factors (e.g. stress and strain) and cell-cell communications (Lang et al. 
2011) are important elements that need to be controlled. 
Oxygen is another sensitive issue in hepatocyte cultures. In the liver, the 
oxygen content on the blood flow from the periportal to the perivenous hepatocytes 
decreases from 8-9% to 3-5% which will affect the enzymatic profiles of the 
hepatocytes in each region (Stevens 1965; Jungermann and Kietzmann 1997; 
Kietzmann and Jungermann 1997; Kidambi et al. 2009; Yan et al. 2010) leading to 
the so called liver zonated metabolism  (Kietzmann and Jungermann 1997; Allen et 
al. 2005). Several studies state that regular cellular cultures are over-oxygenated 
(Kidambi et al. 2009; Yan et al. 2010) since cells are exposed to the 21% of oxygen 
present in the air while in the liver the oxygen levels are much smaller (Kietzmann 
and Jungermann 1997), and this could cause oxidative stress. On the other hand, 
some works defend that cells are exposed to an unlimited oxygen gradient as a 
consequence of the presence of the hemoglobin in the blood (Nahmias et al. 2006; 
Kidambi et al. 2009) and thus low oxygen concentrations do not mimic the natural 
hepatic environment (Cho et al. 2007), so cells oxygenation is a controversial issue.  
On the following subsection it will be addressed the more relevant hepatic 
culture models. Figure 1.5 depicts regular hepatocyte cultures in 2D. 
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A 
Primary culture of 
Human Hepatocytes 
 
B 
HepG2 cell line 
 
C 
HepaRG cell line 
 
Figure. 1.5. Hepatocyte cultures in 2D. A – Primary culture of Human Hepatocytes; B- HepG2; C – 
HepaRG. 
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3.1. Human Hepatocytes 
In the last few years, freshly isolated hepatocytes (Fig. 1.5 A) have been 
recognized as one of the most relevant models to study drug metabolism and 
transporter interactions, since this is the culture model that can best retain liver 
functionalities in vitro (Gomez-Lechon et al. 2010). Considered the golden standard 
of hepatic cultures, the use of freshly isolated hepatocytes is recommended both by 
the US Food and Drug Administration (FDA) and the European Medines Agency 
(EMA) for in vitro liver-related studies, such as induction determination. 
Several studies with human hepatocytes have  shown that, within the proper 
environment, human hepatocytes can retain the biotransformation mechanisms in an 
integrated form, including transporters and induction (Silva et al. 1999; Courtois et al. 
2002; Donato et al. 2010; Rotroff et al. 2010; Perry et al. 2011), reproducing the in 
vivo paths and constituting a valuable tool to anticipate potential drug-induced liver 
toxicity. Thus, human hepatocytes have been used for hepatotoxicity studies, namely 
for: screening cytotoxicity and genotoxicity; characterizing drug-induced lesions, 
describing toxic mechanisms and determining biotransformation pathways (Coecke 
et al. 1999; Gomez-Lechon et al. 2010). However,  liver-specific markers are hardly 
maintained in primary cultures and not at all after the maintenance of isolated human 
hepatocytes for several weeks. After isolation, hepatocytes undergo a natural de-
differentiation that is characterized by the declining of protein synthesis, leading to a 
drop in the overall protein content and finally to cell death (Moshage et al. 1988). 
To overcome de-differentiation several strategies have been developed to 
improve and prolong the human hepatocytes functionalities, these have focused on 
trying to reproduce in vitro a more physiological environment. For instances, human 
hepatocytes have shown a good adaptation and improved functionality when cultured 
in bioreactors (Schmelzer et al. 2009; Prot et al. 2011; Tostões 2011).  
Another characteristic of these cells is the high donor-variability. In spite of 
being a limitation in terms of the reproducibility of some studies, is not really a 
disadvantage since it reflects the in vivo inter-individual differences. Moreover, this 
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model has shown robustness as it was possible to proceed to inter-laboratory 
validation. Reproducible results were obtained in different laboratories with 
harmonized protocols even for different donor cells (Richert et al. 2010). 
As a way to further improve the human hepatocyte model, significant work on 
improving the efficiency of freezing and platting after thawing techniques has been 
done (Silva et al. 1999; Hewitt et al. 2007). Cryohepatocytes are freshly isolated 
hepatocytes that are maintained at -80ºC until use and have shown to perform 
similarly to the freshly isolated hepatocytes (Li et al. 1999; Li 2007). This has the 
advantage of having the possibility of using cells from same batch at different times. 
After thawing, they present lower cell viability, but the cells that are viable and able to 
attach, can perform similarly to fresh hepatocytes in spite of showing lower basal 
activities (Abadie-Viollon et al. 2010). 
Human hepatocytes can be obtained from different sources such as livers 
unsuitable for transplantation, surgical waste material (after reduced-size or split-liver 
transplantation) and waste material from partial hepatectomy (Richert et al. 2010). 
However, the human liver tissue is sparsely available, being necessary to develop 
and use alternative hepatic culture models.  
 
3.2. Rat hepatocytes 
Alternatively to human cells, different mamalian cells have been used for 
development of in vitro liver models and hepatotoxicity assays since they are easier 
to obtain, namely monkey (Silkworth et al. 2005), porcine (Custer and Mullon 1998; 
Hoebe et al. 2000; Kostrubsky et al. 2000), rat (Guyomard et al. 1996; Shen et al. 
2008; Hrach et al. 2011; Schutte et al. 2011) and mouse hepatocytes (Kulkarni and 
Khanna 2006; Jemnitz et al. 2008; Jaeschke et al. 2010). 
Compared to the use of human cell lines, using animal freshly isolated 
hepatocytes has the advantage of better reflecting the in vivo hepatic features, 
having a more active and reliable metabolism. Within the different animal species it is 
difficult to choose the one that would best predict the human drug interactions. 
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Currently, the selection of a specie for toxicological assays is mostly based on the 
knowledge and historical use of that specie, the costs, the amount of hepatocytes 
obtained per each individual and the availability (O’Brien 2004), evaluating these 
parameters makes rat hepatocytes perfect candidates. 
Primary cultures of rat hepatocytes are a good alternative often used by the 
pharmaceutical industry because: (i) they present higher metabolic responses than 
the common human cell lines and (ii) the inter-donor variability can be minimized by  
selecting animals of the same sex, age and similar feeding regimes (Coecke et al. 
2000; O'Brien et al. 2004).  
Rat hepatocytes, have shown good hepatocyte-specific characteristics such 
as  cell shape and arrangement (Abu-Absi et al. 2002), biotransformation activities, 
(Kocarek et al. 1990; O'Brien et al. 2004) albumin secretion (Feldhoff et al. 1977), 
hormonal regulation (Coecke et al. 2000) and bilary transporters (Nakanishi et al. 
2011). 
In spite of the interspecies differences between rat and human, rat 
hepatocytes can be a good tool to explore culture strategies and undisclosed toxic 
cellular mechanisms. In the specific case of induction studies, although the 
differences in the sequences of the ligand domain of the nuclear receptor genes and 
the CYP lead to different induction responses (Lin 2006), the obtained  information 
allows to interpret in vivo rodent results and thus conduct to the Refinement and 
Reducing of animal testing. 
Moreover, the strategies developed to improve hepatocytes functionalities can 
often be easily applied to primary human hepatocytes. These extrapolations have 
shown successful results on the use of scaffolds (Bierwolf et al. 2010), 3D strategies 
(Brophy et al. 2009; Nakanishi et al. 2011), bioreaction (Allen et al. 2005; Miranda et 
al. 2009; Nakao et al. 2011), oxygen requirements (Kietzmann and Jungermann 
1997; Nahmias et al. 2006; Cho et al. 2007; Kidambi et al. 2009) stem differentiation 
(Qihao et al. 2007) and co-culture (Coecke et al. 2000; Tilles et al. 2001). 
In summary, the values obtained on rat hepatocytes are not physiological 
relevant, but the strategies adopted, and the methods developed have a good 
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correlation with what happens in human hepatocytes and with what happens in vivo 
(Richert et al. 2009).  
3.3. Human Hepatic Cell lines  
The main advantage on the use of hepatocyte cell lines, in comparison with 
freshly isolated hepatocytes is the easiness to culture: (i) is possible to freeze and 
thaw the cells with no further damage, (ii) cell karyotype can be maintain and (iii) 
have almost unlimited growth. 
HepG2 is the hepatic cell line being used for a longer period of time, is a 
popular and good human cell line used to study a broad variety of toxicity 
mechanisms (Farkas and Tannenbaum 2005). The cells can be unlimited expanded 
while conserving the polyhedric hepatocyte-specific morphology in vitro (Fig. 1.5 B).  
In spite of being good models for toxicity accessment, on metabolism studies, like 
CYP induction, these cells have shown low metabolic competency (Farkas and 
Tannenbaum 2005). 
After HepG2, several hepatic cell lines (HLE, THLE, BC2, Hep 3B) with 
increased metabolic competencies were developed. For instances, the recently 
developed cell line – Fa2N-4 – has shown promising results on its application for 
CYP3A4 induction during Drug-Drug interactions (Ripp et al. 2006).  In spite of 
showing punctual relevant competencies, the major limitation of hepatic cell lines is 
that they do not show an overall metabolic realistic profile  thus being of little value 
for integrative studies. 
In 2002, a promising cell line called HepaRG was developed by Gripon et al 
which performed similar to human hepatocytes (Gripon et al. 2002). HepaRG is an 
hepatocarcinoma cell line with limited caryotype alterations, characterized by a 
surnumerary and remodeled chromosome 7 (Gripon et al. 2002).  
After 4 weeks of differentiation including treatment with 2% DMSO, HepaRG 
generate two liver cell types: one resembling hepatocytes and the other resembling 
biliary canaliculi-like structures (Fig. 1.5 C). After detachment both structures can 
trans-differentiate into progenitor cells, which are able to differentiate again (Cerec et 
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al. 2007). During the last years, intensive characterization of HepaRG cells has 
shown that when differentiated these cells express the major cytochrome P450 
(CYP), drug-conjugating enzymes, transporter proteins, nuclear receptors and 
transcription factors as well as other liver-specific proteins at levels close to those 
found in primary hepatocytes (Aninat et al. 2006; Guillouzo et al. 2007; Kanebratt 
and Andersson 2008; Turpeinen et al. 2009; Lubberstedt et al. 2011). These 
characteristics make HepaRG a good hepatic model for hepatotoxicity studies 
(McGill et al. 2011), CYP induction studies (Lambert et al. 2009; Andersson 2010), 
clearance (Zanelli et al. 2011) and liver pathological situations (Gripon et al. 2002; 
Schulze et al. 2011). 
Moreover, this cell line has also shown good competency on an upper level of 
the development of 3R’s ideology, by being compatible with more physiological 
models such as bioreactors (Darnell et al. 2011; Hoekstra et al. 2011) and even in 
vivo engraftment (Jiang et al. 2010). 
3.4. Co-Cultures 
For studies of metabolism, transporters as well as in hepatoxicity assays, 
monocultures of hepatocytes are usually preferred to mixed cultures. However, this 
scenario does not reflect the in vivo environment and the results can be misleading 
mainly because of the low hepatic performance in vitro, but also due to the lack of 
other cells that can affect the drug interaction with the hepatocyte as it occurs in vivo. 
Regarding hepatic functionality, different studies have shown that cell-cell 
interactions, especially heterotypic cell interactions (Bhatia et al., 1998), are more 
effective in maintaining  hepatocyte functions than ECM configurations 
(Michalopoulos et al. 1979; Khetani and Bhatia 2008). Significant enhancements in 
hepatocytes phenotype maintenance and function were described by the use of 
feeder cells in co-cultures with hepatocytes such as connective tissue or 
nonparenchymal cells in several species (Bhatia et al. 1998; Bhandari et al. 2001; Lu 
et al. 2005; Khetani and Bhatia 2008). Feeder cells are able to either secrete soluble 
signaling molecules (e.g. cytokines, hormones and growth factors) or provide other 
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cell-associated signals (i.e., insoluble extracellular matrix or membrane bound 
proteins).  
The nonparenchymal cells used in co-culture with hepatocytes are usually 
endothelial cells, Kupfer cells, biliary cells but mostly fibroblasts. Fibroblasts are the 
most common cell type of connective tissue with a crucial role in the synthesis of 
extracellular matrix for tissue remodeling and repair. Additionally, they are the main 
producers of hepatocyte growth factor (HGF) (Stoker et al. 1987), a molecule 
involved in the anti-apoptotic mechanisms of hepatocytes (Hiramatsu et al. 2005), 
and since they have no ability of xenobiotic biotransformation their metabolism does 
not interfere with the toxicological assays (Donato et al. 1990). 
Moreover, fibroblasts can increase the cell adherence both in 2D (Hui and 
Bhatia 2007; Evenou et al. 2011) and 3D cultures (Qihao et al. 2007) which improves 
cell stability, polarization and cell-cell contact. 
The beneficial effects of feeder cells on hepatic performance was already 
validated in vivo, in studies where the engraftment of hepatocytes in co-culture with 
fibroblasts has shown to improve their secretory functionalities (Chen et al. 2011). 
Additionally, co-cultures can also be a good model to study the cross-talk 
between different cell types. There are some successful studies performed with the 
co-culture of adipocytemyocyte/neuron/hepatocyte to study adipokines function. 
Recently Du et al., by co-culturing hepatocytes with epididymal and iguinal white 
adipose tissues have shown the depot-dependent effects of adipose tissue explants 
on the co-cultured hepatocytes in relation to the development of hepatic insulin 
resistance and cytotoxicity (Du et al. 2011).  
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4. HEPATOTOXICITY 
The major cause of a compound failure in the Drug Development process is 
drug hepatotoxicity in the clinical phase (Ostapowicz et al. 2002), often due to the 
lack of knowledge about the toxic process. A bioactivated drug can either have a 
pharmacological or a toxicological effect in the liver and, in fact, most liver injuries 
are caused by bioactivated compounds (Gomez-Lechon et al. 2010). Due to its high 
vascularization and biotransformation function, the liver is the first target of drug toxic 
effects causing different type of lesions that can be classified in: i) zonal 
hepatocellular alterations without inflammatory reaction, ii) intra-hepatic cholestasis 
(including cirrosis), iii) hepatic necrosis with inflammatory reaction or iv) 
hepatocarcinoma (Casarett and Doull 1991). However the toxic mechanism of  drugs 
is still not fully understood, and Drug-induced liver injury (DILI) diseases still 
represent a major challenge for clinicians, the pharmaceutical industry and regulatory 
agencies worldwide, including EMA (EMA 2010) and the FDA (Kaplowitz 2005).  
Inside the cell, hepatoxicity can be the consequence of chemical reactions 
such as covalent binding, oxidative stress, lipid peroxidation, alteration of Ca2+ 
homeostasis and mitochondrial injury that will lead to apoptosis or necrosis (Gomez-
Lechon et al. 2010). For a better understanding of the hepatotoxicity events, it is 
important to use in vitro detection methods that allow to follow the different cellular 
events such as decreasing of viability (MTT, XTT, Neutral Red, Alamar Blue), cell 
death (leakage of lactate dehydrogenage and alanine amino transferase), cell 
damage (DNA damage, protein adducts, lipid peroxidation, morphological alterations 
and changes in drug metabolism, gene expression and protein expression) and also 
use appropriate methods to access hepatocyte-specific metabolisms (i.e. 
gluconeogenesis, ureogenesis, plasma protein synthesis, GSH, NADH and ATP 
levels) (Kaplowitz 2005; Gomez-Lechon et al. 2010). 
Having such diverse possibilities of drug effects, it is important to have in vitro 
cell culture strategies that allow simultaneous screening of conditions. In the last 
years the high-throughput concept has been largely developed and implemented, 
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and thus it is already included in the new technologies for drug toxicity applications 
(Weyermann et al. 2005; Nakanishi et al. 2011) and is part of the basic requirements 
of in vitro liver models for drug screening in industrial scale   (Sundberg 2000; Zhang 
et al. 2011).  
 
5.  IN VITRO 3D MODELS IN TOXICOLOGY 
Most of in vitro cell assays/tests are commonly performed in the two-
dimensional (2D) cultures assuming that this will reflect the in vivo response. In 
general, this type of cultures consists of a monolayer of cells attached to a rigid 
surface that do not represent the essential physiology and architecture of the real 
tissues. In the last years the use of cell culture strategies that could better represent 
the physiological cell environment has been the focus of many research groups that 
aim at achieving structures presenting more cell-cell contacts, the so called three 
dimensional (3D) strategies. In the last two decades, studies have, in fact, shown 
that  3D cultures can reduce the gap between cell cultures and physiological tissue. 
In addition to  increasing the cell-cell contact, 3D structures induce the cells to 
secrete extracellular matrix (ECM) proteins which results in a gel-like stiffness 
geometry, and specific in vivo biochemistry (Evenou et al. 2011) that is impossible to 
obtain with the 2D structures. 
Considering their improved features, 3D cultures have been applied to the 
reconstitution of many types of tissues and structures, such as different types of 
tumours, skin tests, osteogenesis studies, absorption assessment and in tissues 
such as cornea, brain, heart, lung, kidney and liver (Pampaloni et al. 2007; Santos et 
al. 2007; Gurkan et al. 2011; Jung et al. 2011; Nyga et al. 2011; Shamis et al. 2011; 
Wu et al. 2011). All together, the availability of the several approaches and the 
results brought up by 3D strategies lead the scientific community to believe that they 
will have a crucial role on the replacement of animals for drug testing (Bhogal et al. 
2005; Pampaloni et al. 2007; Pelkonen 2010).  
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The complexity of the validation process concerning both time and money, 
has only allowed the validation of a short number of 3D models (ECVAM, 
http://ecvam.jrc.it). Nevertheless, some 3D models are already fully validated, 
namely models for skin (EPISKINTM, EpidermTM and SKinEthicTM) (Bhogal et al. 2005; 
Netzlaff et al. 2005), Corneal epithelium, Tracheal/bronchial epithelium, vaginal 
cervical and for bucal and gingival mucosa (MakTek, SkinEthic) (Pampaloni et al. 
2009). 
Moreover, in order to have 3D models representing other tissue types, that 
fullfill the previous metionted requirments for validation (sub-Chapter 1.1.) there  are 
still missing a few features including accurate compatible methods regarding 
systemic sample collection, innovative methods for biochemical analyses, 
improvement and standardization of 3D cell culture protocols and new quality control 
parameters (Pampaloni et al. 2007; Mazzoleni et al. 2009).  
Table 1.3 summarizes the 3D strategies currently used or with potential 
application for toxicological assays. Despite the  advantages of 3D approaches, all 
the current strategies still present some limitations highlighting the need of further 
development of these approaches. 
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5.1. 3D Liver Systems 
The rapid de-differentiation of cultured hepatocytes together with the low 
metabolic profile of hepatic cell constitute the major limitations of in vitro hepatic 
approaches. Thus, in the last years, the reconstructing of the spatial liver re-
arrangement using 3D strategies has been adopted as a strategy to improve the 
recreation of liver-specific functions in vitro.  
Moreover, 3D liver systems have been used to improve models associated 
with some aspects of drug discovery and transport studies. Using different 
approaches it has been shown that 3D strategies lead to a specific or global 
improvement and extend of hepatic activities and their use has already been 
successfully applied to toxicity studies (Schutte et al. 2011). The functional 
improvement of hepatocytes observed in 3D cultures results first of all from the cell 
organization. More specifically, studies which profiled the integrin expression of 
primary hepatocytes in vitro, suggest a dependence on juxtacrine cell interactions in 
3D  for the maintenance of important functions such as biotranformation and albumin 
synthesis (Liu Tsang et al. 2007). Furthermore, the 3D arrangement enables cell 
polarization as it occurs  in vivo (Fig. 1.3 A), allowing a better function of the 
transporters and  the phosphoralization of receptors such as Hepatocyte Growth 
Factor (HGF) and Epidermal Growth Factor receptors which are important factors for 
hepatocellular differentiation and activation (Engl et al. 2004). 
A broad range of 3D cell culture techniques have been employed to develop 
liver models, in this sub-section the most significant strategies used over the last 
years to perform 3D hepatic cultures will be described.  
 
5.1.1. Liver slices 
The use of liver slices for in vitro hepatic studies has been used since 1923 
(Ekins 1996), and is still currently the approach more representative of the in vivo 
structure (Fig. 1.6 A). Slices have two-cut surfaces with a  thickness greater than 
100 µm to maintain a significant ratio of undamaged to damaged cells (Vickers and 
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Fisher 2004). The use of liver slices has several advantages, such as being from an 
human source, keeping the in vivo structural arrangement and polarization (since no 
proteolytic enzymes are used), have high cell-cell contact and the presence of other 
cells (Vickers and Fisher 2004) and thus it is considered a good in vitro model. These  
characteristics have shown to maintain organelle integrity, and cellular functions such 
as induction of CYP2B, CYP3A, CYP1A, CYP2A5 (Glockner and Muller 1995; Lake 
et al. 1996; Gokhale et al. 1997; Lake et al. 1997). However, the performance 
accuracy of the studies always relies on the availability of human livers and specially 
on the quality of the tissue used (Vickers and Fisher 2004). Furthermore, culture 
oxygenation and nutrient diffusion from the culture medium are not enough to 
maintain viable and active cells longer then 24-72h (Engl et al. 2004; Farkas and 
Tannenbaum 2005). 
 
A 
Liver 
slices  
 
C 
Cell 
Spheroid 
 B 
Sandwich 
D 
3D 
Scaffolds: 
spheroid 
entrapment 
 
Figure. 1.6: 3D approaches for hepatocyte cultures A – Liver perfused slices (Adapted from (Vickers et al. 
2004; Alino et al. 2007)); B – Human hepatocytes in Sandwich cultures (adapted from (Kostrubsky et al. 2003) 
and http://www-alt.igb.fraunhofer.de/www/gf/tissueengineering/gewebemodelle/en /liver-models.en.html); C – 
cell spheroids; D – gel entrapped cells (Adapted from (Tostões et al. 2011)). 
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5.1.2. Sandwich 
The actual Sandwich strategy consists of culturing hepatocytes in between 
two layers of gelled extracellular matrix proteins, including collagen I and matrigel 
proteins (Hewitt et al. 2007) (Fig. 1.6 B). The first approach to this strategy was 
performed by Dunn and his co-workers in 1989 by culturing rat hepatocytes in the 
middle of two collagen layers (Dunn et al. 1989). This was the first 3D strategy that 
allowed prolonging the longevity of hepatic-functions in culture while maintaining the 
cell polarity.  
Recently, this strategy has been further improved and adapted to include 
among other features, oxygen control  (Bader et al. 1999) and high-throughput 
studies (Zhang et al. 2011). In addition to metabolic studies, this strategy has also 
been applied to hepatocyte differentiation studies (Novik et al. 2008) as well as to in 
vitro model of excretion (Liu et al. 1999). 
In spite of all these factors, the use of collagen in culture brings several 
limitations to the culture. This gelatin matrix is from animal origin, bringing different 
species factors to the culture, with a high batch to batch variation (Kim and Mooney 
1998). Furthermore, there are also other drawbacks to its application to drug testing, 
namely it is observed that the mass transfer through the collagen matrix is poor 
which is accompanied by variable drug absorptions (Du et al. 2008).  
5.1.3. Cell Spheroids 
Hepatocyte spheroids (Fig. 1.6 C) are the best characterized 3D model with a 
wider range of applications as result of its simplicity, reproducibility and similarity to 
the in vivo system (Tung et al. 2010). The 3D hepatic spheroid is usually 
characterized by a smooth surface containing pore like openings that help on  
diffusion and can, in many cases, resemble the bile canaliculi (van Zijl and Mikulits 
2010). 
There are multiple possibilities of culturing 3D hepatospheres such as: 
spontaneous spheroid formation in non-adherent Petri dishes or well plates (Gurkan 
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et al. 2011); matrices/micropattern which facilitates the formation of spheroids (Lee et 
al. 2008; Okuyama et al. 2010; Fukuda and Nakazawa 2011) (cells are seeded on 
non-adhesive surfaces, such as 3D alginate porous scaffolds, where small amounts 
of cell suspension are incubated upside down until spontaneous spheroid formation 
occurs – hanging drops) (Tung et al. 2010); or even through the application of 
mechanical forces such as the rocking technique, employing a rotating wall vessel 
(Pampaloni et al. 2007; Brophy et al. 2009; Ishikawa et al. 2011) or even using 
stirred tanks (spinner vessels) (Abu-Absi et al. 2002; Miranda et al. 2009; Leite et al. 
2011; Tostões et al. 2011). 
In all the described cases, the common characteristic is the possibility to 
prolonge the life-span of hepatocytes by increasing their specific functionalities. 
Moreover, studies have demonstrated that hepatospheres can increase the genetic 
expression of both the xenobiotic metabolism and the lipid metabolism by increasing 
the up-regulation of leukotrine and cholesterol metabolism and of the synthesis of 
glutathione, albumin and ATP. In addition, hepatocytes cultured as 3D spheroids 
present an active urea cycle and express liver-enriched transcription factors (van Zijl 
and Mikulits 2010). 
 
In summary, spheroid cultures have been shown to be a promising 
physiological structure for in vitro toxicity assessment, to investigate the impact of 
drugs in the liver, but also for tissue engineering. The limitations of the 3D spheroids 
are dependent on the apparatus use to generate them, some of those limitations are 
described in the bioreactor section and also on Table 1.3. 
 
5.1.4. 3D Scaffolds 
Hepatocyte entrapped cells have been used in a diverse array of studies such 
as toxicity studies (Meng et al. 2007; Shen et al. 2008), cryopreservation (Guyomard 
et al. 1996; Rialland et al. 2000) and cell therapy applications (Clement et al. 1998; 
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Haque et al. 2005) showing successful results in terms of cell activity or protection 
from physical forces. 
The use of hydrogel matrices intends somehow to mimic the in vivo 
extracellular matrix (ECM) creating a more physiological stiffness. Providing a cell 
ECM will generate a microenvironment where the cells will be protected from 
external damages and the provided structural support will help to generate a 3D 
structure (Fig. 6 D). Besides the physical properties, these structures allow the ECM-
cell contact providing the cells with signaling moieties, proteins and growth factors 
present either on the gel molecular composition or immobilized within it. Moreover 
the entrapment of cells in gelic scaffolds allows the application of dynamic/perfused 
culture systems without cell damage (Mazzoleni et al. 2009). 
Currently, the selection of hydrogel scaffold methods is largely based on 
material availability, nonetheless in the case of hepatocyte cultures, Collagen, 
Matrigel and Alginate are preferably used. Properties like biodegradability and 
biocompatibility are a major concern due to the need to immobilize hepatocyte 
aggregates for tissue engineering and to generate bioartificial organs. 
Substantial efforts have been done to develop these applications; however 
there are still some limitations common in the use of hydrogels. The scaffold can 
modify randomly the cell behavior and dead cells might remain entrapped within the 
gel signaling the neighbor cells with necrotic factors. In addition to the already 
mentioned diffusion limitations and the unwelcome interactions within the scaffold, 
the gel can also induce variations on the nutrient, oxygen and metabolite 
concentrations  (Mazzoleni et al. 2009). 
 
5.2  Bioreactor Systems 
Mammalian tissues, due to their specific nutrient needs, sensitivity to 
nitrogenated wastes and their fragility to sheer stress have in general several 
limitations to their in vitro maintenance (Mazzoleni et al. 2009). Biotechnology 
developments are leading to bioreactors that closer and closer mimick the in vivo cell 
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environment. From the first approach, using orbital shaken Petri dishes, to the 
current state-of-the-art bioreactors have exponentially progress in terms of oxygen 
control, nutrient supply, amenable and well characterized environment. The concept 
of dynamic culture conditions has been introduced allowing for improved mass 
transport, especially in 3D cell structures. 
Many parameters have to be taken into consideration in order to develop an 
accurate system that mimics the in vivo milieu by adapting the necessary 
thermodynamic and environmental parameters. The specific surroundings of each 
tissue within the body require different optimal in vitro cell environments, which are 
obtained through the control and monitoring of the bioreactor settings such as flow, 
temperature, pH and oxygen, according to the cell’s demands. 
Regarding hepatocyte cultures, oxygen is a special sensitive parameter as it 
was already described in sub-Chapter 1.3. Hepatocellular oxygen uptake rates in 
culture are limited by the medium thickness as well as its surrounding oxygen 
concentration. In spite of the fact that hepatocytes can tolerate hypoxia, since they 
can satisfy their ATP levels by anaerobic glycolysis (Bader et al. 1999), this is 
nonetheless a non physiological  approach. 
Having limiting levels of oxygen in culture will affect hepatocyte polarization 
(Kidambi et al. 2009) and enzymatic performance, specially moonoxygenases 
reactions (phase I CYP 450) (Jungermann and Kietzmann 1997). On the other hand, 
supraphysiological oxygen concentrations lead to the formation of free radicals which 
in turns results in cell injury (Stevens 1965). The perfect balance can be obtained by 
using oxygen carries (Nahmias et al. 2006) or by culturing the cells in bioreactors 
since these allow to measure and control the oxygen levels in the medium, in 
addition bioreactors flow system helps diffusion both in the culture medium and in the 
cells. 
Furthermore, the possibility to impose different oxygenations can mimic 
pathological situations (such as tumours) as well as the perivenous (3-5%) and 
periportal oxygenations (8-9%) (Jungermann and Kietzmann 1997) known to 
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modulate the zonal gene expression and affect drug metabolism and toxicity (Allen et 
al. 2005; Yan et al. 2010). 
In toxicological studies it is important to have a system that does not imply the 
use of large amounts of compounds, but that at the same time can be expanded 
generating large amounts of cells in the same unique microenvironment allowing it to 
be compatible with screening tools that enable the parallelization of biological assays 
thus, facilitating better diagnostics and improving functionality. 
Over the last years, several bioreactors that allow the monitoring and control  
of the above described parameters have been develop with the aim of culturing 
hepatocytes as 3D cultures. These include hollowfiber systems (De Bartolo et al. 
2000), low shear perfusion systems (Chen 1992), stirred tank bioreactors (Reuss 
1995), airlift bioreactors (Wang et al. 2005) and rotary cell culture reactors (Saxena 
et al. 2007) among others. In this section the most relevant bioreactors currently 
being used for 3D hepatocyte culturing are discussed (Fig. 1.7). 
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5.2.1. Multi-compartment 3D perfusion bioreactors 
The perfused hollowfiber bioreactor developed by Gerlach et al (Fig. 1.7 A,B) 
(Gerlach et al. 1994) was designed based on the vascularized structure of the liver, 
having a synosoid like structure, with inlet and outlet of medium resembling the blood 
flow. The technology is based on the use of interwoven hollow fiber capillary 
membranes that provide independent, decentralized medium and gas supply to the 
cells located between the capillaries. When cultured in this type of bioreactors, 
porcine and human liver cells have shown to retain in vivo like properties and are 
arranged in tissue-like structures including the formation of biliary canalicular 
networks and neo-sinusoids (Zeilinger et al. 2004; Schmelzer et al. 2009), 
maintaining liver specific function such as urea and albumin synthesis, glucose 
metabolism and CYP activities. Later, similar results were obtained when culturing 
the hepatoblastoma cell line HepaRG (Darnell et al. 2011). Furthermore, this 
technology has been developed not only for toxicological applications but also as an 
extracorporeal liver support system, as in vitro liver cell cultures provide an option for 
bridging the organ functions until regeneration occurs or until transplantation can be 
performed (Schmelzer et al. 2009). Depending on the application, it is possible to use 
different sizes of the hollow-fiber bioreactor, being possible to minimize the use of 
expensive compounds using small volume bioreactors (Zeilinger et al. 2011). 
In spite of being a very good strategy for culturing hepatocytes, this system 
has the disadvantage of not allowing cell sampling/recover, for further analysis. 
Moreover, the possibility of polyethersulphone capillars influencing  the solubility of 
the drug test compounds in the medium cannot be clearly excluded. 
 
5.2.2. Rotational Wall Vessel (RWV)  
The Rotating Wall Vessel (RWV) bioreactors developed by N.A.S.A.’s 
Johnson Space Center technological research in USA (http://science.nasa.gov/ 
NEWHOME/br/bioreactor.htm) consists of an horizontally rotating, transparent 
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clinostats that leave no head space between atmosphere and culture medium (Fig. 
1.7 C-E). The rotation allows the formation of 3D spheroid structures that will improve 
the cell-cell contacts yielding a higher gene expression of several cell types 
(Mazzoleni et al. 2009). Since this system does not have internal moving parts, shear 
forces and turbulence normally associated with impeller-driven stirred bioreactors, 
are reduced to a minimum. The vessel design and motion avoids cell sedimentation 
and inadequate gas/nutrients supply guaranteeing the most favorable conditions for 
cell/tissue culturing (Mazzoleni et al. 2009). In general, the main relevant 
characteristic of RWV is to ensure a good ratio of low shear environment to high 
mass transfer.  
When applied to toxicological studies, the main limitation of RTW together with 
the fact of being an expensive technology is the impossibility to use for screening test 
purposes. 
 
5.2.3. Microfluidic / Multicompartmental bioreactors 
The Microfluidic or Multicompartmental bioreactors (MCmB) (Fig. 1.7F-H) are 
modular devices where different cell types are cultured in separated chambers but 
are connected by medium flow. In spite of their main common characteristics there 
are different types of microfluidic bioreactors that slightly differ from each other being 
possible to have microfabricated devices such as perfused microarray bioreactors 
(Powers et al. 2002), micro cell culture chambers (Lee et al. 2006) or  micro cell 
culture analogs (Sung and Shuler 2009). The cells within these devices can be 
entrapped in gels, organized as spheroids or attached to the wall of microchannels 
and microchambers located in the bioreactors.  
The advantages of the flow systems are the continuous renewal of nutrients 
and oxygen as well as the facilitated waste removal, these simultaneously induce 
shear stress which helps the diffusion inside the cells stimulating both cell growth 
and function (Vozzi et al. 2011). Furthermore, the flow creates physiological like 
situations on the hepatic tissues, such as liver zonation or shear stress (Tilles et al. 
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2001; Allen et al. 2005), and allows to perform drug metabolism induction following 
chemical administration (Fukuda and Nakazawa 2011). 
In a physiological perspective, this system resembles the human body. 
Studies carried on by Vinci et al. (Vinci et al. 2011) have shown that the culture of 3 
types of cells in this system, namely adipose tissue, endothelial cells and hepatocyte 
cells,  reproduces in vivo the regulatory characteristics act homeostatic-like regarding 
the control of glucose and in addition the metabolic cross-talking of hepatocytes 
leads to in vitro cell regulation.  
These systems have the additional advantages of being highly flexible 
towards adaption and being compatible with high-throughput technologies. However, 
the low volume of these reactors limits the sampling and metabolites analyses, as 
well as cells recovery. Furthermore, surface and edge effects are amplified whereas 
physiological cell–cell interactions are under-represented (Mazzei et al. 2010; Vozzi 
et al. 2011).  
The miniaturized characteristic of this bioreactors make them easy to work 
and cost effective regarding the use of culture medium and test compounds. 
However, they have inherent mass transfer limitations on the maintenance of 3D 
structures, only overcame by increasing the perfusion rates which implies a higher 
shear cell stress. Additionally, it is difficult to control parameters such as oxygen and 
pH in these microsystems.  
5.2.4. Stirred culture vessels  
Stirred culture vessels, including spinner vessels and environmental controled 
stirred bioreactors (Fig. 1.7 I-K), are hydrodynamically well described vessels with an 
inner impeller that generates convective forces provided by the stirrer and medium 
flows around the cells. This stirring, at the same time that allows spontaneous 
generation of 3D spheroids, helps the diffusion of nutrients and oxygen inside the 
cells and the removal of cell’s waste products.  
The main advantage of these bioreactors in comparison to the previously ones 
(Fig. 1.7 A-H) is the possibility of sampling and cell recovery during culture time. Cell 
Chapter I 
 
44 
sampling will allow an on-line cell characterization and quantification but also the 
feeding of smaller systems, such as well-plates, with cells from a common bulk for 
screening tests.  
Spinner vessels (Fig. 1.7 I) are very attractive approaches due to their 
simplicity and low costs, but on the other hand environmental control stirred 
bioreactors provide an automated control of the environment (Fig. 1.7 J,K), allowing 
the on-line monitoring and control of specific culture variables (temperature, pH, 
dissolved oxygen, nutrients) improving culture outcome and ensuring reproducibility. 
In the special case of oxygen, the sensitivity of hepatocytes to this parameter can be 
overcome by this type of bioreactors with internal probes and automatic gas injectors 
allowing the generation of a continuous oxygen supply avoiding the commun 
exposure of the cells to supraphysiological oxygen levels (Miranda et al. 2009; Leite 
et al. 2011; Tostões 2011; Tostões et al. 2011). 
However, these culture systems also present some drawback such as the 
production of spheroids with variable diameters (Tostões 2011), the need for 
significant high volumes and inducing some shear stress on the cells of the outside 
layer of the spheroids with the padle stirring.  
6. SCOPE OF THE THESIS 
This thesis is focused on the development of 3D strategies for hepatocyte 
culturing using bioreactor devices towards the development of in vitro competent, 
highly predictable methods for application on Drug development. More specifically, 
the 3D spheroid approach was used to culture hepatocytes in stirred vessels, taking 
the described advantages to enhance hepatocyte-specific functions and extend its 
life span in culture, thus improving on the previously available models. 
The overall goal was to obtain a more physiological, reproducible and robust 
approach that could be applied in drug testing for both acute and chronic toxicity. To 
achieve this, three relevant hepatic cultures were used:  
i) Human Hepatocytes, cells freshly isolated from human 
liver. These retain better the liver specific activities and are considered 
INTRODUCTION 
 
45 
C
h
ap
te
r 
I 
the golden standard of hepatic cultures. Aiming at prolonging human 
hepatocytes longevity by improving their metabolic profile a 3D strategy 
was used. 
ii) Rat Hepatocytes, freshly isolated from the animal. Since 
Human hepatocytes are sparsely available, while developing and 
optimizing the system rat hepatocytes were used instead of human 
hepatoytes as model system. 
iii) HepaRG cell line, was used as an alternative to the use of 
human hepatocytes. This human cell line has shown higher activity 
than other cell lines and could be an attractive alternative to the use of 
primary cultures, overcoming their limited availability problem. 
 
Specifically, the strategy developed intendeds to improve the hepatocyte 
biotransformation profile. When cultured in the environmental controlled stirred 
bioreactor, the parameters were set close to the in vivo values. To address the 
biotransformation capacity phase I and phase II activities were assessed during 
culture time by measuring CYP and UGT specific activities respectively. Moreover, 
as a whole system characterization, it was also monitored the albumin secretion and 
ammonia detoxification by synthesis of urea. These values together with 
immunofluorescence characterization of the cell spheroids could give an overall 
image of the system in development. 
Furthermore, to test the physiological response of the system, the 3D Cultures 
in stirred vessels were challenged by testing clearance, different oxygenations and 
toxicity, using specific reference compounds. The capacity of the cells to respond to 
induction was also evaluated as an important quality control of hepatic metabolism. 
Additionally, testing induction capacity of the hepatocytes, a complex cell path can be 
assessed by performing a simple assay. 
A schematic representation of the main goal proposed for this thesis as well 
as the strategy that was employed to address it is summarized on Figure 1.8. 
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 II 
RAT HEPATOCYTES IN 3D 
This chapter is based on the following manuscript: 
 
Toward Extended Functional Hepatocyte In Vitro Culture 
Joana P. Miranda, Sofia B. Leite, Ursula Muller-Vieira, Armanda 
Rodrigues, Manuel J.T. Carrondo, and Paula M. Alves (2009) 
Tissue Engineering: Part C, 15(2) (2009): 157-67. 
  
Sofia B. Leite had carried out all the experimental part performed on the bioreactor, as well 
as involved on the decisions on how to execute the experiments, as well as on the 
discussion and interpretation of the results. 
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ABSTRACT 
Primary cultures of human hepatocytes are a reference cellular model, because 
they maintain key features of liver cells in vivo, such as expression of drug-
metabolizing enzymes, response to enzyme inducers, and generation of hepatic 
metabolites. However, there is a restricted availability of primary hepatocytes, and 
they show phenotypic instability in culture. Thus, different alternatives have been 
developed to overcome the culture limitations and to mimic in vivo tissue material. 
Herein, culture conditions, such as medium composition, impeller type, and cell 
inoculum concentration, were optimized in stirred culture vessels and applied to a 
three-dimensional (3D) bioreactor system. Cultures of rat hepatocytes as 3D 
structures on bioreactor, better resembling in vivo cellular organization, were 
compared to traditional monolayer cultures. Liver-specific functions, such as albumin 
and urea secretion, phase I and phase II enzyme activities, and the capacity to 
metabolize diphenhydramine and troglitazone, were measured over time. Hepatocyte 
functions were preserved for longer time in the 3D bioreactor than in the monolayer 
system. Moreover, rat hepatocytes grown in 3D system maintained the ability to 
metabolize such compounds, as well as in vivo. Our results indicate that hepatocytes 
cultured as 3D structures are a qualified model system to study hepatocyte drug 
metabolism over a long period of time. Moreover, these cultures can be used as 
feeding systems to obtain cells for other tests in a short time.  
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1. INTRODUCTION 
Primary cultures of hepatocytes constitute a powerful tool that has been 
extensively used in biomedical research both in academia and in bioindustry settings. 
In particular, hepatocyte cultures have been extremely useful in drug development. 
Liver damage caused by medications or chemical compounds is a key reason for the 
ever increasing and expensive phenomenon of drug recalls. Because the liver is the 
main organ for biotransformation and metabolism of numerous endogenous 
substances and pharmacological agents, various in vitro liver models, including 
isolated liver slices and perfused livers, primary cultures of hepatocytes, and 
immortalized hepatic cell lines in different cultivation formats, have been utilized to 
better understand drug response in humans (Fabre et al. 1990; Castell et al. 2006). 
Although cultures of human hepatocytes would be the ideal model to perform such 
studies, to overcome interspecies differences in all aspects of hepatic function, their 
source is limited because they can only be obtained from liver biopsies (Li et al. 
1999; Grompe 2001). Rodent hepatocytes, on the other hand, have been 
successfully used in pharmacological and toxicological studies (Bort et al. 1999; Yan 
and Caldwell 2001; Jaeschke et al. 2002; Wang et al. 2002). These resources of 
hepatocytes have the advantage of being easy to access; the results drawn from 
these experiments are reproducible and consistent, and therefore optimal when it 
concerns to the development of new culture methods. Primary cultures of 
hepatocytes currently are the system that better mimics the organism. However, 
hepatocytes grown in culture and maintained under standard in vitro cell culture 
conditions are known to rapidly lose liver-specific functions, especially in 
biotransformation involving phase I and phase II enzymes (Skett et al. 1999). 
Therefore, a system where primary hepatocytes maintain in vivo–like hepatic-specific 
functions in culture for longer periods of time would powerfully contribute for drug 
metabolism research. Among many reasons that may account for a deficit of 
hepatocyte-like functions in vitro, cell adaptation to culture conditions after withdrawal 
from their organ environment seems to be one of the major problems. Several 
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strategies have been developed to overcome this loss of function, such as protein 
synthesis, cell membrane integrity, and maintenance of life span limit and of 
cytochrome P450 (CYP 450) activity (Li et al. 1999). Cultivation of hepatocytes on 
different extracellular matrices (Kern et al. 1997) and in different culture systems, or 
the supplementation of media with different hormones and growth factors was shown 
to improve in vitro hepatocyte quality (Kern et al. 1997; Nussler et al. 2001; Pfaller et 
al. 2001). Culturing hepatocytes as three-dimensional (3D) structures provide cells 
with an in vivo–like environment, enabling the retention of important hepatic functions 
(Dunn et al. 1989; Kern et al. 1997; Schmitmeier et al. 2006) without the need to add 
extracellular matrix components. Approaches such as gel encapsulating systems and 
spheroid cultures have dramatically improved our understanding of the role of 3D 
culture strategies upon hepatocyte functions, but in vitro and in vivo models under 
well-defined and reproducible conditions are still needed (Fischbach et al. 2007). To 
fully control a culture environment, one has to resort to bioreactors. Several 
bioreactors of bioartificial livers have already been applied in therapy (De Bartolo et 
al. 2000; Gerlach et al. 2003; Gerlach 2006; Son et al. 2006; Fiegel et al. 2008). 
Further, bioreactors for application in both pharmacological and toxicological studies 
have been developed (Brown et al. 2003; Schmitmeier et al. 2006). In our laboratory 
a system with a fully controlled environment, successfully applied to other cell types 
(Sa Santos et al. 2005), could be adapted to hepatocyte cultures bringing several 
advantages over the others. Besides providing a better control of cellular 
environment, it would give a more predictive response of in vitro cultures that would 
improve the economics of cell-based testing. Herein, the challenge was to establish a 
3D in vitro model for primary rat hepatocytes consisting of a fully controlled 
minibioreactor that would allow for drug screening. The final result consists of a 
stirred tank with a controlled environment (temperature, pH, and pO2), which is 
reproducible, allows access to the cells (sampling), and is amenable to large-scale 
use. Besides, it could be easily adaptable to other types of cells, such as human 
hepatocytes or even human embryonic stem cells (hESC)-derived hepatocytes, and 
to be used as a feeding system for parallel cell tests.  
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2. MATERIALS AND METHODS 
2.1. Rat hepatocyte isolation 
Hepatocytes were isolated from male Wistar rats, 6–9 weeks old, with 200–300g 
body weight (from Instituto de Higiene e Medicina Tropical, Lisbon, Portugal, Animal 
House). A two-step collagenase perfusion–based method described by Seglen 
(Seglen 1976), with slight modifications, was used. Briefly, the rats were 
anesthetized with an intraperitoneal injection of ketamine (90mg/kg body weight) and 
xylazine (10mg/kg body weight) solution. The liver was perfused via the vena portae 
for 10min with a perfusion buffer I (0.14M sodium chloride, 6.7mM potassium 
chloride, and 10Mm HEPES), adjusted to pH 7.5 with 2.4M ethylene glycol 
tetraacetic acid (EGTA) at 39ºC. Subsequently, perfusion was continued with a 
collagenase buffer, consisting of 67mM sodium chloride, 6.7mM potassium chloride, 
100mM HEPES, albumin (0.5%) adjusted to pH 7.6, and 4.8mM CaCl2 · 2H2O, at 
39ºC for 7min. The flow rate for the perfusion buffers was 10mL/min. After perfusion 
the liver was removed from the animal and dissociated in cold perfusion buffer I with 
10g/L of albumin. The resultant cell suspension was filtered through gauze, 
centrifuged for 10min at 50g, washed once with medium, centrifuged again, and 
resuspended in medium in a final concentration of not more than 3.5x106cells/mL. 
For the enrichment of the final hepatocyte population, an additional Percoll-step was 
included by layering 5mL of cell suspension over a 25% Percoll solution. After 
centrifuging at 1300 g at 4ºC for 20 min, hepatocytes were obtained as a pellet. The 
cell pellet was diluted in phosphate-buffered saline (PBS), centrifuged for 10 min at 
50 g, and washed twice with PBS for removing the Percoll solution. Finally, the cells 
were harvested in supplemented Williams’ E medium for culturing. The cellular 
viability of the isolated hepatocytes was assessed by trypan blue exclusion; routinely, 
values within an 85–95% range were obtained.  
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2.2. Cell culture  
Freshly harvested hepatocytes were cultured with Williams’ E medium 
supplemented with 10% fetal bovine serum (FBS) (v/v), 1.4µM hydrocortisone, 
0.032U/mL insulin, 15mM HEPES, 1mM sodium pyruvate, 1mM of nonessential 
aminoacids (NEAA), and antibiotics (100U/mL penicillin/100mg/mL streptomycin and 
40 mg/mL gentamicin) (Williams’ E complete medium), or Vito 142 basal medium 
(Vito medium) (Biochrom AG, Berlin, Germany) with the corresponding supplement 
supplied by the manufacturer and antibiotics (100U/mL penicillin/100 mg/mL 
streptomycin and 40 mg/mL gentamicin), added accordingly. In static monolayer 
cultures (two-dimensional (2D) cultures), cells were seeded onto Matrigel®-precoated 
culture plates at a density of 5x104cells/cm2. Hepatocytes were left untreated for at 
least 12h at 37ºC in a humidified atmosphere with 5% CO2 in air, allowing cell 
attachment. The medium was changed the following day to remove unattached cells. 
The culture medium was renewed every 24h, and the cells were routinely examined 
under phase contrast microscopy before every culture medium renewal. The 
supernatants and cells were collected according to the protocol at the indicated time 
points and stored at -20ºC for further assays. In stirred tank cultures (3D cultures), 
single-cell suspensions were seeded in 125mL spinner vessels or in a 250mL stirred 
tank bioreactor. An inoculum of 1.2x105cells/mL or 2.4x105cells/mL was used for a 
final volume of 70 or 200mL, in the spinner vessels or in the bioreactor, respectively, 
with supplemented medium at 15% FBS (to promote cell aggregation). Stirred tanks 
were placed on a magnetic stirrer, agitated at 60rpm, and kept at 37ºC in a 
humidified atmosphere of 5% CO2 in air. After 3h in culture, to avoid settling of the 
cells, the stirring rate was increased to 80rpm. After 24h, 50% culture medium was 
changed and added to a final culture volume of 125 or 250mL, in the spinner vessels 
or in the bioreactor, respectively, and the FBS concentration was adjusted to 10% 
(v/v). To maintain the aggregates, the operational mode applied was a 50% medium 
substitution (refeed mode) every 4 days, for nutrient availability and to decrease the 
accumulation of bioproducts of cellular metabolism that can be toxic to the cells. 
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Cells were counted using a Neubauer counting chamber, and the cell viability was 
determined by the trypan blue exclusion method. Cell counting data was presented 
as percentage of cell survival considering cell number at day 1 as 100%. 
 
2.3. Cultures in the bioreactor 
To ensure a fully controlled cell culture environment, a glass vessel (Fig. 2.1) 
that could be adapted to a commercially available bioreactor control unit (B-DCU; B-
Braun Biotech International, Melsungen, Germany) was designed and developed in 
our laboratory.  
 
 
Figure 2.1.: Minibioreactor apparatus. (A) Bioreactor controller module used to control pH, 
pO2, and temperature. (B) Glass vessel with multiple (up to eight) upper cap ports for different 
applications (e.g., pH and pO2 meters and sampling tube) and a water jacket where 
temperature is controlled by a thermocirculator bath. 
 
The internal geometry and the stirrer (paddle impeller) of the vessel are similar 
to the commercially available spinner vessels. The vessel has multiple (up to eight) 
upper cap ports for different applications, such as pH and pO2 meters (Mettler-
Toledo, Urdorf, Switzerland), that allow online measurement and control of these 
parameters, as well as easy sampling and the addition or removal of medium or 
other supplements or solutions. The pH is kept at 7.4 by injection of CO2 and 
addition of base solution (NaOH, 2M). The dissolved oxygen concentration is 
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maintained at 30% via surface aeration with air. The temperature was kept at 37ºC 
by water recirculation in the vessel jacket controlled by a thermocirculator bath. The 
bioreactor controller unit was used to monitor and control pH, pO2, and temperature. 
Data acquisition and process control were performed using Multiple Fermenter 
Control System for Microsoft Windows (MFCS)/Win Supervisory Control and Data 
Acquisition (SCADA) software (B-Braun Biotech International).  
 
2.4. Determination of lactate dehydrogenase activity 
The release of intracellular enzymes – in particular, lactate dehydrogenase 
(LDH) – in the culture supernatant can be correlated with cell viability along the 
culture. This approach assumes that higher rates of release of enzymatic activity 
correspond to increased cellular damage and thus a loss in culture viability (Racher 
1998). Hence, the extent of cell lysis was assessed by determination of LDH 
released to the medium as previously described by Vassault (Vassault 1983).  
 
2.5. Determination of albumin secretion and urea synthesis 
The secretion of albumin from hepatocytes was measured by an enzyme-linked 
immunosorbent assay (ELISA) using NEPHRAT albumin test kit (ref. NR002; 
Exocell, Philadelphia, PA). The assay was performed according to the 
manufacturer’s description. The results were expressed as mg/day/106cells at the 
indicated time point. The urea synthesis rate was determined using a quantitative 
colorimetric urea kit (QuantiChromTM Urea Assay Kit, DIUR-500, ref DIUR-500; 
BioAssay Systems), according to the manufacturer’s instructions. The results were 
expressed as mg/day/106cells at the indicated time point. 
 
2.6. Testosterone hydroxylation 
Testosterone is regio- and stereoselectively metabolized by CYPs to several 
hydroxylated metabolites that were extracted and analyzed. In this study, 4-
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androstene-3,17-dione (androstenodione), and 2α, 7α, 6β, and 16β-
hydroxytestosterone were analyzed. Briefly, 250 µM testosterone dissolved in culture 
medium was added to cells and incubated for 2h at 37ºC. Hydroxylated metabolites 
were extracted with dichloromethane. After centrifugation (2000g, 5min), the organic 
phase was collected to a new clean tube and allowed to evaporate. The pellets were 
resolubilized in a mixture of methanol and water (50%/50%, v/v) for high-
performance liquid chromatography (HPLC) analysis. Separations were performed 
on a 250x4mm RP18 Lichrocart, 5µm column using a Merck Hitachi LabChrom Elite 
chromatograph equipped with an autosampler, column oven, and diode array 
detector. Data analysis was performed with EZChrom Elite data system. 
 
2.7. 7-ethoxycoumarin-O-deethylase (ECOD) activity 
7-ethoxycoumarin-O-deethylase (ECOD) activity was measured according to 
Gomez-Lechon et al. (Gomez-Lechon et al. 1997) with slight modifications. 
Salicylamide (1.5mM) was added to the medium to prevent conjugation of 7-hydroxy 
metabolites (7-HC) of 7-ethoxycoumarin (Burke and Orrenius 1978). Therefore, 
hydrolyzation treatment with β-glucuronidase/arylsulfatase was overcome. The 
activity is expressed as nmol of 7-hydroxycoumarin formed per hour and per 106cells.  
 
2.8. Uridine diphosphate glucuronoltransferase activity 
The uridine diphosphate glucuronoltransferase (UGT) activity was determined by 
quantification of the substrate, 4-methylumbelliferone (4-MU), before and after cell 
incubation with the substrate. The procedure was performed according to Gomez-
Lechon et al (Gomez-Lechon et al. 1997) with slight modifications. Briefly, a 100µM 
solution of 4-MU in 0.01M PBS was incubated with cells for an hour at 37ºC. 
Samples were measured by fluorescence with emission at 450nm and excitation at 
320nm. The 4-MU remaining concentration was determined based on a standard 
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curve generated in PBS spiked with 0, 1.56, 3.12, 6.25, 12.5, 25, 50, and 100µM. 
The activity is expressed as nmol of 4-MU metabolized per hour and per 106cells. 
 
2.9. Preparation of test compounds 
All compounds used for metabolic stability assays were purchased from Sigma-
Aldrich (Taufenkirchen, Germany). Stock solutions were prepared by dissolving 
diphenhydramine in acetonitrile (Carl Roth, Karlsruhe, Germany) and troglitazone in 
dimethyl sulfoxide (Carl Roth) at a final concentration of 10mM. The highest solvent 
concentration used was 0.05% (v/v).  
 
2.10. Metabolic stability assay 
Stock solutions (10mM) in acetonitrile and dimethyl sulfoxide were diluted in 
Williams’ E complete medium to obtain working solutions. The concentration of final 
compounds during each assay was 5µM.  
In 2D cultures (24-well plates), the reaction was initiated by the addition of 
250µL of test item working solution at a concentration of 5µM to the pre-incubated 
hepatocytes at 37ºC for 5min. For 3D cultures, 125µL of the compounds stock 
solution (10mM) was added to the 250mL bioreactor 3D culture resulting in a final 
concentration of 5µM. Cell concentration in each culture system was as described in 
the Cell Culture section. Controls consisting of compounds dissolved in 
supplemented medium, but not in the presence of cells, incubated at 37ºC, were 
always performed in parallel. To stop the reaction, 250µL of the test item samples 
was removed from the incubations at the respective time points and processed for 
acetonitrile precipitation. Isolation of the test items was performed by addition of 
107µL acetonitrile containing the internal standard griseofulvin (ISTD, 1µM) to 
250µL sample and calibration standard, respectively. After vigorously shaking (10s), 
sonification (10s), and centrifugation (5000 g, 10 min), an aliquot of the particle-free 
supernatant was subsequently subjected to liquid chromatography-mass 
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spectrometry (LC-MS/MS) for analysis. The HPLC system consisted of a MS Plus 
pump (Surveyor, Waltham, MA) and an auto sampler (Surveyor). Mass spectrometry 
was performed on a TSQ Quantum Discovery Max triple quadruple mass 
spectrometer equipped with an electrospray (ESI) interface (Thermo-Finnigan, 
Waltham, MA) and connected to a PC running the standard software Xcalibur 1.4. 
 
2.11. Statistics 
The data presented for the different culture parameters represent mean values 
for three independent experiments with two determinations each. Comparison of 
mean values between 2D monolayer, 3D spinner, and 3D bioreactor cultures, as well 
as the effect of inoculum concentration study, was performed using an appropriate 
one-way analysis of variance (ANOVA) test. Data evaluation between 2D and 3D 
spinner cultures maintained with Williams’ E and Vito medium, on the other hand, 
was performed using a two-way ANOVA test. Multiple comparisons between groups 
in each case were performed using a Tukey’s honestly significant difference test. 
Level of confidence was set at α=0.05 for all tests, with p-values lower than 0.05 
considered statistically significant. 
 
 
3. RESULTS 
3.1. 3D culture optimization 
Evaluation of culture conditions that better granted specific hepatocyte cellular 
functions, using previously established biochemical assays, was examined. Albumin 
secretion and urea secretion by hepatocytes are indicators for long term functional 
performance of hepatic cultures, whereas the activity of phase I (such as CYP 450) 
and phase II enzymes mirrors the capacity of hepatocytes to metabolize xenobiotics.  
On the other hand, general culture parameters, such as LDH, glucose, and 
lactate levels, have also been considered. The spheroid performance as 3D 
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structures cultured in spinner vessels (3D cultures) was evaluated against 
conventional cultures in monolayer static conditions (2D cultures).  
Immediately after isolation, cells were inoculated in 3D and 2D conditions and 
allowed to stabilize overnight. Cultures were maintained for 2 weeks.  
 
 
 
Figure 2.2.: Phase contrast microscopy with an amplification of 100x, of a 3D hepatocyte 
spheroid, cultured in stirred tanks and sample collected at day 3 of culture. 
 
 
Stirring rate in suspension cultures was kept at 60 rpm overnight. On day 1, cell 
adhesion to the plastic surface of the culture dish was observed in static conditions, 
whereas in suspension cultures small tightly packed groups of cells, of approximately 
100µm, were detected. During the remaining culture time, stirring rate was increased 
to 80 rpm in 3D cultures; spheroids became larger, reaching sizes of 100–300µm in 
diameter (Fig. 2.2). Such size range was not critical regarding the formation of 
necrotic centres as assessed by LDH (data not shown).  
In both monolayer (2D) and spheroid (3D) cultures, no cell proliferation was 
observed, as expected for hepatocyte primary cultures. However, in general, 
approximately 2.5-fold higher viability for a longer period of time (as shown in Fig. 
2.5 D) could be achieved when hepatocytes were cultured as 3D structures. 
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3.1.1. Effect of inoculum concentration, impeller type and medium 
composition on cultures performance.  
Two different inoculum concentrations (1.2x105 and 2.4x105 cells/mL) and two 
impeller types (ball and paddle) were compared when optimizing the 3D culture 
conditions. As for culture performance, the albumin secretion levels and ECOD 
activity did not vary much with different impeller (data not shown) or inoculum 
concentrations within 3D cultures, although they were consistently higher in 3D than 
in 2D conditions (Fig. 2.3) (p<0.05).  
Albumin production decreased dramatically in 2D cultures, reaching residual 
levels after 2–3 days in culture, whereas 3D cultures allowed albumin secretion to 
continue for more than 8 days in culture (Fig. 2.3 A). ECOD activity, on the other 
hand, was generally five times higher in 3D cultures than in 2D cultures (Fig. 2.3 B) 
(p<0.05). No significant difference could be observed between cultures with an 
inoculum of 1.2x105 and 2.4x105 cells/mL at days 2 and 7 of culture (p>0.05). Urea 
synthesis was significantly higher in spheroid cultures with an inoculum of 1.2x105 
cells/mL (p<0.05). Moreover, overall synthesis of testosterone metabolites was also 
higher in the later culture conditions, detectable up to day 12.  
In summary, spheroid cultures, with an inoculum of 1.2x105 cells/mL using a 
paddle impeller, resulted in enhanced hepatocyte functionality.  
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Figure 2.3.: Effect of culture time in (A) 
albumin secretion and (B) activity of phase I 
enzyme ECOD for cells cultured in monolayer 
2D(white bars) and spinner vessels 3D with 
paddle impeller with an inoculum 
concentration of 2.4x105 cells/mL (black bars) 
and 1.2x105 cells/mL (gray bars). 
Figure 2.4.: Effect of culture time on (A) 
albumin secretion and (B) activity of phase I 
enzyme ECOD for cells cultured in Williams’ 
E medium in monolayer 2D (white bars) and 
spinner vessels 3D (black bars), Vito 
medium in monolayer 2D (hatched bars), 
and spinner vessels 3D (gray bars). 
 
Regarding medium composition, Williams’ E medium and Vito medium were 
selected. Our results showed that although spheroids cultured in Vito medium 
allowed 20% higher survival rate maintenance, 3D cultures in Williams’ E resulted in 
significantly higher albumin secretion (Fig. 2.4 A) (p<0.05), for longer periods of time, 
never reaching residual levels before day 9, whereas with Vito medium residual 
levels were observed after 3 days in culture.  
Overall, CYP 450 activity, determined by measuring ECOD (Fig. 2.4 B) and 
testosterone metabolites (data not shown), was significantly higher in 3D when 
Williams’ E medium was used (p<0.05). Therefore, Williams’ E medium was adopted 
in the following cultures. However, in cell cultures a compromise between cell 
viability and cell functionality must be achieved; in hepatocyte cultures for 
pharmacological purposes, it is critical to keep hepatocytes functionality for as long 
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as possible; therefore, Williams’ E medium overall results showed greater advantage 
over Vito medium results. 
 
3.2. Metabolic performance of bioreactor cultures 
Because the optimized 3D cultures in spinner vessel improved liver-specific 
functions, we went forward to apply the optimized parameters to a bioreactor (fully 
controlled environment) (Fig. 2.5 A–C) where an equivalent or better culture 
performance could be expected. Cultures were maintained for a total of 21 days in 
the bioreactor, as well as in spinner vessels and in monolayer, herein used as control 
cultures. Higher survival rates could be achieved when hepatocytes were cultured as 
3D structures (Fig. 2.5 D), confirming the results obtained in spinner vessels 
described above.  
 
 
Figure 2.5.: Profiles of (A) pH, (B) jacket temperature, and (C) dissolved oxygen (pO2) collected in the 
bioreactor used for the cultivation of hepatocyte spheroids. (D) Survival rate curves of rat hepatocytes 
cultured in monolayer 2D (•),  bioreactor 3D (), and spinner vessels 3D () culture systems. 
 
In both 3D cultures, after an adaptation phase that lasted about 3–4 days, cells 
showed relatively stable metabolic activity over at least 10 more days of culture. LDH 
leakage rates were high at day 1 but declined during the culture time, followed by a 
slow increase from day 14 in 3D cultures.  
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Biochemical data for days 4–14 showed no significant difference among 3D 
cultures, whereas 2D cultures reached residual levels after 2–3 days in culture 
without recovering. In 3D bioreactor cultures, urea secretion (Fig. 2.6 A) values were 
maintained at a stable level, showing only a slight decrease from day 14 onward. 
Still, urea production was significantly higher in 3D bioreactor than in the other two 
culture systems (p<0.05). Albumin production (Fig. 2.6 B) in 3D bioreactor culture 
after day 1 was maintained at nearly constant levels throughout culture time, 
decreasing approximately 75% only on day 21. Significantly higher albumin 
production values were obtained in 3D culture systems (p<0.05), although even 
higher in the 3D bioreactor cultures (p<0.05). 
 
 
 
Figure 2.6.: Functional capacity of hepatocytes 
over long-term cultivation periods was assessed 
by determining (A) urea production and (B) 
albumin secretion by the cells cultured in 
monolayer 2D (white bars), bioreactor 3D (black 
bars), and spinner vessels 3D (gray bars) culture 
systems. 
Figure 2.7.: Hepatic metabolic function was 
assessed by determining the activities of (A) 
phase I enzymes ECOD and (B) phase II 
enzymes UGT in cells cultured in monolayer 2D 
(white bars), bioreactor 3D (black bars), and 
spinner 3D (gray bars) culture systems. 
 
The testosterone metabolism and ECOD activity are critical routine assays to 
determine the activity of the CYP 450 (CYP) isozyme system. In Figure 2.7 A, it is 
shown that ECOD activity was significantly improved in 3D cultures when compared 
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to 2D cultures from day 1 onward (p<0.05), with even higher values being obtained in 
the bioreactor (p<0.05).  
Concerning the testosterone metabolism, metabolites such as androstenodione 
and 2α, 7α, 6β, and 16β-hydroxytestosterone were considered. The formation of 
those metabolites by isolated hepatocytes cultured in 2D and 3D conditions 
(spheroids cultured in spinners vessels or in the bioreactor) during 21 days was 
quantified. The quantity of hydroxytestosterone metabolites produced by freshly 
isolated cells was variable depending on the metabolite and on the culture system. 
However, clearly testosterone hydroxylation profiles were always higher in both 3D 
systems. In monolayer cultures, results showed that the testosterone metabolism 
dropped dramatically after day 4 in culture, where no more activity could be detected. 
In contrast, in 3D bioreactor cultures, activity increased with culture time to 
approximately 4.5-fold that of fresh cells after 3–4 days in culture. Testosterone 
metabolites were detected up to day 16 in the bioreactor culture and up to day 12 in 
the spinner vessels. Metabolism of testosterone to 6β and 2α-hydroxytestosterone 
was similar in both 3D culture systems, showing average values of 
4.4pmol/min/106cells and 4.6pmol/min/106cells, respectively. On the other hand, 
metabolism of testosterone by combined CYP 2B1, 2C11, and 2B2 activity (resulting 
in the formation of androstenodione) in the bioreactor was 5.2-fold greater than in the 
spinner vessel. Metabolism of 7α-hydroxytestosterone and 16β-hydroxytestosterone 
in the bioreactor was 3.2- and 2.7-fold greater than in the spinner vessel, 
respectively.  
Among phase II enzymes, UGT is involved in conjugation processes of 
substrates. Figure 2.7 B shows results for UGT activity. A significant improvement of 
UGT activity in the bioreactor system could be observed (p<0.05) reaching a 
maximum activity at day 14 when compared to the other two culture systems. 
Although a considerably lower activity was found, the hepatocytes cultured on 3D 
structures in the spinner vessel still exhibited a UGT activity significantly higher than 
those cultured in monolayer (p<0.05). 
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3.3. Metabolic stability assays 
 
 
Figure 2.8.: Metabolic stability of (A) diphenhydramine and (B) troglitazone observed in 
hepatocyte primary cultures in bioreactor 3D at day 2 (•) and day 21 () of culture; and in 
monolayer 2D at day 2 () of culture. 
 
To further validate the newly developed bioreactor-based 3D primary 
hepatocytes culture system, metabolic stability of a couple of compounds 
(troglitazone and diphenhydramine) was examined both in the 3D bioreactor and in 
the 2D culture system. The incubations were always performed in supplemented 
medium because this was mandatory for the bioreactor and data had to be 
comparable. No influence of the incubation medium in the compounds metabolism 
was observed. In Figure 2.8 A and B, it is shown that, at day 2 of culture, cells in 
both culture types were able to metabolize the compounds equally. Moreover, at day 
21 bioreactor cells in 3D cultures were still able to metabolize the compounds, 
whereas in 2D cultures, because cell viability was very low (Fig. 2.5 D), the same 
could no longer be performed.  
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4. DISCUSSION 
 
An important scientific achievement in this study was the development of an 
alternative in vitro hepatocyte culture system that can be used for both toxicological 
and pharmacological studies. 
The choice of a 3D system was based on the fact that hepatocytes retain both 
high viability and differentiated liver functions when cultured as 3D aggregates. This 
was shown by Li et al. (Li et al. 1992) who successfully cultured viable spheroids on 
non-tissue culture plastic plates for 1 month. Li et al. and Yoffe et al. (Yoffe et al. 
1999) were also among the first authors to report hepatocyte aggregates cultured in 
rotating wall vessels. Aggregates could be cultured for a prolonged period with 
differentiated cell morphology and functions. The advantage of our system over 
previously described in vitro models is that it conjugates several characteristics that 
are important for functional hepatocytes culture and for culture practicability in 
general. The cells were cultured in a fully controlled environment bioreactor where 
sampling throughout the whole culture time was made possible. It is a setup based 
on commercially available equipment and therefore accessible to any laboratory or 
company. Such system decreases the biological cell-to-cell and culture-to-culture 
variability that has thus far limited the size of cell based experiments. Further, not 
only this minibioreactor did allow for oxygen control in suspended cultures (Moreira 
et al. 1995; Balis et al. 1999) but also the stirred tank environment enabled a better 
medium oxygenation further resembling the physiological blood flow (Bader et al. 
1999). It has been shown that the absence of oxygen in culture can lead to a cellular 
metabolic state of sensitive or even rapid hypoxic injury, due to the depletion of 
dissolved oxygen; regular culture conditions do not allow this control as a bioreactor 
would (Cho et al. 2007). 
In this study, before the application of the 3D hepatocyte cultures to the 
bioreactor system, some culture parameters were tested in spinner vessels to 
establish a culture system for hepatocytes in vitro maintenance. The maintenance of 
a viable cell culture in suspension conditions requires optimization of several 
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cultivation parameters. In particular, for spheroid cultures, it is mandatory to control 
their size hydrodynamically, to avoid necrotic centers resulting from oxygen and 
nutrient transport limitations. Experimental parameters such as stirring rate and 
impeller design can be optimized to circumvent such drawbacks without the 
decrease in culture viability (Moreira et al. 1995).  
Moreover, medium composition and inoculum concentration are also crucial 
parameters to be considered when developing a new culture system. Therefore, 
parameters such as inoculum concentration, medium formulation, impeller type, and 
stirring rate were studied herein.  
Concerning the media, higher survival rates, but lower hepatocyte-specific 
activities were observed with Vito medium than with Williams’ E medium. Probably, it 
was due to the fact that Vito medium was designed for culturing human rather than 
rat hepatocytes, although it was specially developed for culturing hepatocytes in 
bioreactors (Zeilinger et al. 2002). On the other hand, both the lower inoculum 
concentration and paddle impeller type showed better results (Fig. 2.3), the lower 
inoculum being an advantage to minimize the low availability of hepatocytes. 
In this context, the optimized conditions (1.2x105 cells/mL inoculum, cultured in 
supplemented Williams’ E medium with a paddle impeller) were used in the 
bioreactor. 
Hepatocyte-specific functions such as albumin and urea secretion are important 
indicators when evaluating hepatocyte cultures. Albumin secretion is a general 
marker of protein synthesis in hepatocytes as it is synthesized almost entirely by the 
liver. It is a source of amino acids for various tissues. Decreased albumin level can 
serve as an index of impaired synthetic protein capacity by the liver (Weigand and 
Otto 1974). Likewise, the conversion of ammonia to urea is a vital liver function. The 
ammonia produced through amino acid deamination can be detoxified by the 
combination of ammonia with CO2 to form urea in the liver (Watts et al. 1995). In this 
study, albumin secretion rapidly decreased in monolayer cultures but not in 3D 
cultures. This is not an unexpected finding because studies of the albumin 
metabolism have shown that the synthesis and albumin secretion by isolated 
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hepatocytes occur only in early culture phases (Weigand and Otto 1974). However, 
in our culture system this effect was circumvented because albumin secretion could 
be detected throughout a significant period of time, decreasing only after day 14.  
Although higher values were observed in both 3D culture systems, in contrast to 
the 2D system, the bioreactor clearly showed higher values than the spinner vessels. 
Accordingly, in both 3D cultures urea production levels were clearly higher than 
those produced by hepatocytes cultured in monolayer. Still, higher levels were 
observed in the bioreactor than in the spinner vessel, suggesting that not only does 
growth in 3D structures enhance liver-specific functions, but also a fully controlled 
environment, resembling the in vivo conditions, is an issue in this type of cultures. 
One parameter further controlled in the bioreactor is the dissolved oxygen, a key 
factor on hepatocyte cell long-term cultures (Bader et al. 1999). Therefore, an 
oxygenated environment may be the reason why better results are observed in the 
bioreactor. 
 Biotransformation of xenobiotics by cultured hepatocytes can be assessed in 
terms of activity using specific substrates. Synthetic substrates metabolism by 
primary cultures of hepatocytes cultured in plates and in stirred tanks (spinner 
vessels and bioreactor) was examined by measuring phase I and phase II enzyme 
activities. The functionality of CYP 450 enzymes in the culture systems was assayed 
via the regiospecific hydroxylation of testosterone and the 7-ethoxycoumarin O-
deethylation (ECOD activity), whereas phase II enzymes were assayed by UGT. 
Metabolism of several endo- and exogenous substances is carried out by a set of 
phase I and phase II enzymes. Their activities determine the overall therapeutic and 
toxic profiles of a drug (Schenkman 1993). The 6β-hydroxylation of testosterone is 
predominantly mediated by CYP 3A, the major isoform being 3A4 in humans 
(Waxman et al. 1991) and 3A1 in rats (Sonderfan et al. 1987). Oxidation of 
testosterone to 4-androstene-3,17-dione in rats is predominantly catalyzed by CYP 
2B1 with minor contributions from CYP 2C11 and CYP 2B2 (Sonderfan et al. 1989). 
In human hepatocytes, CYP 2C19 and to a lesser extent CYP 2C9, are responsible 
for production of 4-androstene-3,17-dione, with potential contribution from CYP 2B6 
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(Yamazaki and Shimada 1997). 2α-Hydroxylation is predominantly mediated by CYP 
2C11 in rat (Sonderfan et al. 1989). A CYP 2C11 orthologous enzyme has not yet 
been identified in humans, but 2α-hydroxylation is presumably mediated by an 
enzyme belonging to the 2C subfamily (Raucy et al. 2002; Thomas et al. 2005). 
ECOD activity in rat hepatocytes is mostly mediated by CYP 1A and 2A families 
(Rogiers et al. 1986). Research in the area of drugs biotransformation in static 2D 
primary human and rat hepatic sandwich cultures has revealed a preservation of the 
major forms of phase I and phase II enzymes that respond to rifampicin by increasing 
their activities (Kern et al. 1997). However, the long-term maintenance of the phase I 
enzymes Ethoxyresorufin-O-deethylase (EROD) (CYP1A1/2) and ECOD 
(CYP2B1/2), as well as of the phase II enzyme UGT, was achieved in sandwiched 
primary porcine hepatocyte cultures in a dynamic flat-sheet bioreactor with a gas-
permeable membrane (Langsch and Bader 2001) and in a small-scale bioreactor 
with an hepatic sandwich model and a gaspermeable membrane (Schmitmeier et al. 
2006). Similarly, our work using a fully controlled bioreactor showed that these 
activities were also well preserved in rat hepatocytes. Here, the importance of an 
adequate oxygenation for the phase I, but mostly phase II metabolism, is 
emphasized by the lower activities in spinner vessels and by the lack of an effective 
phase I and phase II enzymatic activities in the conventional 2D monolayer culture 
dishes after 2–3 days in culture. 
The metabolic stability of a drug candidate is an important consideration in 
determining its potential for human use. Those studies are usually conducted during 
earlier stages of drug development to allow the selection of structures with the most 
appropriate stability for further development.  
Because of the presence of all hepatic drug metabolizing enzymes and cofactors 
at physiological levels, intact hepatocytes represent a more relevant experimental 
system than liver microsomes for general metabolic stability screening. An interesting 
achievement in the application of intact hepatocytes for the evaluation of metabolic 
stability is the incubation of the test compound and hepatocytes in 100% human 
serum, therefore providing an experimental condition similar to humans in vivo. For 
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instance, it has been reported that hepatic clearance in vivo can be predicted more 
accurately from data obtained with hepatocytes incubated in serum than from data 
obtained in the absence of serum, using either rat or human hepatocytes (Li 2007). 
Thus, the use of a compound whose behavior in metabolic stability assays is known 
can be considered as reference for the evaluation of a culture system under 
development. In this work, metabolic stability of reference compounds 
(diphenhydramine and troglitazone) was evaluated with the new in vitro culture 
system using serum-supplemented medium. In fact, the results clearly showed that 
compound clearance was as in vivo, thus highlighting its potential for 
pharmacological studies.  
This work shows that it is possible to culture primary rat hepatocytes as 3D 
structures using a fully controlled bioreactor and that this culture strategy improves 
hepatocyte functionality. By more closely resembling the in vivo environment, due to 
its three-dimensionality and cell–cell interaction, this model supported long-term 
viability and the maintenance of several differentiated hepatocytes properties, 
including xenobiotic metabolism, for up to 21 days. In contrast, traditional monolayer 
cultures lost these properties after 3-4 days in culture. Therefore, this system offers a 
much improved alternative culture system for predictive in vitro studies, to study 
mechanisms of CYP isoforms and to perform metabolic stability studies. It is also a 
new method for testing drug interaction under 3D conditions, because it has the 
advantage of offering a better in vitro–in vivo correlation. This culture system can be 
implemented for primary human hepatocytes avoiding interspecies differences. 
Another promising application is for human stem cell–derived hepatocytes culture, 
which is currently being assessed in our laboratory. 
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ABSTRACT 
 
During the last years an increasing number of in vitro models have been 
developed for drug screening and toxicity testing. Primary cultures of hepatocytes 
are, by far, the model of choice for those high-throughput studies but their 
spontaneous dedifferentiation after some time in culture hinders long-term studies. 
Thus, novel cell culture systems allowing extended hepatocyte maintenance and 
more predictive long term in vitro studies are required.  
It has been shown that hepatocytes functionality can be improved and extended in 
time when cultured as 3D-cell aggregates in environmental controlled stirred 
bioreactors. In this work, aiming at further improving hepatocytes functionality in such 
3D cellular structures, co-cultures with fibroblasts were performed. An inoculum 
concentration of 1.2x105 cell/mL and a 1:2 hepatocyte:mouse embryonic fibroblast 
ratio allowed to improve significantly the albumin secretion rate and ECOD (phase I) 
and UGT (phase II) enzymatic activities in 3D co-cultures, as compared to the 
routinely used 2D hepatocyte monocultures. Significant improvements were also 
observed in relation to 3D monocultures of hepatocytes. Furthermore, hepatocytes 
were able to respond to the addition of Beta-Naphtoflavone by increasing ECOD 
activity showing CYP1A inducibility. The dependence of CYP activity on oxygen 
concentration was also observed. In summary, the improved hepatocyte specific 
functions during long term incubation of 3D co-cultures of hepatocytes with 
fibroblasts indicate that this system is a promising in vitro model for long term 
toxicological studies. 
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1. INTRODUCTION  
Primary cultures of freshly isolated hepatocytes are currently the in vitro model 
of choice for drug screening applications. When cultured under well-defined and 
stringent conditions, these primary cells perform alike common hepatocyte cell lines 
(e.g. HepG2) in terms of ability to induce P450 (CYP) activity upon addition of 
specific compounds; however, they have improved synthesis and secretion rates of 
both albumin and urea as well as improved capacity for phase I metabolism (Donato 
et al. 1994; Viollon-Abadie et al. 2000; Gebhardt et al. 2003). 
As explain on Chapter I, hepatocyte cultures of human origin can be obtained 
from different sources. However, these cells are rather difficult to obtain and often 
their profile is highly dependent on the donor sources presenting a high batch-to-
batch variability. Primary cultures of rat hepatocytes are a good alternative often 
used by the pharmaceutical industry because (i) they have higher metabolic 
responses than common human cell lines and (ii) the inter-donor variability can be 
minimized by selecting animals of the same sex, age and similar feeding regimes 
(Coecke et al. 2000; O'Brien et al. 2004). Moreover, the strategies developed to 
improve hepatocytes functionalities can often be applied easily to primary human 
hepatocytes.  
Conventional 2D in vitro models of hepatocytes present the major drawback of 
quick loss of expression of specific liver-functions (O'Brien et al. 2004). Strategies to 
decrease or, ideally, overcome, in vitro dedifferentiation of hepatocytes constitute a 
major goal in drug development. Several reports on the effect of (i) extracellular 
matrices (ECM) that promote cell adhesion (Skett 1994) and/or of (ii) 3D culture 
methodologies (cell spheroids) that allow for a closer to in vivo cell-cell contact 
(Rotem et al. 1992; Fischbach et al. 2007; Pampaloni et al. 2007; Yamada and 
Cukierman 2007; Lin and Chang 2008), in hepatocytes functionality, are available in 
the literature. In particular, different studies have shown that cell-cell interactions, 
especially heterotypic cell interactions (Bhatia et al. 1998), are more effective in the 
maintenance of hepatocyte functions than ECM configuration (Michalopoulos et al. 
1979; Khetani and Bhatia 2008). Significant enhancements in hepatocytes 
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phenotype maintenance and function were described for co-cultures of hepatocytes 
with connective tissue or non-parenchymal cells (Bhatia et al. 1998; Bhandari et al. 
2001; Lu et al. 2005; Khetani and Bhatia 2008). These cells are able to either secrete 
soluble signaling molecules (e.g. cytokines, hormones and growth factors) or provide 
other cell-associated signals (i.e., insoluble extracellular matrix or membrane bound 
proteins). Furthermore, the combined strategy of co-cultures and 3D cellular 
organization permits cell-to-cell interactions between both cell types at various points 
of contact, as oppose to the single anchorage site between co-cultured cells 
maintained in 2D (Lu et al. 2005).  
Fibroblasts are the most common cell type of connective tissue with a crucial 
role in the synthesis of extracellular matrix for tissue remodeling and repair. 
Additionally, they are the main producers of hepatocyte growth factor (HGF) (Stoker 
et al. 1987), a molecule involved in anti-apoptotic mechanisms in hepatocytes 
(Hiramatsu et al. 2005), and as they have no ability of xenobiotic biotransformation 
their metabolism does not interfere in toxicological  assays (Donato et al. 1990).  
Mouse fibroblasts have been successfully used as feeder cells of rat hepatocytes 
(Bhatia et al. 1998; Kang et al. 2004; Lu et al. 2005; Cho et al. 2008; Kidambi et al. 
2009; Miyamoto et al. 2009). Also, the presence of human markers on feeder cells 
has been shown to improve rat hepatocyte functionalities (Michalopoulos et al. 
1979). Recently, Cho et al. (Cho et al. 2010) reported uniform intracellular albumin 
staining and E-cadherin expression, increased liver-specific functions and active 
glycogen synthesis in the hepatocytes when they were co-cultured in 2D with 
fibroblasts in a controlled microenvironment and the heterotypic interface between 
both cell types was increased by the layered patterning technique.  
 Several bioreactors have been developed for culturing hepatocytes, in 
particular for  cell therapy applications (e.g bioartificial livers) (De Bartolo et al. 2000; 
Gerlach et al. 2003; Son et al. 2006; Fiegel et al. 2008) or for pharmacological and 
toxicology studies (Brown et al. 2003; Schmitmeier et al. 2006). The bioreactor 
technology presents several advantages for cell culturing as it allows a well defined 
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environment with control of critical culture parameters such as oxygen concentration, 
pH and temperature (Sa Santos et al. 2005; Miranda et al. 2009; Miranda et al. 
2010). In particular, it is known that an adequate oxygen delivery to hepatocytes in 
culture is imperative for the maintenance of liver-specific functions such as alanine 
transferase, aspartate aminotransferase or phase I and phase II biotransformation 
enzymes, as gene expression rapidly declines when the cells are exposed to low 
oxygen concentrations (Cho et al. 2007). Moreover, cultures performed in stirred tank 
bioreactors can be sampled over culture time, with minimal perturbation and without 
compromising the sterility of the culture. Additionally, these bioreactors can be 
instrumented with specific devices to support perfusion operation which has been 
shown to bring additional advantages to hepatocyte cultures (Tostoes et al. 2011). 
Previous work from our group showed improved and extended functionality for 
hepatocytes cultured as 3D spheroids (or aggregates) in small scale stirred tank 
bioreactors (Miranda et al. 2009). In the present work we aimed at improving even 
further this in vitro model by combining it with a co-culture approach. Taking the 
advantages of an accurate system for oxygen monitoring and control, the effect of 
oxygen concentration in hepatocytes functionality was also assessed.  
 
2. MATERIALS AND METHODS 
2.1. Animals, Materials and Biologics 
Wistar male rats (6-9 weeks old, with 200–300 g body weight) were obtained 
from the animal house of Instituto de Higiene e Medicina Tropical (Lisbon, Portugal). 
All animal experiments were performed according to experimental procedures 
approved by the Portuguese Ethics Committee on animal experimental research. 
Williams’E medium, Essential Medium Eagle (MEM), foetal bovine serum (FBS), 
phosphate-buffered saline (PBS) solution and trypsin-EDTA as well as the remaining 
medium supplements were purchased from Invitrogen (Glasgow, UK). Culture flasks 
were obtained from Nunc (Roskilde, Denmark). The cell membrane labeling kit 
(PKH67 Fluorescent Cell Linker Mini Kit) was purchased from Sigma.  
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2.2. CELL CULTURES 
2.2.1. Rat hepatocyte isolation and 2D cultures maintenance 
Hepatocytes were isolated from rats using the two-step collagenase  
perfusion–based method described by Seglen (Seglen 1976) with slight 
modifications. Briefly, the rats were anesthetized with an intraperitoneal injection of 
ketamine (90 mg/kg body weight) and xylazine (10 mg/kg body weight) solutions. 
The liver was perfused via the vena portae for 10 min with perfusion buffer I (0.14 M 
sodium chloride, 6.7 mM potassium chloride and 10 mM HEPES), adjusted to pH 7.5 
with 2.4 mM EGTA at 37ºC. Subsequently, perfusion was continued with a 
collagenase buffer, consisting of 200 mg/L collagenase P (Roche applied Science), 
67 mM sodium chloride, 6.7 mM potassium chloride, 100 mM HEPES, Bovine Serum 
Albumin (BSA, 200 g/L) adjusted to pH 7.6, and 4.8 mM calcium chloride dihydrated, 
at 37ºC for 7 min. The flow rate for the perfusion buffers was 10 mL/min. After 
perfusion the liver was removed from the animal and dissociated in cold perfusion 
buffer I with 10 g/L of albumin. The resultant cell suspension was filtered through 
gauze, centrifuged for 10 min at 50 g, washed once with medium, centrifuged again, 
and resuspended in medium in a final concentration of 3.5x106 cells/mL. An 
additional Percoll-step was included for hepatocytes purification thereby eliminating 
both non-viable and non-parenchymal cells, by layering 5 mL of cell suspension over 
a 25% Percoll solution. After centrifuging at 1300 g at 4ºC for 20 min, the pellet of 
hepatocytes was diluted in PBS, centrifuged for 10 min at 50 g, and washed twice 
with PBS for removing the Percoll solution. Finally, the cells were resuspended in 
complete Williams’ E medium (described below). The viability of the freshly isolated 
hepatocytes was assessed by counting the cells in a haemaocytometer using the 
trypan blue exclusion method; values within an 85–95% range were routinely 
obtained.  
For 2D cultures, freshly harvested hepatocytes were seeded onto matrigel® 
pre-coated culture plates at a density of 5x104 cells/cm2 total cells. Hepatocytes were 
cultured with WilliamsE medium supplemented with 10% FBS (v/v), 1.4 µM 
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hydrocortisone, 0.032 U/mL insulin, 15mM HEPES, 1mM sodium pyruvate, 1mM 
non-essential aminoacids, and antibiotics - 100 U/mL penicillin, 100 mg/mL 
streptomycin and 40 ug/mL gentamicin (WE complete medium). In 2D cultures, 
hepatocytes expressed liver-specific functions during approx. 7 days.  
 
2.2.2. Fibroblasts cultures 
Three types of fibroblasts were tested: mouse embryonic fibroblasts (mef), 
human foreskin fibroblasts (hff) and NIH 3T3 fibroblasts. Mouse embryonic 
fibroblasts were isolated after fibrous tissue trypsin digestion of fetuses with 12 to 14 
gestation days using the methods described by Robertson (Robertson 1987). Both 
hff and NIH 3T3 fibroblasts were purchased from ATCC. 
Fibroblasts were routinely cultured in tissue culture flasks and maintained in 
medium MEM supplemented with 10% (v/v) FBS and 100 U/ml 
(Penicillin/Streptomycin). The culture medium was exchanged every 3 days and 
fibroblasts were diluted 1:2 (first passage) and 1:3 upon (first passage) confluence. 
For co-cultures, confluent fibroblasts were growth arrested by adding 100µM of 
Mytomicin for 3 hours into the culture medium. Afterwards, cells were rinsed three 
times in PBS, trypsinized, gently mixed with the hepatocytes suspension and 
inoculated in spinner vessels or bioreactors as described below. 
 
2.2.3. 2D Co-cultures of Hepatocytes and Fibroblast  
Freshly harvested hepatocytes and fibroblasts were seeded simultaneously 
onto matrigel® pre-coated culture plates at a density of 1.25x105 cells/cm2, according 
to Bhatia (Bhatia et al. 1998). After seeding, cultures were kept untouched for at least 
12h at 37°C in a humidified atmosphere with 95% air and 5% CO2, to allow cell 
attachment. Unattached cells were then removed by medium exchange. The culture 
medium was renewed every 24h and cells were routinely examined under phase 
contrast microscopy before every culture medium renewal. Culture supernatant and 
cells were collected according to the protocol at the same time points as 3D cultures 
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and stored at -20°C for further assay. In 2D co-cultures, hepatocytes expressed liver-
specific functions during approx. 10 days.  
 
2.2.4. 3D Co-cultures of Hepatocytes and Fibroblast  
3D co-cultures of hepatocytes/fibroblasts were performed in bioreactor and 
spinner vessels. Spinner cultures were maintained inside an incubator at 37ºC with a 
humidified atmosphere of 5% CO2 in air. The inoculation of both spinner and 
bioreactor vessels was performed as follows: single-cell suspensions of hepatocytes 
and fibroblasts were mixed together at an agitation rate of 60 rpm in 70/200 ml 
(spinner/bioreactor) of Williams E complete medium supplemented with 15% (v/v) 
FBS to promote cell aggregation. Three hours post inoculation, the agitation rate was 
increased to 80 rpm to avoid sedimentation of the cell spheroids and after 24 h, half 
of the culture medium was replaced by fresh medium (supplemented with FBS, to 
obtain a final concentration of 10% (v/v)) resulting a final culture volume of 125 ml in 
the spinners and of 300 ml in the bioreactors. Three inoculums were used in the 
spinner vessel cultures, namely 1.2x105, 2.4x105 or 3.6x105 cells/mL. 
To perform cultures under environment-controlled conditions, commercially 
available bioreactors (Sartorius-Stedim Biostat Q-Plus system) with volume 
capacities between 200 and 500 ml were used. The agitation in the bioreactors was 
provided by marine impellers (in contrast to the paddle impellers in the spinners). 
The top of the bioreactors has multiple ports for different applications, such as 
sampling, addition or removal of medium or other supplements or solutions and 
placement of the temperature, pH and pO2 sensors. Both pH and oxygen were 
controlled through the addition of gases via surface aeration. The pH of the culture 
was controlled at 7.4 with CO2 and the pO2 at 30% (of air saturation) with air and N2. 
The temperature was kept at 37ºC by water recirculation in the vessel jacket 
controlled by a thermocirculator bath. Data acquisition and process control were 
performed using MFCS/Win Supervisory Control and Data Acquisition (SCADA) 
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software (B-Braun Biotech International GmbH, Melsungen, Germany). The inoculum 
used in the bioreactor cultures was 1.2x105 cells/mL.  
To avoid nutrient limitations and the accumulation of products of cellular 
metabolism that can be toxic to the cells, 50% of the culture medium was replaced 
every 4 days (in both spinner vessel and bioreactor cultures). To evaluate the effect 
of oxygen concentration in hepatocyte functionality and inducibility, three bioreactors 
were run in parallel using different oxygen levels (5%, 30% and 70 % of air 
saturation).  
 
2.2.5. Sampling 
Samples of cell spheroids and culture medium were collected at several time 
points to evaluate cell morphology and the synthesis/secretion and biotransformation 
capacities of hepatocytes. The samples were centrifuged at 50 g, and the 
supernatants were stored at -20ºC for albumin and urea quantification and at 4ºC for 
Lactate dehydrogenase (LDH) analysis as described by Racher (Racher 1998). Cell 
spheroid pellets were used for incubation with the proper substrates of ECOD and 
UGT to assess biotransformation capacities (described below in detail). Although 
some cellular death occurs mainly during the first days of culture (probed by LDH 
analysis), due to difficulties in disaggregating cell spheroids to assess the exact cell 
number, the ECOD and UGT activities are expressed by seeded hepatocytes (this is 
also a more accurate comparison between mono- and co-cultures since feeder cells 
have no hepatocyte specific functional capacities).  
 
2.2.6. Fluorescent cell staining 
To evaluate co-aggregation between hepatocytes and fibroblasts, both cells 
were stained separately (hepatocytes in green and fibroblasts in red), using a kit for 
general cell membrane labelling (PKH67 Fluorescent Cell Linker Mini Kit) following 
the instructions of the manufacturer. Briefly, cells were washed and then incubated 
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for 15 min in a dye at a concentration of 2.5x105 cell/µl. Afterwards, cells were 
washed with culture medium and put together in culture. 
 
2.2.7. Determination of albumin secretion and urea synthesis 
Albumin secretion was measured by an enzyme-linked immunosorbent assay 
(NEPHRAT, Exocell, Philadelphia, USA). The urea synthesis rate was determined 
using a quantitative colorimetric kit (QuantiChromTM Urea Assay Kit, DIUR-500, ref 
DIUR-500; BioAssay Systems), according to the manufacturer’s instructions.  
 
2.2.8. 7-ethoxycoumarin-O-deethylase (ECOD) activity 
7-ethoxycoumarin-O-deethylase (ECOD) activity was measured according to 
Gomez-Lechon et al. (1997) with slight modifications. Salicylamide (1.5 mM) was 
added to the medium to prevent conjugation of 7-hydroxy metabolites of 7-
ethoxycoumarin. Therefore, hydrolyzation treatment with β-
glucuronidase/arylsulfatase was avoided. The activity is expressed as µmol of 7-
hydroxycoumarin formed per hour and per 106 hepatocytes inoculated. Day zero 
assay corresponds to the enzymatic activity of hepatocytes immediately after 
isolation. The activity refers to 7-hydroxycoumarin formed and is expressed as 
µmol/hour/106 hepatocytes. 
 
2.2.9. Uridine diphosphate glucuronoltransferase (UGT) activity 
Uridine diphosphate glucuronoltransferase (UGT) activity was determined by 
quantification of the substrate, 4-methylumbelliferone (4-MU), before and after cell 
incubation with the substrate. The procedure was performed according to Gomez-
Lechon et al. (Gomez-Lechon et al. 1997) with slight modifications. Briefly, 100 µM 
solution of 4-MU in 0.01M PBS was incubated with cells for an hour at 37ºC. 
Samples fluorescence was analyzed at an excitation wavelength of 320 nm and 
emission of 450 nm. The 4-MU remaining concentration was determined based on a 
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standard curve generated in PBS spiked with 0, 1.5, 3, 6, 12.5, 25, 50 and 100 µM. 
The activity is expressed as µmol of 4-MU metabolized per hour and per 106 
hepatocytes inoculated. Day zero assay corresponds to the enzymatic activity of 
hepatocytes immediately after isolation. The activity refers to 4-MU metabolized and 
is expressed as µmol/hour/106 hepatocytes.  
 
2.2.10. Induction Assay 
For the induction assay, the compound beta-Naphthoflavone (BNF), a CYP 
1A2 inducer, was added to the bioreactor co-cultures at day 3, to a final 
concentration of 25 µM. Cultures were exposed to the inducer for a 72 h period. 
Samples were collected daily and enzymatic activity of ECOD was then measured as 
described above.  
 
2.2.11. Statistics 
Error bars correspond to the standard deviation of the average values. Data 
comparison between systems was performed using a two-way ANOVA test. Level of 
confidence was set at 0.05 for all tests, with p-values lower than 0.05 considered 
statistically significant. The albumin, urea, ECOD and UGT quantifications were 
performed in triplicate. The complete experiment (1 co-culture bioreactor, 1 co-
culture spinner vessel, 1 mono-culture bioreactor, 1 monoculture spinner vessel, 1 
2D co-culture and 1 2D mono-culture) was run twice (n=2).   
 
3. RESULTS 
3.1. Establishment of hepatocytes-fibroblasts 3D cultures 
The aim of this work was to evaluate how 3D co-culture strategies impact 
hepatocytes functionality in vitro. For that purpose, freshly isolated rat hepatocytes 
were mixed with fibroblasts suspensions and inoculated under stirring conditions in 
small scale bioreactors or spinner vessels. The experimental set up is represented in 
Figure 3.1.  
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Figure 3.1.: Experimental set-up used to evaluate the effect of fibroblasts type, 
hepatocyte:fibroblast ratio and total cell inoculum concentration in hepatocytes 
functionality. 
Three types of fibroblasts (mouse embryonic fibroblasts (mef), human foreskin 
fibroblasts (hff) and NIH 3T3 fibroblasts), as well as three ratios between hepatocytes 
and fibroblasts (1:1, 1:2 and 2:1) and different cell inoculum concentrations were first 
screened in 125 ml spinner vessels. These agitated culture vessels were used in this 
phase as they are hydrodynamically well characterized and their smaller working 
volumes allow more parallel experiments from the same hepatocytes batch 
preparation. Hepatocytes functionality was evaluated by measuring albumin and urea 
secretion and the activities of enzymes from phase I and phase II, namely ECOD and 
UGT, respectively. The best results were obtained when mouse embryonic 
fibroblasts were used as feeder cells, with a 1:2 ratio of hepatocytes to fibroblasts 
and an initial cell concentration of 1.2 x105 cell/mL (data not shown). Noteworthy, for 
all types of fibroblasts tested, the passage number (number of cell population 
doublings) was critical for the culture performance, with the best results being 
obtained for passages up to 5. Moreover, it could be observed that aggregates were 
more tightly packed when a higher number of fibroblasts per hepatocytes was used.  
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Figure 3.2.: Cell spheroids collected at day 3 from: (A) stirred tank bioreactors containing co-
cultures of mouse embryonic fibroblasts (mef) and hepatocytes; (B) stirred tank bioreactors 
containing monocultures of hepatocytes; (C) spinner monocultures of hepatocytes used for 
comparison and evaluation of bioreactor performance; (D) co-culture with a ratio of 
1hepatocyte:2mef; hepatocytes are stained in green and mef in red. Scale bars correspond to 
100 µm. 
 
As previously described for monotypic cultures of hepatocytes (Miranda et al. 
2009), 3D cell spheroids could be detected in culture approximately 3 days after 
inoculation (Fig. 3.2 A-C). The increased difficulty in dissociating aggregates by 
trypsinization of mixed populations of hepatocytes and fibroblasts suggest a higher 
degree of cell-to-cell contact in co-culture aggregates when compared to 
monocultures. In co-cultures, the majority of the cells were assembled within the 3D 
spheroids (Fig. 3.2 A) while in hepatocyte monocultures single cells and cell 
doublets could be observed along culture time (Fig. 3.2 B-C). Evidence on 3D 
aggregates composed by both cells types can be seen on Figure 3.2 D, with 
hepatocytes staining in green and fibroblasts in red. The cell spheroids reach their 
maximum diameter by day 3 of culture. As cultured hepatocytes and inactivated 
fibroblasts lack the capacity of dividing, spheroid diameter depends mainly on the 
aggregation of more single cells (or small clusters of cells), which occurs essentially 
during the first three days of culture. 
Our results show that the presence of fibroblast potentiate hepatocytes 
aggregation in both bioreactor and spinner vessels but more homogeneous 
populations of larger aggregates (ranging from 50-300 µm) are obtained in 
bioreactor cultures. Limitation on oxygen diffusion in spheroids bigger than 200 µm 
has been described in previous studies (Curcio et al. 2007), but this phenomenon is 
expected to be absent in our system, since the mechanic stirring facilitates oxygen 
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diffusion (as well as medium homogenization) both outside and inside the 3D cell 
structures, thereby avoiding the formation of necrotic cores (Moreira et al. 1995). 
 
3.2. Stirred systems for the maintenance of 3D co-cultures: effect in 
hepatocytes functionality 
Hepatocytes obtained from the same freshly isolated batch were cultured 
alone or with mouse embryonic fibroblasts in both bioreactor and spinner vessels. 
The total cell concentration at inoculation was equal for all cultures (1.2x105cells/mL), 
with the concentration of hepatocytes being three times lower in co-cultures (as a 1:2 
of hepatocytes to fibroblasts ratio was used). These cultures were sampled during 21 
days to evaluate the impact of both the presence of mouse embryonic fibroblasts and 
of a controlled environment on hepatocytes functionality. As a way to assess culture 
viability, the activity of LDH released to the supernatant by cell lysis was monitored 
over culture time (Racher 1998). This enzyme accumulated in the supernatant during 
the first five days of culture while cells adapt to the new environment but then their 
release decreased considerably until the end of the experiment.  
Urea and albumin secretion rates were analyzed for the different culture 
systems. Urea secretion was observed during 21 days in all 3D cultures, without 
significant differences between them (data not shown). Figure 3.3 shows albumin 
secretion rate per unit volume along culture time in the 3D culture systems. 
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Figure 3.3.: Albumin secretion rate per unit volume along culture time in 3D stirred cultures. Full 
symbols correspond to bioreactor cultures and open symbols correspond to spinner cultures. 
Squares correspond to mono-cultures and triangles correspond to co-cultures. Solid and dashed 
lines correspond to trend lines of bioreactor and spinner cultures, respectively. 
 
When co-cultured, hepatocytes exhibit significantly higher albumin production 
rates in both spinner and bioreactor vessels in comparison to the corresponding 
monotypic cultures (p<0.05). On the other hand, the controlled environment of the 
bioreactors allowed improved albumin secretion levels for the co-cultures but had no 
significant effect in the monotypic cultures. A constant decrease in albumin secretion 
rate along culture time is observed in spinner cultures whereas in the bioreactor 
cultures the secretion rate is low in the beginning but then increases, remaining high 
during an extended period in the bioreactor co-culture.  
The biotransformation capacity of hepatocytes in the different culture systems 
was examined by measuring ECOD (Phase I enzyme) and UGT (Phase II enzyme) 
activities at different culture time points (Fig. 3.4).  
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Figure 3.4.: Non-induced enzymatic activities along culture time in the different stirred 3D 
cultures (A) 7-ethoxycoumarin-O-deethylase (ECOD) and (B) uridine diphosphate 
glucuronoltransferase (UGT). Solid bars correspond to bioreactor cultures and dashed bars 
correspond to spinner cultures. Black bars correspond to co-cultures of hepatocytes and 
fibroblasts and grey bars correspond to hepatocyte monocultures. Day zero assay corresponds to 
the enzymatic activity of hepatocytes immediately after isolation. 
 
Basal (non-induced) levels of the two enzymes remained at nearly the initial 
levels during the 21 days of culture for all culture systems and were significantly 
higher for hepatocytes co-cultured with fibroblasts. It is worthwhile to mention that 
these activities were either similar or even higher than the ones obtained immediately 
after hepatocytes isolation from the liver (Fig. 3.4). In general, liver-specific functions 
were significantly lower in 2D versus 3D cultures, as reported previously for both 
mono-cultures (Miranda et al. 2009) and co-cultures (Chia et al. 2005). A rapid loss 
of functionality was observed within 7 days for 2D mono-cultures. These values could 
be improved and extended until day 10 when hepatocytes were mixed with mef in 2D 
cultures. 
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3.3. Evaluation of hepatocytes response to CYP induction at different oxygen 
concentrations  
 
 
Figure 3.5.: Relative ECOD activity in 3D co-cultures performed in bioreactors operated at 
different oxygen levels, namely 5% (open squares, grey line), 30% (black circles, black line) and 
70% (grey triangles, dashed line) of air saturation. The arrow indicates induction time with beta-
Naphtoflavone. 
The response of hepatocytes to the CYP1A inducer beta-Naphtoflavone 
(BNF) in different oxygen concentrations was examined for 3D co-cultures in 
bioreactors. Hepatocytes from the same freshly isolated batch were mixed with 
fibroblasts in a ratio 1:2 and used to inoculate three bioreactors: one with normoxic 
oxygen levels (30 % of air saturation) and the other two with extreme oxygen levels 
(5% and 70% of air saturation), in order to mimic hypoxia and high oxygen perfusion 
conditions. Induction was performed in these bioreactor co-cultures with BNF 
between days 3 (when the majority of cells are assembled in aggregates) and 6. 
ECOD activity was analyzed daily (during ten days) in all bioreactor cultures (Fig. 
3.5). The ECOD activity ratio was maintained at inoculation levels in the high oxygen 
culture (70% of air saturation) but increased for cells exposed to low oxygen and 
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decreased for cells under normoxic conditions (Fig. 3.5). Differences in basal ratios 
of ECOD activity were observed among cultures: during the first three days, the 
ECOD activity ratio was maintained at inoculation levels in the high oxygen culture 
(70% of air saturation) but increased for cells exposed to low oxygen and decreased 
for cells under normoxic conditions. The induction response of hepatocytes to BNF 
exposure was observed for all cultures with the major fold increase in ECOD activity 
in the culture running at normoxic oxygen levels, 48 hours after induction.  
The effect of dissolved oxygen in cellular glycolytic metabolism was also 
assessed. The ratio between lactate production and glucose consumption (Lac/Glc) 
was 0.5±0.07, 0.30±0.05 and 0.35±0.06 for cultures exposed to 5%, 30% and 70% 
of dissolved oxygen, respectively. The values obtained for cells exposed to normoxic 
and hyperoxic conditions were similar to the ratio Lac/Glc = 0.27 reported for 
hepatocytes cultured in a membrane aerated mini bioreactor (Schmitmeier et al 
2006). The higher ratio observed for cells exposed to low oxygen levels (0.5; p<0.05) 
reflects a more anaerobic metabolism for this bioreactor co-culture. 
  
4. DISCUSSION 
The aim of this work was to develop a culture strategy for improving the 
overall hepatocyte functionalities in vitro. Three-dimensional (3D) cultures, where a 
cellular context “more-like” in vivo occurs, allows cells to integrate external signals, 
including those from cell-cell direct interaction and secretion/exchange of soluble 
factors and/or metabolites. Thus, strategically, we combined co-culturing approaches 
(by inoculating freshly isolated rat hepatocytes with fibroblasts) with scalable 
bioreactor technology (where sampling with minimal perturbation and long-term 
studies can be performed (Miranda et al. 2009)). 2D monolayer co-cultures 
previously described in several studies (e.g. (Bhatia et al. 1999; Cho et al. 2007)) 
were used as reference. We show that when co-cultured, both hepatocytes and 
fibroblasts self-assemble in 3D structures shortly after inoculation (Fig. 3.2 D) and 
that these cell spheroids can be maintained during long term in culture (up to 21 
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days). Moreover, we verified that fibroblast source and ratio to hepatocytes affect 
hepatocytes performance. From the three types of fibroblasts tested in the present 
study, the mouse embryonic were the type that allowed for the best improvement in 
hepatocyte functions. Many different fibroblasts from various organs and species 
have been shown to influence rat hepatocytes functionality (Bhatia et al. 1999). The 
specific mechanisms of interaction between cell types remain unclear. 
Hepatocytes performance in the different culture conditions was assessed by 
monitoring several liver-specific functions, such as albumin and urea secretion. Drug 
detoxification capacity was also studied by evaluating biotransformation of 
xenobiotics, such as ECOD (phase I enzyme) and UGT (phase II enzyme) activities. 
We show that, not only the co-cultivation of hepatocytes with mouse embryonic 
fibroblasts (at a ratio of 1:2) improved their performance in vitro as compared to 
monotypic 2D and 3D cultures, but also that the effect of the feeder cells on 
hepatocytes functionality was potentiated when 3D approaches were used.  
The long-term maintenance and inducibility of biotransformation enzymes in 
hepatic cultures have to be considered when determining drug metabolic pattern and 
predicting hepatotoxicity. Induction of CYP450 enzymes is clinically important as it 
can modify the metabolism of drugs, either potentiating their pharmacological action, 
diminishing their efficacy or producing unexpected hepatic side-effects. In this study, 
we evaluated the response of hepatic biotransformation enzymes to the action of 
BNF, a classical in vivo CYP1A inducer, in 3D co-cultures exposed to different 
oxygen levels (5%, 30% and 70% of air saturation). Dissolved oxygen has been 
described as a key factor to obtain long term functional hepatocyte cell cultures 
(Bader et al. 1999). There is still no consensus in the literature regarding the oxygen 
concentrations which reflect normoxic and hypoxic conditions in hepatocyte cultures 
(Fariss 1990; Martin et al. 2002; Nahmias et al. 2006). However, the levels in 
perivenous and periportal liver regions vary from 24% to 45% pO2 (Jungermann and 
Kietzmann 1997). ECOD activity increased in the 3 bioreactor cultures after the 
induction insult (Fig. 3.5) with the higher increase observed at normoxic oxygen 
levels (30% of air saturation). It has been reported that hepatocytes tolerate well 
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hypoxic levels, due to their extraordinary capacity to satisfy energy requirements by 
anaerobic glycolysis (Bader et al. 1999). CYP forms are expressed and induced 
mainly downstream in the perivenous region where the cells have less oxygen 
available, but CYP1A inducibility in each zone depends on the inducer used, being 
BNF a stronger inducer of CYP1A on the periportal region (Oinonen and Lindros 
1998). Our results follow this trend, i.e. before induction ECOD activity is higher in 
the lower oxygenated bioreactor (5% of air saturation) but after induction with BNF, 
cells exposed to high oxygen levels (30% and 70% of air saturation) showed 
improved inducibility. Some in vitro (Aninat et al. 2006; Josse et al. 2008) and in vivo 
(Diaz et al. 1990) studies have reported higher induction levels for lower basal 
CYP1A activities.  
 
All together, our data show that co-culturing freshly isolated rat hepatocytes 
with mef cells, as 3D structures, in bioreactors, promotes hepatic cells maintenance 
for longer period of time (up to 21 days). By significantly enhancing and extending 
hepatocytes functionality, when compared with the traditional monotypic 2D 
monolayer cultures routinely used for toxicology studies, this in vitro model represent 
a promising and alternative tool for drug screening applications and drug 
development.  
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ABSTRACT 
Primary cultures of human hepatocyte spheroids are a promising in vitro 
model for long term studies of hepatic metabolism and cytotoxicity. The lack of robust 
methodologies to culture cell spheroids, a poor characterization of the human 
hepatocyte spheroids architecture and liver-specific functionality have hampered a 
widespread adoption of this 3D culture format. In this work, an automated perfusion 
bioreactor was used to obtain and maintain human hepatocyte spheroids. These 
spheroids were cultured for 3-4 weeks in serum-free conditions, sustaining their 
phase I enzyme expression and permitting repeated induction during long culture 
times; the rate of albumin and urea synthesis, as well as phase I and II drug 
metabolizing enzymes’ gene expression and activity of the spheroid hepatocyte 
cultures presented reproducible profiles, despite the basal inter-donor variability (n=3 
donors). Immunofluorescence microscopy of human hepatocyte spheroids after 3-4 
weeks of long term culture confirmed the presence of  the liver-specific markers 
hepatocyte nuclear factor 4α, albumin, cytokeratin 18 and cytochrome P450 3A. 
Moreover, immunostaining of the atypical protein kinase C apical marker, as well as 
the excretion of a fluorescent dye, evidenced that these spheroids spontaneously 
assemble a functional bile canaliculi network extending from the surface to the 
interior of the spheroids after 3-4 weeks of culture. Conclusion: Perfusion bioreactor 
cultures of primary human hepatocyte spheroids maintain a liver-specific activity and 
architecture and are thus suitable for drug testing in a long term, repeated dose 
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1. INTRODUCTION 
The liver-specific functions of hepatocytes, such as albumin secretion or drug 
metabolizing activity, are rapidly downregulated during in vitro primary cultures, 
limiting their use for drug development and toxicity tests (Gomez-Lechon et al. 2003). 
For such assays, the current gold standard for long term human hepatocyte culture is 
the collagen sandwich in vitro model (Hewitt et al. 2007). The overlaying collagen 
layer increases cell-cell and cell-matrix contacts, providing a more 3D-like 
architecture than a monolayer culture. For rat hepatocyte spheroids, where cell-cell 
interactions are maximized, liver-specific functions (Wu et al. 1999; Miranda et al. 
2009) and multicellular architecture (Abu-Absi et al. 2002; Dvir-Ginzberg et al. 2004) 
are increased, when compared to monolayer cultures. 
The use of microfluidic devices for primary cultures of hepatocytes is a 
promising approach to enable high throughput screening in drug development (Goral 
et al. 2010; Nishimura et al. 2010). However, the down scaling enabled by these 
technologies makes the culture environment harder to be controlled and limits the 
application of microfluidics for long term primary cultures of hepatocytes. In fact, the 
most useful applications of micro technologies for such cultures couple either 
microfluidic perfusion or co-culture micropatterning to 12 (Domansky et al. 2010) or 
24 well plate culture plates (Khetani and Bhatia 2008), respectively; still, these 
technologies do not enable a physiologically relevant long-term culture of primary 
hepatocytes. 
Bioartificial liver devices (BAL) using human hepatocytes are often built in 
hollow fiber formats; this configuration is likely among the best options for 
maintaining cultures of large numbers of hepatocytes for prolonged culture periods 
(Carpentier et al. 2009); recently, one of such devices has also been scaled down 
and adapted to drug testing, using human liver cells (Zeilinger et al. 2011). The 
configuration of these bioreactors enables the formation of a liver-like hepatic mass 
throughout the culture time, making them long-term end point assays; nevertheless, 
Chapter IV 
 
 
 
118
these bioreactors were not designed for high throughput screening and do not allow 
sampling of the cellular mass throughout the culture period. 
CYP450 expression is downregulated during in vitro primary culture of 
hepatocytes; these enzymes are fundamental to xenobiotic metabolization studies, 
namely in drug development, and the orphan receptor-mediated induction of their 
mRNA synthesis is one of the most important parameters to be assessed in such 
tests (LeCluyse 2001). After these enzymes have oxidized a given xenobiotic, the 
compound is further conjugated with polar groups by phase II enzymes and secreted 
in the bile canaliculi by phase III enzymes. Thus, a long-term hepatocyte culture 
system must not only maintain CYP450 basal expression but also to enable their de 
novo mRNA synthesis upon exposure to prototypical CYP450 inducers, while 
maintaining the remaining phase II and III activities. Since phase III activity depends 
on the transport of phase II metabolites through the apical membrane, the presence 
of bile canaliculi is also necessary for a thorough assessment of drug metabolizing 
activity in primary cultures of hepatocytes. 
This work focuses on the use of perfusion stirred tank bioreactors for primary 
cultures of human hepatocyte as spheroids. When cultured in a bioreactor with 
essentially convective mass transfer and environmental control, the hepatocytes 
experience much smaller changes in pH, dissolved oxygen (DO) and culture medium 
composition than any culture system with a constant atmosphere and discrete 
medium exchanges. The pH and DO are controlled by CO2 and N2 injection through 
the reactor headspace, respectively, whereas the continuous addition of nutrients 
and removal of metabolic by-products is ensured by the automated perfusion system 
(Tostoes et al. 2011); the good mixing minimizes the gradients of these soluble 
factors in the culture bulk. The results indicate that this bioreactor system of primary 
culture of human hepatocyte spheroids enables the robust formation of hepatic-like 
micro-tissue units that can be repeatedly induced in long-term periods.  
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2. MATERIALS AND METHODS 
2.1. Primary cultures of human hepatocytes 
Human liver samples originating from patients undergoing liver resection 
(Table 4.1), were obtained from Sahlgrenska´s Hospital (Gothenburg, Sweden) upon 
written consent in agreement with ethical approval and from the patient signed 
informed consent agreement. The human liver samples were isolated by a two-step 
EDTA/collagenase type IV perfusion, followed by slow-speed centrifugation to reduce 
red blood cell content. Cells were resupended in Williams E medium, and stored over 
night (shipped over night) at 4ºC in Williams E medium before use. At the beginning 
of the experiments (upon arrival) cell viability was higher than 80% as determined by 
trypan blue exclusion, using a Fuchs-Rosenthal counting chamber. 
 
Table 4.1: Donor Information 
Donor Gender Age Weight Ethnicity 
0 M 73 89 Caucasian 
A F 42 78 Caucasian 
B M 57 80 Not known 
C F 73 70 Not known 
D F 30 56 Caucasian 
E F 39 71 Caucasian 
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2.2. Perfusion Bioreactor Culture 
Primary cultures of human hepatocytes were performed in Williams’ E medium 
supplemented with 1% Glutamax, 1% Penicilin/Streptomycin (all from 
GIBCO/Invitrogen) and Hepatocyte Culture Medium (HCM) Single Quots (Lonza, 
Walkersville, MD) (WE). The bioreactor cultures were inoculated at a cell 
concentration of 0.2x106 viable hepatocytes/ml. To promote cell aggregation into 
spheroids WE complete medium was supplemented with 10% FBS; cells were 
cultured in this medium for 72h and in serum free conditions afterwards (Fig. 4.1); 
the hepatocyte culture viability after aggregation was always above 90%, as 
assessed by the Trypan Blue exclusion method. The initial bioreactor working 
volume (V) was 300 ml and the perfusion rate (F) was set to 60 ml/day; this rate was 
adjusted throughout the culture time (as the culture volume decreased due to 
sampling) to maintain a dilution rate (D) of 0.2 day-1 (i.e., 20% medium exchange per 
day; D=F/V). The bioreactor (Sartorius-Stedim Biostat Q-Plus system) cultures were 
controlled at 37ºC, pH=7.4 and DO at 30% air saturation (approximately 60 µM of O2 
or 6.3% oxygen in a controlled atmosphere incubator, assuming an efficient mass 
transfer to the culture bulk). 
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Figure 4.1.: Experimental design of the induction of the CYP450 enzymes in primary cultures of 
hepatocyte spheroids in the bioreactor. 
 
2.3. Hepatocyte CYP450 enzyme inductions 
Inductions of the hepatocyte spheroids’ CYP450 enzymes were performed as 
depicted in Figure 4.1. Briefly, inductions in bioreactors were started by adding 
Rifampicin (Rif) and β-Naphtoflavone (BNF) at concentrations of 10 and 25 µM, 
respectively. The bioreactors were perfused with culture medium, containing the 
same concentrations of both inducers, at a dilution rate of 0.5 day-1 (2.5 times the 
dilution rate used for normal perfusion culture), for 72h; after this period, culture 
medium was fully exchanged to ensure a complete removal of the induction medium. 
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This induction procedure was performed twice, at day 3 and 2-4 weeks later, for all 
donors (Fig. 4.1).  
 
2.4. Cell concentration determination 
Spheroids were digested with 0.05% Trypsin/EDTA (GIBCO) and the resulting 
single cell suspension viability was assessed by the Trypan Blue exclusion method. 
Cell counting was performed using a Fuchs Rosenthal counting chamber. 
 
2.5. Hepatocyte spheroids visualization and measurement 
Hepatocyte spheroids were visualized by phase contrast microscopy (Leica 
Microsystems GmbH, Wetzlar, Germany) and their average diameter (dave) was 
determined by a geometric mean of three diameters per spheroid using the equation 
dave=(d1 × d2 × d3)1/3; spheroid diameters were measured using the ImageJ software. 
Diameter distribution plots were done using the GraphPad Prism software (La Jolla, 
CA 92037 USA). 
 
2.6. Determination of albumin and urea synthesis 
The secretion of albumin from hepatocytes was measured by an enzyme-
linked immunosorbent assay (ELISA) using the Exocell Albuwell albumin test kit 
(Philadelphia, PA, USA). The assay was performed according to the manufacturer’s 
description. The urea synthesis rate was determined using a quantitative colorimetric 
urea kit (QuantiChromTM Urea Assay Kit, DIUR-500, BioAssay Systems), according 
to the manufacturer’s instructions. The albumin and urea specific synthesis rates 
were calculated according to the general mass balance equation for a continuous 
system: q=(∆C/∆t – D × ( Cin – Cout))/ [X]V average where q is the specific synthesis 
rate, ∆C/∆t is the rate of change of the metabolite (either urea or albumin) in the 
supernatant, D is the dilution rate (0.2 day-1), Cin and Cout are the inlet and outlet 
concentrations of the metabolite and [X]V average is the average viable cell 
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concentration during ∆t. The results were expressed as µg/106 cells/day at the 
indicated time points. 
 
2.7. CYP450 activity Measurement 
7-Ethoxycoumarin O-deethylation (ECOD) activity was measured using the 
method described in (Castell and Gómez-Lechón 1997) with slight modifications. 
Briefly, Salicylamide (1.5 mM), was added to the medium to prevent conjugation of 7-
hydroxy metabolites (7-HC) of 7-ethoxycoumarin. The activity is measured by the 
rate of formation of 7-hydroxycoumarin (Umbelliferone) in nmol/106 cells/day. 
 
2.8. qRT-PCR 
Hepatocyte spheroids were collected from bioreactor cultures at different time 
points and stored at -20ºC with RNAprotect Cell Reagent (Qiagen, Valencia, CA).  
Later total RNA was extracted using RNEasy Plus Mini Kit   (Qiagen) according to 
the manufacturer´s instructions. Reverse transcription was performed using 0.6ug of 
total RNA in a final volume of 20 µl reaction mix using High Capacity cDNA Reverse 
Transcriptase Kit (Applied Biosystems).  Real time PCR was performed using ready-
to-use TaqMan Gene Expression Assays (applied Biosystems) according to the 
manufacturer´s instructions. GAPDH was used as endogenous control. 
 
2.9. Structural arrangement of the cell spheroids 
2.9.1.Whole mount Immunofluorescence microscopy 
Hepatocyte spheroids were fixed in 4% (w/v) paraformaldehyde (PFA) in PBS 
for 1 hour at room temperature (RT), blocked overnight (O/N) at 4ºC in 0.1 % Triton 
X-100 (Sigma-Aldrich) and 0.2% fish skin gelatin solution in PBS and subsequently 
incubated with primary antibodies diluted (1:100) in 0.125% fish skin gelatine in PBS 
for 2 days at 4°C. Cells were washed three times with PBS and the secondary 
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antibodies (diluted 1:500 in 0.125% fish skin gelatine in PBS) were applied to the 
cells overnight at 4ºC in the dark. After three washes with PBS, the samples were 
mounted in Prolong gold anti-fade containing 4,6-diamidino-2-phenylindole (DAPI). 
Cells were visualized using point scanning (SP5, Leica Microsystems GmbH, 
Wetzlar, Germany) or spinning disk (Andor Technology, Belfast, Northern Ireland) 
confocal microscopy. 
 
2.9.2. CryoSection immunofluorescence microscopy 
Hepatocyte spheroids were frozen in O.C.T.TM Tissue Tek (Sakura Finetek 
Europe, NL) and sectioned in 10 µm thick slices onto glass coverslips. These 
coverslips were blocked for 10 minutes at RT in 0.1 % Triton X-100 (Sigma-Aldrich) 
and 0.2% fish skin gelatin solution in PBS and subsequently incubated with primary 
antibodies diluted (1:100) in 0.125% fish skin gelatine in PBS for 2 hours at 4°C. 
Cells were washed three times with PBS and the secondary antibodies (diluted 1:500 
in 0.125% fish skin gelatine in PBS) were applied to the cells for 1h at 4ºC in the 
dark. After three washes in PBS, the samples were mounted in Prolong gold anti-
fade containing DAPI. Cells were visualized using a Leica DMI 6000 epifluorescence 
microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
 
2.9.3. Antibodies for confocal immunofluorescence microscopy 
Primary antibodies used were: goat anti-albumin, mouse anti-HNF4α (Abcam, 
Cambridge, UK), goat anti-CYP450 3A, mouse anti-aPKC (Santa Cruz, CA. 95060), 
FITC conjugated anti-Cytokeratin 18 (Sigma Aldrich, St. Louis, MO), Alexa 488 
conjugated Phalloidin (Molecular Probes, Eugene, OR). Secundary antibodies used 
were anti-mouse Alexa Fluor 488, anti-goat Alexa Fluor 594 (Molecular Probes, 
Eugene, OR) and anti-mouse Cy5 (Abcam, Cambridge, UK). 
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2.9.4. Bile canaliculi functionality 
Human hepatocyte spheroids were collected from the reactor after 2 weeks of 
culture, washed with PBS and incubated for 10 minutes in 2 µg/ml of 5-(and-6)-
carboxy-2',7'-dichlorofluorescein diacetate (CDFDA; Molecular Probes, Eugene, OR) 
in Williams E medium. Afterwards, spheroids were washed for 3 times with PBS and 
imaged in by confocal spinning disk microscopy (Andor Technology, Belfast, 
Northern Ireland). 
 
2.10. Co-Culture 
Preliminary studies of the influence of human forskin fibroblasts (hff) in the 
functionalities of human hepatocytes were performed in the bioreactor with no 
perfusion. In this study, were used cells from Donor E. Cultures were performed as 
described in Chapter 3 (Leite et al. 2011). Briefly, hff (from ATCC) were cultured in 
monolayer culture flasks until reach confluence. Before inoculation of the bioreactor, 
hff were growth arrested by adding 100µM of Mytomicin for 3 hours into the culture 
medium and then washed away. For bioreactor innoculation single-cell suspensions 
of hepatocytes and fibroblasts were mixed together with a proportion of 
1hepatocyte:2hff. Bioreactor was run at a final concentration of 0.12x106 cells/ml. A 
Mono-culture bioreactor was performed in parallel as control. Both bioreactor were 
performed as described in section 2.2., but instead of using perfusion system, culture 
medium was exchanged every 4 days. 
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2.10.1. Hepatic functionalities in Co-Culture 
For functionality assessment it was quantified the albumin in the culture 
medium and the ECOD activity of the cells as described before (sections 2.5 and 
2.6). The quantified values are expressed in µg albumin/106 hepatocytes inoculated 
and nmol of Umbeliferone formed/h/106 hepatocytes inoculated respectively. 
 
2.11. Statistical analysis 
Unless otherwise stated, all results were subject to an ANOVA single factor 
analysis, with α=0.05, using Microsoft Excell’s data analysis toolpack; p values are 
presented for statistically significant results (p<0.05). 
 
3. RESULTS 
3.1. Hepatocyte spheroid size distribution, viability and liver-specific 
synthesis time-course profiles in bioreactor cultures.  
The hepatocyte spheroid diameter is a critical variable for the maintenance of 
viability (Curcio et al. 2007) and hepatic phenotype (Glicklis et al. 2004) in primary rat 
hepatocyte cultures. Thus, the average spheroid diameters in bioreactor cultures 
were measured based on phase-contrast images after 1 and 2 weeks of culture, as 
depicted in Figures 4.2 a and 4.2 b (Donor C), yielding a size distribution plot as 
shown in Figure 4.2 c. On average, the spheroid diameters were 65 ± 7 µm after 1 
week and 81 ± 4 µm (value ± standard error of the mean) after 2 weeks, for the 3 
different donors (Fig. 4.2 d), and the viability of the primary bioreactor cultures of 
hepatocyte spheroids was maintained above 70% of the inoculated viable 
hepatocytes without major cell death during culture time (Fig. 4.2 d).  
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Figure 4.2.: Hepatocyte spheroid diameter distribution and cell viability. Bright field pictures of 
human hepatocyte spheroids in the first (a) and second (b) week of culture show an increase in 
average diameter, as quantified in c (Donor C, n= 100 spheroids; bars=200 µm). The average 
diameter of the hepatocyte spheroids and the average cell culture viability (in % of viable inoculated 
hepatocytes) are depicted in d. Bars in d represent standard deviations of n= 3 donors. 
Urea and albumin secretion, two liver-specific functions essential for ammonia 
detoxification and to maintain the blood osmotic pressure, respectively, were 
analyzed during the hepatocyte spheroid bioreactor culture; Figure 4.3 shows that 
the time course profiles for urea (a) and albumin (b) synthesis were comparable and 
reproducible among the 3 donors. The specific albumin production rate increases 
steadily along the 15 days culture time, whereas urea production decreases from the 
onset of the culture, reaching a steady state after 1 week of bioreactor culture. For 
both liver-specific activities, as much as 10 fold inter-donor variability was observed. 
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Figure 4.3.: Urea and albumin synthesis in bioreactor hepatocyte spheroid cultures. Bioreactor 
cultures of human hepatocyte spheroids show reproducible profiles for urea (a) and albumin (b) 
synthesis for donors A (○), B (□) and C (). 
 
3.2. Phase I and II enzyme expression and activity in bioreactor cultures. 
Hepatic drug metabolization typically involves phase I monooxygenase activity 
(CYP450 activity) followed by phase II conjugation activity and the transport of 
hydrophilic metabolites by phase III transporters. The gene expression for 3 CYP450 
isoforms (1A2, 2C9 and 3A4) and 2 conjugation enzymes (GSTA1 and UGT2B7) 
was measured, for the 3 donors, after spheroid aggregation (i.e., at day 3; Fig. 4.4 a) 
and during the remaining culture time (Fig. 4.4 b-d); in addition, 2 prototypical 
inducers, Rifampicin and β-Naphtoflavone, were added to the cultures in a repeated 
dose (Fig. 4.4 b-d, dashed boxes).  
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Figure 4.4.: Inter-donor variability and time course profiles of phase I and II enzymes in human 
hepatocyte spheroids bioreactor cultures. The gene expression of the CYP450/phase I enzymes 
1A2, 2C9 and 3A4, phase II enzymes GSTA1 and UGT2B7 was measured at day 3 (when 
spheroids were formed) and normalized to Donor A values (a); the same genes’ expression was 
monitored for the remaining culture time for donors A (b), B (c) and C (d). The gene expression 
values in (b,c,d) were normalized to the respective gene expression at day 3. CYP450 1A2 (), 
2C9 (), 3A4 (); phase II enzymes GSTA1 () and UGT2B7 (). The dashed areas 
represent the induction period, when spheroids were exposed to both Rif (10 M) and BNF (25 
M). Bars represent standard deviations of 3 different samples from bioreactor. 
Differences between donors for the gene expression of these drug 
metabolizing enzymes may vary 10-100 fold (Hewitt et al. 2006); this inter-donor 
variability is depicted in Figure 4.4 a, where gene expression for each enzyme was 
normalized to donor A values. Thus, normalization of relative gene expression to day 
3 is required to compare the temporal evolution of the system between donors, as 
depicted in Figures 4.4 b-d. An increase in the mRNA expression of drug 
metabolizing enzymes has been observed at day 5, after the addition of the inducer 
cocktail (at day 3), for all donors; these expression levels decrease after the first 
induction period, for donors A and C, whereas for donor B not all enzymes had a 
reduction in expression level. The second induction period was performed 72h before 
the end of the cultures (between weeks 2 and 4), while for donors A and C cultures 
there was a general upregulation of gene expression, donor B culture only showed 
an increase in CYP3A4 mRNA after this induction. 
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Figure 4.5.: Induction of ECOD activity in bioreactor (see also Figure 4.1 for methodology). The ECOD 
activity of the bioreactor cultures was assessed after 48 and 72h of RIF and BNF exposure. Bars 
represent the standard error of the mean of at least 3 independent cell-based measurements; ANOVA 
was performed by comparing 0h (basal) and 48 or 72h values, for each donor. *, p<0.05; ***, p<0.001. 
The CYP450 activity of the hepatocyte spheroids was measured by the 
metabolization of 7-Ethoxycoumarin to 7-Hydroxycoumarin, a reaction mainly 
catalyzed by the CYP1A family, even though CYP2 and CYP3 s are also involved in 
this deethylation reaction (Waxman and Chang 2006). Samples were collected from 
the bioreactors at 48 and 72h, during the first induction period (Fig. 4.5); the ECOD 
activity of all the 3 donors significantly increased either by 48h (Donor B), 72h (Donor 
A) or at both time points (Donor C). These fold-increases ranged from 2.6 for donors 
A (72h) and B (48h) to 19 and 15 for Donor C (at 48 and 72h, respectively). 
3.3. Liver-specific markers and structural polarity in bioreactor cultured 
spheroids.  
 
Figure 4.6.: Immunofluorescence microscopy of liver-specific antigens in human hepatocyte spheroids 
after 2 weeks of bioreactor culture. (a) HNF4α (green) co-localizes with the nuclear DAPI staining (blue); 
(b) albumin (red), Cytokeratin 18 (green); (c) CYP450 isoform 3A (red), Cytokeratin 18 (green) and nuclei 
(DAPI,blue). Samples for panels a and b were prepared in whole-mount, while the samples for panel c 
were prepared as 10 µm thick cryosections. 
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Human hepatocyte spheroids cultured in fully controlled bioreactors, from 
donors A and C, were analyzed by immunofluorescence microscopy to assess the 
presence of HNF4α, Cytokeratin18, Albumin, CYP450 3A and polarity markers 
inside such spheroids. For donor A, both Albumin (Fig. 4.6 b, red) and CYP450 3A 
(Fig. 4.6 c, red) were still detectable at 30 days of culture, as well as Cytokeratin 18 
(Fig. 4.6 b and c, green); the donor C culture stained positive for HNF4α after 20 
days in culture (Fig. 4.6 a).  
 
 
 
 
 
 
 
Figure 4.7.:   
Fluorescence 
microscopy of structural 
and polarity markers and 
bile canaliculi function in 
human hepatocyte 
spheroids after 2 weeks 
of bioreactor culture. (a) 
F-actin (green) localizes 
to cell membranes and is 
enriched in bile-
canaliculi-like structures 
(arrow); (b) transport of 
CDFDA to the apical 
(canalicular) domain of 
the hepatocytes shows 
an extensive and 
interconnected canaliculi 
network. (c) Confocal z-
sections (numbers 
represent the distance 
from the spheroid 
surface, in µm) of a 
hepatocyte spheroid 
stained for aPKC (green) 
and nuclei (DAPI, blue) 
shows several bile 
canaliculi-like channels 
which extend to the 
interior of the spheroid. 
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In donor D hepatocyte spheroids, actin (phalloidin) staining (Fig. 4.7 a, green) 
shows an absence of stress fibers, with most of these filaments localizing at the 
intercellular borders; furthermore, an actin enrichment can be seen, in some cell-cell 
contacts, which forms canaliculi-like structures (Fig. 4.7 a), very similar to the in vivo 
liver tissue architecture (Dunn et al. 1991). The establishment of de novo polarity is 
more obvious when Donor C hepatocyte spheroids were immunostained for atypical 
Protein Kinase C (aPKC), a kinase associated with the apical domain of epithelial 
cells (Fig. 4.7 c, green): a series of 24 µm confocal Z-stacks shows a bile canaliculi 
network which extends to the inner part of the spheroid (Fig. 4.7 c). The functionality 
of these channels was assessed by imaging the excretion of CDFDA into the 
canaliculi after being metabolized by the hepatocytes’ intracellular esterases (Fig. 
4.7 b), in two week old spheroid cultures of Donor D. 
 
3.4. Effect of feeder cells in the hepatic functionalities  
Following the strategy of work from Chapter 3, and on the advantage of 
coupling the use of feeder cells to the bioreactor approach to improve human 
hepatocyte specific activities (Khetani and Bhatia 2008) a preliminary study with cells 
from Donor E was performed in order to check the effect of fibroblasts on hepatic 
specific functions. Results are shown on Figure 4.8. 
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Figure 4.8.: Albumin quantification (a) and ECOD activity (b) of human hepatocytes (Donor E) in Mono- 
and Co-culture with human fibroblasts (hff). The presence of feeder cells () seem to improve the basal 
functionality of Human hepatocytes ( ).  
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On Figure 4.8a it can be seen the levels of albumin in the medium in Mono- 
and Co- Cultures, run in parallel with same stratagem. It can be seen that after a first 
increase of the levels in the culture medium during the first week, the albumin 
accumulated reaches a lower steady state, that is close to the values of freshly 
isolated cells, in the case of the Mono-culture, and 2-3 times higher in the case of the 
Co-culture. Regarding biotransformation (Fig. 4.8 b) assessment, it can be seen that 
the presence of hff cells improved the ECOD metabolism 2-4 times on first, second 
and third weeks. 
 
4. DISCUSSION 
In this work, a perfused bioreactor system for long term maintenance of 
primary cultures of human hepatocyte spheroids was established and tested. In this 
system, hepatocyte spheroids reproducibly recapitulated in vivo hepatic functions 
and structure, despite inter-donor variability. We hypothesize that these reproducible 
time-course profiles were made possible due to the tight control of critical 
environmental variables at physiological values, such as pH and oxygen levels. 
mRNA expression of CYP450 (phase I), GSTA1 and UGT2B7 (phase II) was 
maintained up to 4 weeks and increased when the cultures were exposed to the 
prototypical CYP450 inducers Rifampicin and β-Naphtoflavone, in repeated dose. 
The phase I ECOD activity of such cultures also responded to such inducers, 
showing the system’s potential for more informative time course experiments. The 
spheroid’s inner structure resembled the liver architecture, with functional bile 
canaliculi-like structures and liver-specific markers. Such a system constitutes an 
ideal long-term culture platform for analyzing hepatic function for drug development 
tests.  
The formation of hepatocyte spheroids was performed during the first 72 
hours of culture; phase contrast microscopy data of this period (data not shown) 
suggests an initial 24h period of cell clustering, when small aggregates (40-50 µm) 
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are formed; these clusters grow in size during the following 2 days (i.e., until 72h), as 
previously reported for primary cultures of rat hepatocyte spheroids (Wu et al. 1996). 
The influence of oxygen concentration in primary cultures of hepatocytes has 
been the subject of several publications (Foy et al. 1994; Curcio et al. 2007; Kidambi 
et al. 2009; Leite et al. 2011) and the conclusions from these studies are not easily 
comparable. This is mainly due to the different culture systems used, i.e., static 
systems (Kidambi et al. 2009) need higher oxygen concentrations for hepatocyte 
culture because the mass transfer relies on diffusion; on the other hand, stirred 
systems, such as the bioreactor described herein, have convective mass transfer 
and nearly homogeneous DO concentrations in the culture bulk. Thus, the bioreactor 
culture oxygen concentration used in this work (30% of air saturation in culture 
medium, i.e., 60 µM) is in the interval between the known periportal and pericentral 
oxygen concentration in the rat liver, 90 and 45 µM, respectively (Jungermann and 
Kietzmann 1997). 
The bulk aggregation of hepatocytes into multicellular spheroids depends on 
parameters such as the agitation type, vessel geometry (Khaoustov et al. 1999; 
Brophy et al. 2009; Miranda et al. 2009) and cell inoculum (Miranda et al. 2009). 
Brophy and colleagues (Brophy et al. 2009) have show that rat hepatocyte spheroids 
could be obtained from single cells by rocking motion with a higher yield of spheroids 
(85%), when compared to rotational motion (54%). However, this rotational motion 
was based on shake flask cultures and previous work by the Hu group (Wu et al. 
1996) had shown  that spinner vessels could yield rat hepatocyte spheroids with an 
80% efficiency in the incorporation of single cells into spheroids, after 72h. The 
differences between the fluid dynamics in orbitally shaken flasks and spinner vessels 
or the different cell inoculum used (1 and 0.3 million hepatocytes per ml, 
respectively) can explain the difference in both publications. In the work described 
herein, the previous knowledge from our group concerning the aggregation of rat 
hepatocytes (Miranda et al. 2009; Leite et al. 2011; Tostoes et al. 2011) was adapted 
to the formation of multicellular spheroids in primary cultures of human hepatocytes. 
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For these cultures the control of spheroid size becomes critical to avoid putative 
nutrient diffusion limitations; in the system described herein, hepatocyte spheroids 
had an average size of 81 µm (Fig. 4.2 d) and the number of spheroids with a 
diameter larger than 200 µm was less than 0.4% of the total population (n=3 donors). 
From previously published studies, it is know that rat hepatocyte spheroids with 
diameters of 100 µm yield a higher albumin production rate than larger ones (Glicklis 
et al. 2004), whereas spheroids of up to 200 µm diameter have been shown not to 
be subject to nutrient (namely oxygen) limitations (Curcio et al. 2007). Since the 
aggregation process here described reproducibly yields spheroids with an average 
81 µm diameter, it is not expected that the hepatocytes within these spheroids are 
subject to any significant mass transfer limitations.  
The data obtained for liver-specific activities (urea and albumin production, 
Fig. 4.3; ECOD activity, Fig. 4.5) and gene expression (CYP450 and phase II 
enzymes, Fig. 4.4) confirm the inter-donor variability, which has been thoroughly 
described for primary human hepatocyte cultures and is a direct reflection of in vivo 
variability (Ponsoda et al. 2001; Gomez-Lechon et al. 2003); however, the tight 
control of critical variables by the perfusion bioreactor system, coupled to an easy 
cell sampling system, allowed reproducible liver-specific profiles to be obtained, 
despite inter-donor variability; the use of serum-free media after aggregation is also a 
likely cause for such a reproducible behavior, since serum is known to downregulate 
both albumin synthesis and CYP450 activity of primary cultures of human 
hepatocytes (Kidambi et al. 2009). The profiles of urea secretion rate for the 3 donors 
have a significant decrease from the beginning of the cultures. This reduction in urea 
productivity has been observed by Zeillinger and colleagues (Schmelzer et al. 2009; 
Zeilinger et al. 2011) in a perfusion hollow fiber bioreactor and may be related to the 
lower oxygen concentrations inside the spheroids: retrograde liver perfusion 
experiments in rats have shown that lower oxygen concentrations partially inhibit the 
periportal urea synthesis (Katz 1992). 
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The primary cultures of human hepatocytes in the perfusion bioreactor were 
inducible for the entire long-term period. The co-administration of Rif and BNF 
ensured increase in mRNA synthesis for CYP3A4 (Rif), CYP2C9 (Rif) and CYP1A2 
(BNF) and despite the possibility of positive or negative synergies due to the use of 
both inducers, there is a significant induction in the 3 CYP450 isozymes; such co-
administration studies constitute a unique tool to study long-term drug-drug 
interactions with easy access to the hepatocytes for cell-based assays. In fact, the 
automated perfusion, as well as the oxygen and pH control in these bioreactors, can 
be used to expose primary cultures of hepatocyte spheroids to repeated drug dosing, 
as herein described, or long term time-varying drug concentrations for chronic toxicity 
assessment. 
The maintenance of these hepatic activities and gene expression is enabled 
by the cell-cell interactions which, during the bioreactor culture, evolve to a liver-like 
phenotype, as shown by the presence of Albumin, Cytokeratin 18, CYP450 3A and 
HNF4α (Fig.s 4.6 a-c), which are typical hepatic markers. The structural and 
functional polarity shown by both actin and aPKC staining and CDFDA 
metabolization (followed by the MRP2-mediated transport through the apical 
membrane of the hepatocytes) demonstrate that these human hepatocytes cultured 
as spheroids resume the cuboidal geometry, without actin stress fibers, and a 
polarized liver-like architecture. The presence of a functional bile canaliculi network 
in the hepatocyte spheroids, which had not been shown to be functional in previous 
studies (Dvir-Ginzberg et al. 2004), ensures an efficient polarized transport of the 
metabolic by-products in these hepatic microtissues. The similarity to in vivo liver 
tissue makes this system an interesting tool for fundamental studies of the hepatic 
functions in physiological or bioreactor-simulated pathological conditions, namely for 
more complex drug transport studies. Further improvements to this system may be 
achieved by adding cell-matrix interactions using spheroids encapsulated in  alginate 
(Tostoes et al. 2011) or heterotypical cell-interactions, by co-culturing hepatocytes 
with endothelial cells (Kidambi et al. 2009) or fibroblasts (Khetani and Bhatia 2008; 
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Leite et al. 2011). In fact, the preliminary studies on co-culture had shown a stable 
and effective improved on hepatic functions for the tested culture time, which makes 
this an attractive strategy to be further explored and adapted to the system for culture 
human hepatocytes developed in this work. 
In conclusion, the perfusion bioreactor system presented herein allows to 
culture defined size human hepatocyte spheroids (80 µm) which maintain hepatic 
liver-specific protein synthesis, CYP450, phase II and III drug metabolizing enzymes’ 
gene expression and activity, as well as liver-like architecture inside the spheroids  
for 2-4 weeks.  
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This chapter is based on the following manuscript: 
 
3D HepaRG Model  
for Toxicokinetic and Toxicodynamic Purposes 
Sofia B. Leite, Iwona Wilk-Zasadna, Jose M. Zaldivar, Elodie Airola, Marcos 
Reis-Fernandes, Milena Minnecozzi, Christianne Guillouzo, Christopher 
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ABSTRACT 
 
The maintenance of differentiated hepatocyte phenotype and its specific 
physiological properties is known to depend on several factors, such as chemical 
signals, cell-cell and extracellular matrix molecular interactions, as well as the use of 
three-dimensional matrices. The culture of HepaRG as 3D structures in stirred tank 
bioreactor could represent an added value as an hepatic test system for toxicokinetic 
and toxicodynamic studies. The use of a cost-effective commercially availability 
bioreactor for routine use and compatible with high-throughput cell analysis 
constitutes and attractive approach on the Drug Testing Industry. 
In order to address the biotransformation capacity of the bioreactor-based 
HepaRG system, CYP1A2, 2B6, 2C9 and 3A4 induction, with prototypic inducers, 
and the activity of the phase II enzyme, UGT were tested. The functionality of the 
system was demonstrated by albumin secretion capacity, CYP3A4 induction and 
UGT activities, which have shown stable profiles up to 7 weeks of culture. 
Immunofluorescence-based measurements demonstrated polarity of transporter 
expression and formation of tissue-like arrangement including bile canaliculi-like 
structures. Moreover, bioactivation of acetaminophen (APAP) and its related 
cytotoxicity was accessed in a system amenable to high-throughput screening and 
the 3D structures results were compared with platted cells (2D) by means of a cell-
based cytotoxicity assay model. The results show the advantage of integration in 
silico models for a better understanding of the in vitro cell behaviour. The developed 
approach had also proved to be a good strategy to reduce the time to obtain fully 
differentiated cell cultures. 
In conclusion, 3D HepaRG cultures performed in stirred tank bioreactors are an 
attractive tool for toxicological studies, since it showing a liver-like performance and a 
practical applicability. 
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1. INTRODUCTION 
It has become increasingly clear that the kinetic and metabolic fate of a 
compound has an important influence on its toxic potential, disposition in the body 
and eventual excretion (Coecke et al. 2006). Although in vitro and in silico human 
metabolic competent test systems are considered essential parts of integrated test 
strategies for systemic toxicities in general, metabolism is still deemed a bottleneck 
in in vitro toxicological test development. Therefore, in order to predictably screen the 
toxic compounds, it is essential to develop reliable and relevant human-based in vitro 
test systems that are metabolically competent and will model the hepatocytes 
process of biotransformation. The in vitro results obtained from such a system can be 
then further integrated by in silico computer models (such as physiologically-based 
toxicokinetic (PBTK) models) and converted into dose-response information for the 
entire organism enabling to assess the safety profile of compounds. This opens the 
possibility of using in silico strategies on kinetic data to bridge the in vitro and in vivo 
paradigm. However, more sophisticated in vitro models that maintain the liver 
function over a long time course for assessing drug metabolism and toxicity are 
currently needed to improve the predictive power of this approach.  
To prove the metabolic competence of any metabolic competent in vitro 
system such as cell lines, liver slices, primary cells or stem cells, the presence and 
activity of phase I and phase II biotransformation enzymes should be evaluated 
(Coecke et al. 2006). Furthermore, it is important that the metabolic machinery 
demonstrates to be functional and the polar arrangement of the hepatocytes in vivo, 
with apical and biliary sides characterised by transporters distribution, is present.  
Human hepatocyte cultures are considered to be the gold standard for testing 
liver toxicity since they better reflect what happens in the human liver. However, 
these cells are rather difficult to obtain and besides undergoing to spontaneously 
dedifferentiation, their profile is highly dependent on the donor and thus presents a 
high inter-donor variability. Moreover, they can keep their functionality in culture for a 
relatively short time. 
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A good alternative to human hepatocytes is represented by the HepaRG cells 
developed by Gripon et. al (Gripon et al. 2002). This is a human hepatoma cell line, 
derived from hepatocellular carcinoma that had shown liver-specific functions 
comparable to the human hepatocytes (Lubberstedt et al. 2011). After treatment with 
2% (v/v) DMSO, the cells fully differentiate in a co-culture of biliar and hepatocyte-
like cells expressing major cytochrome P450 (CYP450) enzymes, nuclear receptors, 
transporter proteins and transcription factors (Aninat et al. 2006; Kanebratt and 
Andersson 2008). These liver-specific functions can be maintained at high levels in 
for longer when compared to primary hepatic cultures. Since liver is a 3D organ, in 
which cells are maintaining cell-cell contacts important for their function and specific 
polarity, a lot of effort is undertaken to mimic the same conditions in vitro. It was 
already proven that human hepatocytes cultured in stirred tank bioreactors (spinner 
vessels) as 3D cultures produce tissue-like structures and maintain the liver-specific 
functions for longer and at higher level (Miranda et al. 2009; Leite et al. 2011; 
Tostões 2011; Tostões et al. 2011). Since the major application of toxicological 
models is in expensive screening of compounds, it is an added value that the 
developed method is compatible with existing standard laboratory equipment and 
high-throughput techniques (Schutte et al. 2011).  Moreover, it takes into 
consideration factors important for toxicological approaches, eg. commercial 
availability of the system, easiness for routine approach, cost-effectiveness and 
avoiding the necessity to use matrixes or tubing that could lead to non-specific 
binding. 
The aim of this study was to apply the 3D culture techniques in the stirred tank 
bioreactor to HepaRG cells, a high standard hepatic cell line. Besides 
characterization of phase I and II enzymes capabilities, the biocompetency of the 
developed system was assessed by testing the bioactivation of acetominophen 
(APAP). This assay also intended to test the applicability of the developed approach 
in toxicological assays, since APAP was activated to the toxic metabolite. Being one 
of the major cause of death by liver failure in US (Hawkins et al. 2007), APAP is 
taken as reference hepatotoxic compound for in vitro assays.  
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Experimental data have been analyzed using a process based modelling 
approach similar to PBTK modelling, but adapted to our cell-based assays with the 
aim of elucidating the main factors responsible of the in vitro behaviour.  
Since the HepaRG differentiation is a quite long process (approx. 14 days) 
and not always complies with the fast drug screening tests, an approach tested 
previously for neuronal cells was evaluated to decrease the time of differentiation 
was evaluated (Serra et al. 2007). 
 
2. MATERIALS AND METHODS 
2.1. HepaRG cell cultures  
Cells were provided by Biopredic International (Rennes, France) and 
maintained as described in Gripon et al. 2002 (Gripon et al. 2002). Briefly, cells were 
expanded in 2D flasks for two weeks. Culture medium was composed of William's 
Medium E (Gibco, Milan, Italy) supplemented with 10% (v/v) of HyClone FetalClone 
(Celbio, Milan, Italy), 2 mM L-glutamine (Gibco), 1% (v/v) Pen/Strep (Gibco, Milan, 
Italy), 5 µg/ml bovine insulin (Sigma, Milan, Italy) and 50 µM hydrocortisone (Sigma, 
Milan, Italy). The 2 weeks process of differentiation was induced by adding 2% (v/v) 
DMSO (Sigma, Milan, Italy) in the culture medium. Culture medium was changed 
twice a week. Before CYP induction studies or cytotoxicity testing, cells were cultured 
in DMSO-free medium for 48h. 
 
2.1.1. Differentiated 3D cultures (3D Diff) 
Inoculation of spinner bioreactors was adapted from protocols developed 
before (Leite et al. 2011; Tostões 2011). Briefly, after expansion and full 
differentiation in 2D monolayers (see 3.1), the cells were trypsinized and 3x106 of 
cells were inoculated into 125 ml spinner bioreactor (from Wheaton, Techne, NJ) in 
DMSO-free medium. The cells viability was above 95% as determined by Trypan 
blue staining. After cell aggregation (at day 3) DMSO was added to the culture up to 
the final concentration of 2% (v/v) (Fig. 5.1 A). Cell spheroid diameter was 
maintained between 50 and 200 µm by maintaining the stirring rate between 50 and 
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80 rpm. Culture was maintained for up to 7 weeks, being day 0 the addition of DMSO 
on 2D culture (Fig. 5.1 A).  
 
 
 
FIGURE 5.1.: Experimental set-up used for 3D HepaRG culture in stirred bioreactor. Cells were 
inoculated in the bioreactor at two different times: after fully differentiation - Diff (A) and for the 
differentiation as 3D – U-Diff (B). 
2.1.2. Under-Differentiation 3D cultures (3D U-Diff)   
After the studies on the characterization of the 3D HepaRG cell culture (3D-
Diff), the same strategy was tested to decrease the differentiation time by inoculation 
the stirred bioreactor earlier in the differentiation process (3D U-Diff) (Fig. 5.1 B) 
adapted from Serra et al. (Serra et al. 2007). Briefly, the cells were expanded as 
monolayers in T-flasks and inoculated in a 125-ml spinner bioreactor (from Wheaton, 
Techne, NJ) at a density of 53x105 cell/ml, before initiation of differentiation process. 
The cells viability was above 95% as determined by Trypan blue staining. After cell 
aggregation (day 3), DMSO was added to the culture up to the final concentration of 
2% (v/v) (Fig. 5.1 B). Cell spheroid diameter was maintained between 50 and 200 
µm by maintaining the stirring rate between 50 and 80 rpm. Culture was maintained 
for 7 weeks starting to count on the addition of DMSO on the bioreactor (Fig. 5.1 B). 
 
2.2. Structural arrangement of the cell spheroids 
Hepatocyte spheroids were fixed in 4% (w/v) paraformaldehyde (PFA) in PBS 
for 1 hour at room temperature (RT), blocked overnight (O/N) at 4ºC in 1% (v/v) 
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Triton X-100 (Sigma-Aldrich) and 0.2% (v/v) fish skin gelatin solution in PBS and 
subsequently incubated with primary antibodies diluted (1:100) in 0.125% (v/v) fish 
skin gelatine in PBS for 2 days at 4°C. Cells were washed three times with PBS and  
secondary antibodies (diluted 1:500 in 0.125% (v/v) fish skin gelatine in PBS) were 
applied to the cells overnight at 4ºC. After three washes with PBS, the samples were 
mounted in Prolong gold anti-fade containing 4,6-diamidino-2-phenylindole (DAPI). 
Cells were visualized using spinning disk (Andor Technology, Belfast, Northern 
Ireland) confocal microscopy. Primary antibodies used were: goat anti-albumin, 
mouse anti-P-Glycoprotein (Abcam, Cambridge, UK), mouse anti-Cytokeratin 19 
(Santa Cruz, CA. 95060), Alexa 488 conjugated Phalloidin (Molecular 194 Probes, 
Eugene, OR). As secondary antibodies anti-mouse Alexa Fluor 488 and anti-goat 
195 Alexa Fluor 594 (Molecular Probes, Eugene, OR) were used. 
 
2.3. Hepatocyte function assays.  
Supernatant samples were taken to quantify the secretion of albumin, 
synthesis of urea and lactate dehydrogenase (LDH) leakage. Spheroid samples were 
used to evaluate cell morphology, cell content in the bioreactor and to normalise the 
values of the measured parameters using Micro BCA Protein Assay kit (Pierce, Italia) 
(according to manufacture instructions). All samples were analysed in triplicates. 
2.3.1 Clinical chemistry indicators 
LDH activities were measured using the colorimetric kit Modular P800 (Roche 
Diagnostics, Mannheim, Germany). Levels of albumin and urea were assessed using 
the enzyme-linked immunosorbent assay (Albuwell, Exocell, Philadelphia, USA) and 
the colorimetric kit (QuantiChromTM Urea Assay Kit, DIUR-500, ref DIUR-500; 
BioAssay Systems), respectively (according to the manufacture instructions).  
 
2.3.2. Hepatocyte CYP450 enzymes activity.  
Cell spheroids were distributed in 96-well plates, approximately 8x104 
cell/well, in DMSO-free medium. After 48h in culture, the induction started with the 
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addition of the reference inducers, namely phenobarbital (PB, 530 µM), rifampicin 
(RIF, 10 µM) and β-naphtoflavone (BNF, 25 µM). The medium with or without the 
proper compounds was refreshed every 24h up to 72h. Each condition was repeated 
in triplicate. At the end of the incubation time, two different procedures were 
performed for i) screening the major CYP enzymes activity or ii) the determination of 
long term CYP3A4 induction: 
i) Cells were incubated with a selective CYP-substrate cocktail consisting of 
26 µM phenacetin (CYP1A1/2), 3 µM midazolam (CYP3A4), 9 µM diclofenac 
(CYP2C9) and 100 µM bupropion (CYP2B6) (from Sigma). After 30 minutes, 
supernatants were collected and stored at 20ºC until LC-MS analysis.  
ii) CYP3A4 activity was assessed using a luminescence kit (CYP3A4 
Luminescent Assay Kit, P450-Glo™, Promega, Italia). The activity refers to the 
increase of the luminescence from the control (wells with no cells). 
In both cases, the obtained values were corrected by the protein content of 
each well, quantified using the micro BCA kit. Results were expressed as fold 
increase of the specific CYP activity (pmol/hour/mg of protein or relative luminescent 
units/hour/mg of protein) when compared to the cells maintained in culture medium 
with the vehicle (DMSO). 
2.3.2.1. LC-MS Analysis.  
After cocktail (referred in 3.3.2.i)) incubation, the qualitative and quantitative 
determination of specific products formed by the respective P450 iso-enzymes, 
namely acetaminophen (CYP1A1/2), 1´-hydroxymidazolam (CYP3A4), 4´-
hydroxydiclofenac (CYP2C9) and hydroxybupropion (CYP2B6) was performed using 
a liquid chromatography-tandem mass spectrometric method (LC-MS/MS)  
developed  in-house and adapted from (Lubberstedt et al. 2011). The internal 
standard used for quantification was griseofulvin. LC-MS/MS analyses were 
performed on a Waters Acquity Ultra Performance Liquid Chromatographic system 
(UPLC) coupled on-line with a Waters Micromass Quattro Ultima Pt triple-quadrupole 
mass spectrometer equipped with an electrospray ionisation source (Waters, Milford, 
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MA, USA). Instrument control, data acquisition and data evaluation were performed 
using the software Waters MassLynxTM version 4.1. 
Analyte separation was performed at 40°C using a Waters Acquity UPLC BEH 
C18 analytical column (1.7 µm, 2.1 x 50 mm) with a Waters VanguardTM Pre-column 
(2.1x5 mm) and a crudcatcher. The binary UPLC pump was operated at a flow rate 
of 400 µl/min. The injection volume was 10 µL and the auto-sampler was operated at 
10°C. The eluents used were: (A) 0.1% (v/v) formic acid in water and (b) 0.1% (v/v) 
formic acid in acetonitrile. The linear gradient used to achieve the separation was as 
follows: 0-0.4 min: 5%B, 0.4-2.2 min: 5-95%B, 2.2-3 min: 95%, 3.0-4.0: 95-5%B. The 
retention times of acetaminophen, hydroxybupropion, 4´-hydroxydiclofenac and 1´- 
hydroxymidazolam were 1.12, 1.46, 1.63, and 1.98 min, respectively. 
The separated compounds were detected in positive electrospray ionisation 
(ESI). The triple-quadrupole mass spectrometer was operated in the Multiple 
Reaction Monitoring (MRM) mode.  
The operating conditions of the mass spectrometer were as follows: capillary 
voltage, 2.8 kV; source temperature, 150°C;desolvation temperature, 350°; 
desolvation nitrogen gas flow ,721 L/h; cone nitrogen gas flow, 72 L/h, argon 
pressure in the collision cell, 3.06e-3 mbar. The fragmentation parameters were 
optimised for each of the four analytes and different values of collision energy (eV) 
were set. The transitions used for quantification were 152.06 > 110.12 (13 eV) for 
acetaminophen, 255.90 > 238.09 (12 eV) for hydroxybupropion,  342.06 > 324.11 (20 
eV) for 1´- hydroxymidazolam and 312.05 > 231.04 for 4´-hydroxydiclofenac (15 eV). 
For qualification, the transitions used were 152.06 > 93.12 for acetaminophen, 
255.90 > 139.13 for hydroxybupropion, 342.06 > 202.98 for 1´- hydroxymidazolam 
and 312.05 > 266.05 for 4´-hydroxydiclofenac. A dwell time of 0.05 sec was used for 
all transitions. The lower limit of quantification (LLOQ) was set to 7.8 nmol/L for each 
analyte.  
 
Chapter V 
 
 
152
2.3.3. Uridine diphosphate glucuronoltransferase (UGT) activity.  
Uridine diphosphate glucuronoltransferase (UGT) activity was determined by 
quantifying the remain substrate, 4-methylumbelliferone (4-MU), after incubating with 
the cells. The UGT activity was measured both in 2D and 3D HepaRG cultures. The 
procedure was performed according to Gomez-Lechon et al (Gomez-Lechon et al. 
1997) with slight modifications. Briefly, 100 µM solution of 4-MU in 0.01M PBS was 
incubated with cells for an hour at 37ºC. Fluorescence samples were analysed at an 
excitation wavelength of 320 nm and emission of 450 nm. At the end of incubation 
with 4-MU, the protein cell content in each well was assessed as described above to 
normalise the specific UGT activity. The 4-MU remaining concentration in the 
supernatant solution was determined based on a standard curve generated in PBS 
spiked with substrate. Each condition was performed in triplicate. The activity of UGT 
was expressed as µmol of 4-MU metabolized per hour and per mg of protein.  
 
2.4. Biocompetency assessment - Acetaminophen (APAP) Toxicity.  
Cells spheroids were distributed in 96-well plates, approximately 8x104 
cell/well, in DMSO-free medium. The APAP concentrations used to generate a dose 
response curve were chosen based on previous determination of the EC50 on 2D 
HepaRG cultures. After 48h incubation at 37ºC, the assay starts by adding, in 
triplicates, different concentrations of APAP: 6.60x103, 3.30x103, 1.65x103, 8.25x102, 
4.13x102, 2.06x102, 1.03x102, 51.6 and 25.8 mM. Culture medium with proper 
concentrations of compound was refreshed every 24h up to 72h. Cell supernatants 
were collected every 24h for LDH activity measurement as described before.  
 
2.5. Cell-based assay model 
A coupled fate, transport, population growth and toxicity model has been 
recently developed to analyse cell-based assays. The model has been previously 
described in Zaldívar et al. (Zaldívar et al. 2011; Zaldívar et al. submitted) where it 
was implemented for several types of platted cells. If we assume that the differences 
between both types of culture systems, 2D and 3D, are due to the transport of APAP 
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to the cells located in the interior of the agglomerate and since diffusion is the sole 
transport mechanism, it is possible to define an effective diffusion coefficient, De, as 
in transport on porous media (Fogler 1999): 
e
DD φ
τ
⋅
=   
where φ is the porosity of the cell aggregate and  is the tortuosity factor defined as 
the actual travelled distance between two points divided by the Euclidean distance. 
Since this diffusion coefficient is related to the APAP transport to the cell we can 
assume that there will be a decrease of APAP transport comparing 2D and 3D 
experiments, and therefore, a decrease in estimated cytotoxicity. To estimate this 
value, we have used the 2D experiments to adjust the toxicity model's parameters – 
referred to internal cellular concentrations-, i.e. NEC (No Effect Concentration) and kt 
(killing rate) , see Koijman and Bedaux (Kooijman and Bedaux 1996) and the 
transport parameter (uptake rate); and the 3D experiments to calculate the value of 
the (φ /τ) factor. In addition, this has allowed us to analyze, if along the duration of 
the experiments, there have been changes in the structure of the spheroids. 
2.6. Calculations and statistical analysis 
Albumin secretion, CYP 450 enzymes activity, UGT activity and APAP 
cytotoxicity were evaluated. Albumin secretion was expressed as µg of albumin per 
day of culture per 106 cells. CYP induction was expressed as improvement on 
specific enzymes activity when compared to the medium control. UGT activity was 
expressed as µmol of substrate (4-MU) disappeared per hour of incubation per mg of 
total cell protein. APAP cytotoxicity was calculated based on the percentage of viable 
cells in comparison with the untreated control cells.  
Data was gathered from two bioreactors with at least three replicates for each 
tested concentration. Statistically significant differences between the mean values 
related to all tested endpoints were determined based on analysis of variance 
(ANOVA single factor analysis, with α=0.05). Values of p<0.01 were considered as 
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statistically significant. All calculations were done using Microsoft Excell’s data 
analysis toolpack (VERSION 2003). 
 
3. RESULTS 
3.1 Hepatocytes function assays – clinical chemistry indicators (3Diff) 
The amount of cells in culture was determined by total protein content and 
neither cell growth nor significant cell death was detected during the culture time 
(data not shown). Stable maintenance of cell content for the 7 weeks was confirmed 
by the low release of LDH into the culture medium (data not shown). The albumin 
secretion capacity of the cells decreased over the time from 11.7±3.7 µg 
albumin/day/106 cells on 3rd week to 6.0 ± 2.3 and 3.5 ± 1.4 µg albumin/day/106 
cells, on the 5th and 7th weeks respectively. No urea production was detected over 
the whole tested period. 
3.2. Structural arrangement of the cell spheroids (3D Diff) 
 
 
 
 
FIGURE 5.2.: Cell arrangement 
within HepaRG 3D culture. 
Spheroid showing the two types 
of cells in culture: hepatocytes 
(red) and biliary cells (green). 
Cell nuclei from both cells are 
stained in blue. White bar 
corresponds to 50 µm. 
Immunofluorescent pictures showing the spheroid characterization are 
presented in Figures 5.2 and 5.3. It can be observed formation of tissue-like 
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structures. Figure 5.2 shows the polarization of biliary marker CK19 (green) at the 
core of the cellular structure, while the hepatocyte-like structures stained for albumin 
(red) were situated at the outside sphere, as it is visible once the focus move away 
from the core of the spheroid.  
 
FIGURE 5.3.: 3D organization of the HepaRG spheroids. (A-D) Details of a spheroid showing the 
polarization of transporter (white arrow). F-actin (green) localizes at the level of cell membranes and 
it is enriched in bile-canaliculi-like structures. Red stains for PGP protein transporter. White dash 
bar (A) corresponds to 50 µm; white full bar corresponds to 15 µm. 
 
The same polarized structure is supported by Figure 5.3 that shows spheroid 
details where it can be seen that the Pgp efflux transporters (red) are not randomly 
distributed, but accumulated near the green actin staining, indicating the formation of 
biliary canaliculum-like structures. The vicinity between the two structures is more 
visible when moving along the depth of the spheroid (z-axis) where it can be seen 
the superposition of the biliary structures on the zones where Pgp is accumulated 
(white arrows), showing an in vivo-like cellular arrangement. In both figures, the 
yellow appearance indicates the superposition of both structures. 
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3.3. Phase I and Phase II hepatocyte enzyme activities (3D Diff) 
3.3.1 Functional activity of CYP450 enzymes  
 
FIGURE 5.4.: Phase I enzymes activity in HepaRG 3D cultures. Induction of CYP1A2 was assessed by 
25 µM of β-naphtaflavone (βNF), and CYP2B6 was induced by 500 µM phenobarbital (PB). Induction 
on both CYP2C9 and CYP3A4 was assessed by adding 10 µM rifampicin (RIF). The assay was 
performed 3 weeks after the addition of DMSO (used for cell differentiation). Results are mean ± SEM 
(n =3)  
 
By measuring the appropriate metabolite concentrations by the LC-MS/MS 
method it is possible to quantify the level of CYP450 enzyme activity (relative to a 
control). Figure 5.4 shows the functional activity of the major phase I enzymes in 3D 
HepaRG culture. After 72h incubation with the respective positive inducers, all tested 
CYPs showed more than 2-fold induction increase (as recommended by FDA Draft 
Guideline for Drug-Drug Interactions). Induction rate catalysed by CYP1A2 
phenacetin-O-dealkylation was found to be 17.8±1.8. The induction rate for 
bupropion-hydroxylase, characteristic for CYP2B6 was observed at the level of 
5.6±1.0. Both, CYP2C9 and CYP3A4 were effectively induced by RIF as the 
induction rates of midazolam-1’hydroxylation and diclofenac-4’-hydroxylation were 
found to be 2.8±0.3 and 4.1±0.3, respectively.  
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3.3.2 Long term characterization of biotransformation- determination of 
CYP3A4 and UGT activity 
The most representative enzymes of the biotransformation phase I and phase 
II were selected and their long term biotransformation capacity was assessed by 
repeated assays on the 3rd, 5th and 7th weeks (Fig. 5.5 - black bars). The CYP3A4 
enzyme functionality is presented as fold induction after addition of the specific 
indicated compounds (Fig. 5.5 A). Stable induction of CYP3A4 was shown during the 
whole culture period (up to 7th week). The induction rate of more then 2-fold was 
observed when the cells were exposed to RIF and PB. The values of 7.15±1.84 and 
2.76±0.29 were obtained, respectively. No induction was observed upon exposure to 
BNF.  
 
 
 
FIGURE 5.5.: Long term biotransformation capacity of HepaRG cells cultured as 3D structures in stirred 
bioreactor. Results are expressed as mean values of two independent culture runs, with 3 test 
replicates for each testing condition and error bars correspond to SEM.  
A - Phase I enzyme activity represented by CYP3A4 induction after addition of reference inducers. Two 
different approaches in terms of cell culture are represented (light grey bars represent cultures seeded 
before the differentiation phase (3D U-Diff) and dark grey bars represent those seeded at the 
differentiated stage) Black horizontal line indicates the threshold value, from which it is considered that 
the enzyme activity has been induced.  
B- Phase II enzyme activity - represented by UGT. Two different approaches in terms of cell culture are 
represented (light grey bars represent cultures seeded before the differentiation phase (3D U-Diff) and 
dark grey bars represent those seeded at the differentiated stage). The results are compared to the 2D 
cultures (striped bars). 
 
For the first time, accordingly to our knowledge, the activity of the phase II 
enzyme UGT was measured in 2D and 3D differentiated cultures (Fig. 5.5 B- stripes 
and full black bars respectively). The UGT activity was detected by the 
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disappearance of the enzyme main substrate 4-methylumbeliferone. In both, 2D and 
3D cultures, the UGT activity was observed over the whole period tested. The UGT 
activity in 2D cultures decreased over the time, whereas in the 3D cultures it was 
maintained at the stable level from the 3rd to the 5th week and increased on 7th week. 
Moreover, the 3D model increases the UGT activity when compared to the 2D 
cultures by approximately 2-20 times.  
 
3.4. Biocompetency: APAP toxicity (3D Diff) 
 
FIGURE 5.6 Bioactivation capacity of the cells. A – Concentration - dependent APAP toxicity at different 
culture times. Each point corresponds to the average value of triplicate determination of cell integrity, at 
24, 48 and 72h of incubation from four stirred bioreactor cultures. B-E – Experimental and simulated 
dose response curves after addition of APAP at different concentrations at different culture times. B 
curve, corresponds to the monolayer HepaRG cells (2D) where the other curves show the comparison 
between 3D experiments and simulations for 3rd, 5th, and 7th weeks assuming a change in the effective 
diffusion of APAP. 
To check the applicability of our 3D developed model in toxicology, the cells 
were exposed to different concentrations of acetaminophen for 72h. Since the APAP 
itself is not toxic but has to be metabolized first to its active metabolite – NAPQI, the 
performed study is also a way to test cells bioactivation/biocompetency capacity. The 
results are showed on Figure 5.6 A. Among the 3 tested weeks (3rd, 5th and 7th), the 
profiles are similar and concentration- dependent decrease of cell viability is 
observed. However, on the 3rd week higher toxicity of APAP at the same range of 
concentrations is observed. 
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3.4.1. Simulated results 
Figure 5.6 B shows the experimental and simulated results for the 2D 
experiment that was used to fit model parameters as well as the obtained results for 
3, 5 and 7 weeks of the 3D culture (Figs. 5.6 C-E). The fit of the model parameters in 
2D (Fig. 5.6B) followed the procedure described in Zaldívar et al (Zaldívar et al. 
submitted). For the fit of the 3D culture, the same parameters were used, but 
applying the factor (φ /τ) to the effective diffusion and hence to the APAP transport 
to the cells. The calculated values for the decrease in mass transfer (mol l-1 s-1) 
related to the platted cells are: 1581, 3844, and 3199, respectively. 
 
3.5. Decreasing differentiation time in 3D (3D U-Diff) 
After  characterizing the 3D HepaRG cultures in stirred systems, it was tested 
if, using the same system, the differentiation time of HepaRG could decrease by 
seeding the bioreactor earlier, i.e. when the necessary amount of cells after 
expansion was reached (Fig. 5.1B), (3D U-Diff). CYP3A4 induction and UGT activity 
were assessed as main endpoints (Fig. 5.5, grey bars) and were compared with 3D 
Diff culture. Regarding CYP3A4 induction (Fig. 5.5A), the positive inducers (RIF and 
PB) acted as such and induced the enzyme to the same extent. No higher induction 
capacity for RIF was observed (as it was the case in the 3D Diff cultures). There was 
no significant difference regarding PB induction between the two 3D cultures and no 
time-dependency was observed. RIF induction potential was much lower in 3D U-Diff 
then in 3D Diff and stability was reached later (from the 5th to the 7th week).  
Regarding the UGT activity, the 3D U-Diff culture has stable activity for the 
whole period (Fig. 5.5B). The values are close to the ones of 3D Diff cells, apart from 
the 7th week, where 3D Diff activity is much higher. For the whole tested period, the 
UGT activity seems to be higher then those in 2D culture. 
However, further studies are necessary in order to understand the impact of 
decrease the differentiation time of HepaRG. 
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4. DISCUSSION 
Central role of metabolism in mediating liver response to drug become one of 
the crucial aspects, addressed in pharmaceutical drug discovery and development. 
Different strategies have been envisaged setting up in vitro systems to prolong cell 
survival, maintain liver-specific functions and mimic in vivo like environment. Various 
approaches combining co-culture, 3D organization and perfused flow have been 
developed (Leite et al. 2011; Schutte et al. 2011; Tostões et al. 2011; Zeilinger et al. 
2011). Several studies have shown that 3D cell-cell contacts reduce the gap between 
cell culture and real tissue (Pampaloni et al. 2009). The liver-like arrangement 
together with the stratified organization, makes 3D model closer to the in vivo, with 
the ability to give more reliable results (Dhiman et al. 2005; Tung et al. 2010).  
In parallel, new cell sources are explored as an alternative to primary human 
hepatocytes. One of the most attractive alternative in terms of long-term 
maintenance of liver-specific competency are the HepaRG cells (Aninat et al. 2006; 
Guillouzo et al. 2007; Turpeinen et al. 2009; Andersson 2010). Besides showing 
metabolic profiles similar to human hepatocytes (Lubberstedt et al. 2011; Zanelli et 
al. 2011), recently it was also shown that HepaRG have a genetic similarity of 81 to 
92% with human hepatocytes (Rogue et al. 2011). However, it still shows some 
limitations regarding the application of in vitro testing (Schulze et al. 2011) and 3D 
models to culture HepaRG in an architecture that better resembles the liver itself are 
still scarce (Darnell et al. 2011; Hoekstra et al. 2011).  
In this work we established a strategy to culture functional 3D HepaRG 
spheroids in stirred tank bioreactor up to 7 weeks. Mimicking the in vivo liver 
morphology, the cell spheroids were composed of both, biliary-like and hepatocyte-
like cells, showing a polarized cell arrangement also supported by polarization of the 
transporters from the MRP family. This type of cellular arrangement was already 
shown in the HepaRG 3D cultures (Darnell et al. 2011) and human hepatocytes 3D 
spheroids cultured in stirred systems (Tostões 2011). Polarized expression of 
transporters in cultured hepatocytes is of outmost importance for in vitro drug-drug 
HEPARG IN 3D 
 
 
161 
C
h
ap
te
r 
V
 
interaction studies (Nakanishi et al. 2011), as well as test studies such as 
transfection with hepatitis B virus (Schulze et al. 2011). 
The stable functionality of our bioreactor-based hepatic system over the tested 
period was demonstrated by several endpoints. The capability of the system to 
secrete albumin remains active for 7 weeks, even if decreasing with time. Moreover, 
comparing the results (11.7 ± 3.7 µg albumin/day/106cells at the 3rd week) to those 
obtained in 2D HepaRG cultures (5 µg albumin/day/106cells cells) (Lubberstedt et al. 
2011) for the same period of time, an improvement of the albumin secretion capacity 
was shown. Like in the study of Lubberstedt at al. (Lubberstedt et al. 2011), no urea 
synthesis competence of HepaRG cells was observed in our system. This may be 
due to the fact that in HepaRG cells, ammonia is predominantly fixed into glutamine 
rather that converted to urea, as previously described by Hoekstra (Hoekstra et al. 
2011).  
We also observed that the established 3D HepaRG cell cultures in the stirred 
bioreactor maintain the functional metabolic machinery of the main phase I CYP 
P450 biotransformation enzymes, namely CYP1A2, CYP2B6, CYP2C9 and CYP3A4. 
All iso-enzymes were present in the system showing diverse basal activity. About 10 
times lower activity was observed for CYP1A2 and CYP2B6 when compared to 
CYP2C9 and CYP3A4 activity (data not shown). As expected (Westerink and 
Schoonen 2007; Abadie-Viollon et al. 2010), the tested iso-enzymes were specifically 
induced by their respective reference inducers (BNF for CYP1A2, PB for CYP2B6 
and RIF for CYP2C9 and CYP3A4, respectively). The induction levels in case of 
CYP1A2 and CYP2C9 (17.8±1.8 and 2.8±0.3 respectively) are in agreement with the 
values obtained for HepaRG cultured 2D conditions (Turpeinen et al. 2009; 
Lubberstedt et al. 2011). Higher induction was observed for CYP2B6 and 3A4, being 
closer to the values seen in human hepatocytes (Lambert et al. 2009; Turpeinen et 
al. 2009).  
Among the human CYP P450 enzymes, CYP3A4 monooxygenase plays the 
major role in the biotransformation, catalyzing the metabolism of about 60% of drugs 
(Lehmann et al. 1998). Therefore the long term biotransformation capacity of our test 
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system was evaluated based on the activity of this enzyme. CYP3A4 was strongly 
induced by RIF up to the 7th week of culture. The 2.5±0.5 to 7.3±2.2 fold-induction 
was observed. Knowing that the effect of RIF on CYP3A4 varies considerably in both 
in vivo and in vitro human hepatocytes, our results indicate that in the established 
stirred 3D system the induction capacity of CYP3A4 is relatively stable. In  previous 
studies the variation from 1.4- to 7.4-fold was documented in in vivo conditions 
(Floyd et al. 2003; Yu et al. 2004; Abadie-Viollon et al. 2010), whereas the range of 
2- to 19-fold induction was shown in vitro (Abadie-Viollon et al. 2010; Tostões 2011). 
Regarding HepaRG cultures, published results vary between 2- to 11-fold (Kanebratt 
and Andersson 2008; Darnell et al. 2011). The lower response of CYP3A4 expressed 
in 3D HepaRG culture to the alternative inducer – PB, is also in agreement with 
previous studies in both, 2D human hepatocytes and HepaRG cells (Turpeinen et al. 
2009; Richert et al. 2010). 
To assess the overall metabolic competency of our 3D in vitro system, we also 
checked the activity of the biotransformation phase II enzyme – UGT, which 
catalyses more then 35% of the conjugation reactions in human drug metabolism 
(Trubetskoy et al. 2007). According to our knowledge, no previous published data 
referring to UGT activity in HepaRG cells are available. Therefore, we tested it in 
both 3D and 2D cultures. 3D cultures showed improvement in the UGT activity from 
1.9- to 21-fold, when compared to 2D. Similar findings were made with rat 
hepatocytes which, when cultured in the same system, increased the UGT activity up 
to 6 times (Miranda et al. 2009).  
The practical applicability of the developed system for toxicological studies 
was evaluated by assessing the mode of action of acetaminophen (APAP) - a known 
liver toxicant. APAP dose-dependent toxicity was observed, proving the capability of 
our system to accurately mimic the mechanisms of APAP toxicity seen in vivo. In 
general, to express the toxicity, the formation of a reactive APAP metabolite (NAPQI) 
is necessary, which is followed by glutathione depletion, mitochondrial dysfunction 
and ultimately cell death. The results obtained in our study provided evidence of the 
concerted action of CYP 2E1,CYP3A4,CYP1A2 enzymes and the MRP2 and MRP3 
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transporters, involved in the described toxic path, up to 7 weeks. The fact that the 
curves are similar among the tested 72h at different time points (3rd, 5th and 7th 
week), shows that the daily death rate of APAP is constant, which is in agreement 
with in vivo toxic action of the compound, since it causes acute liver failure and not 
chronic toxicity (Kaplowitz 2005). However, the highest toxicity of APAP was 
detected only on the 3rd week at concentrations higher then 1650mM, which could 
possibly indicate higher activity of the complex MRP-CYP.  
The observed APAP non-toxic concentrations are not in agreement with the 
available in vivo data (Gibb and Anderson 2008), however, an in vitro model itself 
can not generate the exact human toxic concentrations. According to Pelkonen et al 
(Pelkonen et al. 2008), there are still several in vivo phenomena regarding ADME 
(Absorption, Distribution, Metabolization and Excretion) process which can not be 
mimicked in simple in vitro models. This might be even not necessary if a stable 
correlation between the obtained in vitro values and the known in vivo effects is 
identified and serves to develop an extrapolation models such as physiologically 
based toxicokinetic (PBTK) models (Pelkonen et al. 2008). In this work, we have 
used a cell-based assay  model to estimate the in silico reproducibility of the in vitro 
results and the differences between 2D and 3D assays as a first step towards a 
strategy for future in vitro-in vivo extrapolation (IVIVE). The used cell-based assay 
model was able to generate the experimental profiles considering different diffusion 
parameters based on the porosity/tortuosity of the 3D spheroid.  The values obtained 
for the decrease of the mass transfer for weeks 3, 5 and 7 show that the differences 
observed on APAP toxicity might not be fully related with the metabolic machinery, 
but with the different exposure of the cells to the compound. The results suggest that, 
on 3rd week, the cells are exposed to the compound in a manner which resembles 2D 
model, loosing this feature over the following weeks. This could be caused by 
stronger cell-cell connections, expressed after long time in culture. However, further 
studies need to be performed to understand the reasons and the mechanisms of the 
observed diversity. The actual study intends to demonstrate the applicability of the 
3D model in toxicity studies, and the further advantage of the integration of in silico 
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models, towards the extrapolation and understanding of the data, being the first time 
that this was performed in a HepaRG 3D system. 
After having an extended characterization of the 3D HepaRG system, we tried 
to decrease the differentiation time of HepaRG as it was previously done with 
neuronal cells (Serra et al. 2007). The 3D U-Diff culture was characterised in terms 
of biotransformation capacity and compared with the 3D Diff culture. As it happened 
with 3D Diff cells, CYP3A4 positive and negative inducers had worked as such also 
in the 3D U-Diff culture. However, RIF induction potential in 3D U-Diff was lower then 
in 3D-Diff. This might mean that the CYP3A4 was still not mature enough. From the 
other hand, this diversity might also reflect the observed in vivo hepatic variability 
upon exposure to RIF, which was mentioned before. Regarding UGT activity, 3D U-
Diff has a profile very similar to the 3D Diff, with the same improvement from the 2D 
cultures and similar activities on weeks 3 and 5. However, on the 7th week, instead of 
expected increase, the UGT activity remained constant. There is a probability that 
this improvement would be observed latter on.  
In spite of observing some lower biotransformation activities, the 3D U-Diff is 
still a valid model for 3D hepatic cultures since it reaches the minimal conditions such 
as responding to induction and having a stable metabolic profile for 7 weeks. The 
results lead to believe that the earlier aggregation of HepaRG helps in the early 
maturation of biotransformation enzymes. Furthermore, the applicability of the 3D 
HepaRG U-Diff model should be considered depending on the needs: from one hand 
site, having Diff and U-Diff cultures can mimic the natural in vivo variability, from the 
other hand site, instead of being applied in toxicokinetic (biotransformation) U-Diff 
can function as quicker source of cells for application in toxicodynamic studies 
(mechanisms) since the cell seem to be maturated. 
Although other 3D HepaRG bioreactor studies had already been performed 
with successful results (Darnell et al. 2011), our system has the advantage of lacking 
structures that would lead to non-specific bindings and the possibility of on-line cell 
sampling, allowing the cell characterization and quantification during the culture time. 
Additionally, the easy access to the cell content with minimal perturbation of the bulk 
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culture permits the bioreactor to work as feeder model, generating big amount of 
cells in the same conditions that can be further distributed through smaller high-
throughput models for screening of compounds. Moreover, stirred spinner bioreactor 
is a simple and inexpensive bioreactor system (Rauh et al. 2011), that can be easily 
up-scaled (Leite et al. 2011) for higher amounts of cells for feeding.  
In summary, the 3D HepaRG cultures in stirred tanks are a good model to 
maintain hepatocyte-like features, showing applicability for toxicological studies and 
integration with in silico models. According to our knowledge, this is the first time that 
such approach was tested in HepaRG 3D system. Moreover, it was shown that the 
system can generate early differentiated hepatocytes mimicking natural variability in 
vivo. With further improvements and good extrapolation models, this is a promising 
and attractive strategy for drug testing applications for both, pharma industry and 
CRO's.   
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1. DISCUSSION 
The development of in vitro methods to culture metabolic competent 
hepatocytes can have different applications such as the generation of cells for liver 
engraphment or bioartificial liver (BAL), drug testing, toxicokinetic studies or even for 
studying liver paths and responses following a more toxicodynamical assessment 
under physiological and pathological conditions. An overall improvement of the 
hepatic culture system is needed such that it reacts as close as possible to the in 
vivo cells. However, depending on the application, there are some parameters that 
gain or loose relevance for the optimization of the method. 
In this work the 3D spheroid strategy for hepatocyte culture in stirred tank 
vessels directed at drug testing was pursued as a way to predict toxicity, 
bioactivation and drug-drug interaction, with a special focus on applications for the 
Pharma Industry. Within this context, in vitro methods for these applications should 
take into account specific characteristics, as listed in Table 6.1. 
Table 6.1.: Aimed characteristics of an in vitro method for drug testing applications in the Pharma Industry 
Cells  generation of metabolically competent cells 
 metabolic profile similar to in vivo 
 time-stable metabolism 
Tests   acute toxicity 
 repeated dose effects  
 chronic toxicity 
 drug-drug interactions 
Drug Testing  low amounts of compounds 
 screening 
 compatible with high-throughput 
 low drug interaction apparatus and scaffolds 
Transferability  easy to work 
 easy cell access  
 reproducibility 
 robustness 
 scalability 
Costs  quick generation of cells 
 time effective strategies (large numbers of 
results obtained in a short period of time) 
 cost-effective apparatus 
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Having these factors in mind, our strategy was developed by using three 
different cell types and distinct approaches. Each study conquered novel outcomes 
that constituted the base line for the next study or disclosed additional knowledge 
about the system. The main outcomes obtained in each step are summarized in 
Figure 6.1 as an update from the aims summarized in Figure 1.8. 
 
 
 
Figure 6.1: Main outcomes from the studies performed in this thesis. This figure is based on the aims 
listed in figure 1.8 (Chapter I - Introduction) 
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1.1. The cellular models to predict liver function  
As discussed in detail in Chapter I, animal models, although being integrative 
models, have several limitations for test studies. On one hand, the test in an animal 
as a whole does not allow the assessment of the cell and organ reactions in detail, 
making it impossible to understand the mechanisms of toxicity. On the other hand, 
the minimization of the impact of inter-species variability between humans and 
animals has lead in the past to several mistakes such as the use of Thalidomide 
(Nau 1986). Thus, the relevance of having human-derived in vitro models that can 
generate reliable data regarding the pharmacokinetics of ADME, especially on 
metabolism, is obvious.  
For many years, microsomes have been a powerful in vitro tool to understand 
biotransformation. However, in such simplistic system, it was impossible to express 
the whole cellular metabolic equipment; therefore, cell cultures started to be the most 
obvious option. 
The present work aimed at developing a model that could generate highly 
competent human liver cells. Since freshly isolated human hepatocytes are not easily 
obtained as a regular source and, when in culture, their viability and functionality is 
often compromised (Schutte et al. 2011), our first approach in this work was to use 
rat hepatocytes (Chapters II and III). In addition to being cells with high metabolic 
activity, leading usually to results reproducible in human cells, the generation of a 
more robust and reliable cell culture models of rat hepatocytes is also a way to 
accomplish the 3R’s. Having in vitro models that can predict animal toxicity by 
sacrificing less individuals will further reduce and refine animal testing in the pre-
clinical phase. 
Finally, Chapter V describes the development of a culture strategy using a human 
cell line as a way to overcome the limitations of primary cultures of human 
hepatocytes.  
Having a cell line that can perform similarly to human hepatocytes would be 
valuable both for practical and economic reasons, already stated in subsection 3.3 
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of Chapter I. HepaRG has been presented as one of the best alternative candidates; 
however, there are already other cell lines under development with promising hepatic 
profiles such as the case of FLC cells (Laurent et al. 2011). Moreover, hepatocyte-
like cells derived from stem cells are also a relevant and a very promising approach 
to generate high amounts of hepatocytes. Additionally, in spite of not being 
addressed in this work, remarkable results towards the hepatic stem differentiation 
have been achieved by using 3D strategies and bioreactors (Laurent et al. 2011; Miki 
et al. 2011).  
The use of 3D models in stirred bioreactors has been shown to improve the 
differentiation of under-differentiated cells with other cell types (Serra et al. 2007), as 
well as here when using HepaRG cells (Chapter V). Based on these studies it is 
expected that stirred bioreactors would represent a good strategy to differentiate and 
characterize hepatocyte-like cells. 
 
1.2 The accomplishment of metabolically competent cultures 
Having physiological-like liver cultures consists in maintaining hepatocytes that 
can perform as the liver and mimicking all its functions. However, when the study 
aims to assess toxic effects, biotransformation of drugs has a more relevant role. The 
work of this thesis, besides tackling secretion functions (such as albumin and urea) 
focuses on biotransformation enzymes, their activities improvement and 
maintenance. Moreover, in addition to assessing the basal activity of the developed 
culture model, it has also been challenged to respond to reference compounds that 
affect phase I enzymes by performing studies of Induction, Clearance and 
Bioactivation. In each Chapter, the strategies employed to monitor the cultures were 
not exactly the same in order for the culture model to be more extensively 
characterized. Thus, the best way to analyze the different studies transversely is by 
comparing their activity induction hills, resumed on Table 6.2. 
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Table 6.2.: Resume of CYP activity induction obtained in this thesis 
Fold-induction 
C
Y
P
 1
A
/2
B
 
Rat hepatocytes in 
Co-Culture  
 
(Chapter III) 
5% pO2 1 – 1,5 x 
30% pO2 2 – 3 x 
70% pO2 1 – 1,6 x 
Human hepatocytes  
 
 
(Chapter IV) 
Donor A 1 – 2,6 x 
Donor B 2 – 3 x 
Donor C 15 – 19 x 
HepaRG 
 
(Chapter V) 
Diff 5 – 20 x 
C
Y
P
 
3A
4
 
Under-Diff 2 – 4 x 
Diff 3 – 10 x 
 
Besides the difference on the assessed CYP’s and the inter-donor variability it can 
be observed that it was possible to obtain the same range of fold-induction in the 
different studies, in agreement with in vivo data (Floyd et al. 2003; Gorski et al. 2004; 
Kharasch et al. 2004; Yu et al. 2004; Abadie-Viollon et al. 2010). In general terms, 
the strategy developed with rat cells was also applicable to human cells. Moreover, 
the values and the variability observed for the HepaRG cells are within the range 
detected for freshly isolated hepatocytes. 
 
Drug-induced liver injury (DILI) represents a major challenge for clinicians, the 
pharmaceutical industry and regulatory agencies worldwide (Kaplowitz 2005). DILI 
effects, in particular idiosyncratic reactions highly depend on individual specific 
responses to xenobiotic biotransformation. It is then important that the hepatic 
cellular models, at the same time that they improve metabolic profile can also reflect 
its natural in vivo variability. The work presented on Chapters IV and V has shown 
that besides being a robust and reproducible approach, the 3D mode to culture cells 
using stirred tanks can however preserve or generate human CYP variability. 
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Nevertheless, extrapolating in vitro values to in vivo is limited. For instance, 
considering the different compound partitioning in both situations, in vitro and in vivo, 
the real concentration at which cells and the organ are exposed varies. The 
concentration of the compounds in the plasma is affected by protein binding and 
hydrophobic compartments like phospholipid bilayers or hydrophobic proteins and 
thus it is very difficult to predict the compound concentration at which the organ is 
exposed (Pelkonen et al. 2008; Zaldívar et al. submitted).  
As mentioned before, the accomplishment of a predictive strategy of human toxic 
values will probably not be possible only with metabolic in vitro models. 
A recent strategy to obtain a better prediction of human risk is to use the so called 
humanized models, where human cells are transplanted into rat or mice, having a 
human metabolization (Chen et al. 2011).  However this strategy needs to use the 
cells generated in vitro and works on only 1R (Refinement) of the 3R’s policy. 
Recently, human microdosing is becoming a prospective strategy to better 
understand human metabolism and potentially avoid the use of animals. It consists of 
testing the compounds already tested in vitro, in human volunteers using very small 
doses in order to avoid toxicity, but allowing to trace the resulting metabolites (Ings 
2010), but still the tests are based on in vitro outcomes. 
In any case, the in vitro metabolic models need to generate data that can be 
correlated directly with the in vivo outcome and some 3D models have already 
shown to be able to perform such correlation (Toh et al. 2009). 
 
1.3. The 3D approach as an answer to the need for alternative methods 
The developed work confirmed that culturing hepatocytes in a 3D arrangement 
rather than on the typical 2D monolayers on top of a flat and rigid surfaces, can 
improve their specific functionalities and be maintained for longer periods. The 
adopted approach consisted of maintaining the cells as spheroids, where the cells 
could have an elevated number of cell-cell contact without using any scaffold. We 
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intended to restore the tissue-specific architecture, biochemical cues and avoid the 
loss of cell–cell communication while at the same time reducing the gap between cell 
culture and physiological liver.  
As result of toxicity, in vitro as well as in vivo cell death, can be due to either 
apoptosis or necrosis; different body reactions characterize these two paths. These 
reactions still cannot be predicted by the simple in vitro systems, and many times not 
even the type of induced cell death is in agreement with what happens in vivo 
(Kaplowitz 2005).  
A strategy to better mimic the several occurrences and reactions taking place in 
the body is to use integrative and multiparametric approaches such as co-culture. 
The inclusion of heterotypic cell-cell interactions in the 3D models and the reciprocal 
effect of different cell populations on the whole microenvironment should hence be 
carefully considered when trying to establish physiologically relevant in vitro models 
of tissues/organs. In this work, co-culture was a transversal strategy used in two 
types of approaches: as feeder cells, as for the fibroblasts (Chapters III and IV) or as 
helper cells, as for biliary cells (Chapter V) that help on hepatic metabolism by being 
involved in the excretion and generating polarization. 
For co-culture, it is relevant to use cells that mimic the liver milieu; however, none 
of these cells should interfere with the hepatic metabolism but allow for hepatic 
metabolites to diffuse to the target cells, without further biotransformation. Including 
cells, with specific zonated distribution that will aid hepatocytes on the excretion of 
the metabolites, such as biliary cells, as observed in HepaRG co-cultures, will make 
the model more realistic. On the other hand, when the co-culture cells work uniquely 
as feeders, instead of polarized distribution, it is intended to have an homogeneous 
distribution, since it is known that the observed improved function is generally limited 
to those cells that are located at the heterogeneous cell-cell interface (Bhatia et al. 
1999). Fulfilling such requirement, the observed cell distribution of fibroblasts in rat 
co-culture (Chapter III) was homogeneous.  
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However, due to time limitations, in this work the co-culture strategies were not 
much explored in terms of cell characterization, interactions or even exploring other 
cell types. A good strategy to improve the cell culture model in terms of 
representativeness of the liver milieu can be to mimic capillary structures that could 
improve spheroids permeability to test compounds. This can be achieved by the 
addition of human umbilical vein endothelial cells (HUVECs) as has been done by 
Salerno et al. (Salerno et al. 2011) and Inamori et al. (Inamori et al. 2009). 
 
In spite of the advances that the 3D approaches have brought to the Drug testing 
field, there are still some limitations that can prevent it from being a more predictable 
model of human risk. As an example, although the gel structure presents advantages 
for culturing cells it can also limit the prediction of drug induced cytotoxicity since the 
physico-chemical properties of the compounds can thwart them to reach the cells 
(Schutte et al. 2011). Moreover, 3D systems that combine encapsulation with hollow 
fibers for diffusion are also potentially limited by the fibers adsorbing hydrophobic 
drugs (Schutte et al. 2011) bringing an additional difficulty on the accurate 
identification of the drug concentration to which cells are subjected.  
The use of cell spheroids by itself has as well some limitations; permeation of the 
compounds can be compromised being an important parameter to be controlled. In 
this work, the use of stirred systems was a way to facilitate the diffusion in spheroids, 
as well as the presence of other cells that can create channels; this was assessed 
biochemically on Chapter IV by the CDFDA method, and included on Chapter V by 
the in silico approach. This work also depicts the in silico approach where the results 
can be better integrated, extrapolated and understood. 
The use of integrative (such as co-culture), multiparametric and multidisciplinary 
(such as in vitro + in silico) approaches can decrease the human risk in the clinical 
phases of drug development. 
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1.4. Stirring systems: why use it for the generation of hepatospheroids. 
The generation of 3D cell constructs in fully controlled and monitored bioreactors 
creates a more homogeneous in vivo-like environment, and additionally decreases 
the biological cell-to-cell and culture-to-culture variability.  Animal cells are cultured in 
bioreactors with the aim of maintaining well defined, physiological conditions while 
constituting a robust and reproducible approach (van Zijl and Mikulits 2010). The 
most relevant bioreactors used in this area are detailed in Chapter I; stirred tank 
vessels were selected for the work hereby presented.  
The presence of stirring allows a better homogeneity of the medium and its flow 
can resemble the blood flow within the body while at the same time making it 
possible to overcome mass and gas transfer limitations. Comparing with other types 
of agitation, spinner stirring has shown to have a higher rate of aggregation (Wu et 
al. 1996). Additionally, with stirring it is possible to control the oversizing of spheroids 
avoiding the formation of necrotic cores (Moreira et al. 1995), that result from 
deprivation of nutrients and oxygen. This stirring can be performed with different 
types of impellers, as shown in Chapter II; being a versatile tool, it can be adapted to 
different cell types.  
The spinner tank vessels are a very attractive tool for Pharma Industry as these 
are non-expensive, simple to work with, easy to transfer between laboratories and 
permit in-vivo like structures to be obtained. However, the work presented on this 
thesis has shown that the basal hepatocyte functionalities can be further improved 
when the cells are cultured in environmentally controlled bioreactors (Chapters II 
and III). With a tight and automatic monitoring and an on-line parameter control the 
cells have an homogeneous environment during culture time and a more robust 
model is obtained, which can be applied under GMP (Good Manufacturing Practices) 
conditions. Furthermore, the possibility to control several parameters, allows the 
performance of dynamic studies focusing on each one of them, which is not possible 
with the simple spinner tank vessels. 
DISCUSSION AND CONCLUSION 
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In the special case of hepatocytes, where the importance of oxygen control has 
already been highlighted, this bioreactor system not only allows such control but also 
presents the possibility of subjecting the cells to different oxygenation conditions to 
evaluate distinct responses (Chapter III). In this way, it is possible to mimic the 
perivenous and the periportal oxygen values as well as pathological liver perfusions 
(such as stroke or carcinoma). As a controversial issue, oxygen could have been 
further explored within the aim of this thesis, trying to study the rate perfusion that 
would maximize hepatic functionalities without inducing oxidative stress. Moreover, 
since cell cultures, especially primary cultures, show a dynamic metabolic profile, 
subjecting the cells to different oxygen levels during culture time could be a strategy 
to further extend culture time. However the optimization of these strategies would be 
too time-consuming within the scope of this work.  
 
An additional advantage of these bioreactors regarding its application in 
Toxicology is the possibility to overcome the traditional bioreactor limitations to scale-
up (Naughton 2002; Ratcliffe and Niklason 2002). Higher amounts of cells in the 
same conditions can be generated which, due to the non invasive and easy 
sampling, can be used to feed smaller models for high-throughput screening.  
Furthermore, it is also possible to integrate a perfusion apparatus that will ensure 
the continuous renewal of nutrients and other factors as well as continuous removal 
of metabolic products with low culture perturbation, increasing the robustness of the 
system, as is described in Chapter IV. 
 
Besides the advantages of the bioreactors used in this work, the big limitation is 
the minimum working volume. The system is proven to be compatible with high-
throughput but it is not possible to run high-throughput studies in the bioreactor. The 
cells need to be harvest and being cultured for some hours/days in different 
surfaces/apparatus. Meanwhile, smaller vessels and prototypes are in development 
and hopefully will be commercialized soon. 
Chapter VI 
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Moreover, current strategies towards the accomplishment of in vitro ADME 
include the development of multi-organ systems – such as the IdMOC system (Xu et 
al. 2010) – simulating the whole living organism by having compartments with 
different cell types, hierarchically connected by culture medium. At the moment, this 
is just possible with miniaturized bioreactors (subChapters 5.2.1 and 5.2.3 of 
Chapter I).  
 
2. LOOKING AHEAD 
The developed strategy can improve and extend the metabolic competency of 
hepatocytes for toxicological applications. We developed a cell culture model that 
can be used with reference toxicants in order to generate correlations between the 
data produced and the known in vivo values. Nevertheless the main advantage of 
these cultures, when further extended in time, is their application to chronic and 
repeated-dose toxicity assays. 
 
2.1. Towards the accomplishment of the full replacement of animal models 
In 2003, the 7th amendment to the European Union’s Cosmetics Directive 
(76/768/EEC) has imposed a ban on the use of animals for testing Cosmetic 
compounds from 2009 onwards. In 2005, a team of experts has met and produced a 
report for DG SANCO (Directorate Generale for Health and Consumers) where it was 
stated that within the foreseen time it was not possible to generate alternative 
methods that could give accurate toxicity prediction (Coecke et al. 2005); thus the 
ban was postponed to 2013. Six years later, a similar exercise was performed (Adler 
et al. 2011), and in spite of still not having methods that can fully replace the use of 
animals, this accomplishment is expected in the near future. Since 2005 searching 
alternative methods to animal testing has highly developed, having generated 
several techniques. Nonetheless, integrative and multidisciplinary approaches are 
essential to reach full animal replacement. 
DISCUSSION AND CONCLUSION 
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The strategy developed in this thesis has generated a highly competent metabolic 
culture model that, when integrated with proper in silico strategies such as PBTK 
models, can predict human risk or/and microdosing. Nevertheless, this approach 
does not avoid the use of in vivo testing before approval, but will highly reduce the 
risk and animal testing Reduction and Refinement, within the 3R’s policy.  
 
The combination of different disciplines on the experimental design also allows 
the prediction of important mechanisms such as systemic pharmacological and 
toxicological paths. Multidisciplinary approaches and the generation of consortiums 
such as DNT (Neurodevelopmental Toxicology consortium) constitute growing 
initiatives (Vozzi et al. 2011) that aim at obtaining complete strategies that can 
accurately predict the human risk. It is important to have an active dialogue between 
engineers and biologists in order to further develop the adaptation of the cell 
environment to the cell sensitivities and needs. 
 
3. CONCLUSION 
With this work, by using the strategy of 3D spheroids in stirred tank vessels a 
robust model was obtained, that can generate liver-cultures closer to the in vivo and 
for periods of time further extended than those obtained with regular 2D cultures. 
Moreover, the system hereby developed presents technical characteristics that make 
it an attractive strategy for Toxicological applications. Figure 6.2 summarizes the 
major accomplishments of the developed strategy. 
Chapter VI 
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Figure 6.2:  Schematic view of the focus and outcomes of the work developed in this thesis. 
 
Each of the different approaches has disadvantages and limitations, but 
together they make important contributions to the generation of a robust and 
metabolically competent in vitro method for hepatocyte culture and towards its 
application on the Pharma Industry.   
It is to be hoped that other research groups will further develop this system in 
order to achieve a complete 3R model. 
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direct reference to action and society”
D. Hume (1711-1776)
Enquiry concerning human understanding. Introduction, 9.
